<?xml version="1.0" encoding="utf-8"?>
<Bundle xmlns="http://hl7.org/fhir">
    <id value="910d1748-674b-430c-b4ab-3665b266a31f" />
    <meta>
        <versionId value="1" />
        <lastUpdated value="2021-06-25T20:28:04.643+00:00" />
    </meta>
    <identifier>
        <system value="http://ema.europa.eu/fhir/identifier/documentid" />
        <value value="d6492916-2a98-4ea8-a938-324d5e5c471b" />
    </identifier>
    <type value="document" />
    <timestamp value="2021-06-25T20:28:01+00:00" />
    <entry>
        <fullUrl value="urn:uuid:f51d10d6-a536-4039-a9c2-9459339cf52e" />
        <resource>
            <Composition>
                <language value="en" />
                <contained>
                    <Binary>
                        <id value="stylesheet0" />
                        <contentType value="stylesheet/css" />
                        <data value="PHN0eWxlPg0NCjwhLS0NDQogLyogRm9udCBEZWZpbml0aW9ucyAqLw0NCiBAZm9udC1mYWNlDQ0KCXtmb250LWZhbWlseTpIZWx2ZXRpY2E7DQ0KCXBhbm9zZS0xOjIgMTEgNiA0IDIgMiAyIDIgMiA0O30NDQpAZm9udC1mYWNlDQ0KCXtmb250LWZhbWlseTpDb3VyaWVyOw0NCglwYW5vc2UtMToyIDcgNCA5IDIgMiA1IDIgNCA0O30NDQpAZm9udC1mYWNlDQ0KCXtmb250LWZhbWlseToiVG1zIFJtbiI7DQ0KCXBhbm9zZS0xOjIgMiA2IDMgNCA1IDUgMiAzIDQ7fQ0NCkBmb250LWZhY2UNDQoJe2ZvbnQtZmFtaWx5OkhlbHY7DQ0KCXBhbm9zZS0xOjIgMTEgNiA0IDIgMiAyIDMgMiA0O30NDQpAZm9udC1mYWNlDQ0KCXtmb250LWZhbWlseToiTmV3IFlvcmsiOw0NCglwYW5vc2UtMToyIDQgNSAzIDYgNSA2IDIgMyA0O30NDQpAZm9udC1mYWNlDQ0KCXtmb250LWZhbWlseTpTeXN0ZW07DQ0KCXBhbm9zZS0xOjAgMCAwIDAgMCAwIDAgMCAwIDA7fQ0NCkBmb250LWZhY2UNDQoJe2ZvbnQtZmFtaWx5OldpbmdkaW5nczsNDQoJcGFub3NlLTE6NSAwIDAgMCAwIDAgMCAwIDAgMDt9DQ0KQGZvbnQtZmFjZQ0NCgl7Zm9udC1mYW1pbHk6Ik1TIE1pbmNobyI7DQ0KCXBhbm9zZS0xOjIgMiA2IDkgNCAyIDUgOCAzIDQ7fQ0NCkBmb250LWZhY2UNDQoJe2ZvbnQtZmFtaWx5OkJhdGFuZzsNDQoJcGFub3NlLTE6MiAzIDYgMCAwIDEgMSAxIDEgMTt9DQ0KQGZvbnQtZmFjZQ0NCgl7Zm9udC1mYW1pbHk6U2ltU3VuOw0NCglwYW5vc2UtMToyIDEgNiAwIDMgMSAxIDEgMSAxO30NDQpAZm9udC1mYWNlDQ0KCXtmb250LWZhbWlseTpQTWluZ0xpVTsNDQoJcGFub3NlLTE6MiAxIDYgMSAwIDEgMSAxIDEgMTt9DQ0KQGZvbnQtZmFjZQ0NCgl7Zm9udC1mYW1pbHk6Ik1TIEdvdGhpYyI7DQ0KCXBhbm9zZS0xOjIgMTEgNiA5IDcgMiA1IDggMiA0O30NDQpAZm9udC1mYWNlDQ0KCXtmb250LWZhbWlseTpEb3R1bTsNDQoJcGFub3NlLTE6MiAxMSA2IDAgMCAxIDEgMSAxIDE7fQ0NCkBmb250LWZhY2UNDQoJe2ZvbnQtZmFtaWx5OlNpbUhlaTsNDQoJcGFub3NlLTE6MiAxIDYgMCAzIDEgMSAxIDEgMTt9DQ0KQGZvbnQtZmFjZQ0NCgl7Zm9udC1mYW1pbHk6TWluZ0xpVTsNDQoJcGFub3NlLTE6MiAxIDYgOSAwIDEgMSAxIDEgMTt9DQ0KQGZvbnQtZmFjZQ0NCgl7Zm9udC1mYW1pbHk6TWluY2hvOw0NCglwYW5vc2UtMToyIDIgNiA5IDQgMyA1IDggMyA1O30NDQpAZm9udC1mYWNlDQ0KCXtmb250LWZhbWlseTpHdWxpbTsNDQoJcGFub3NlLTE6MiAxMSA2IDAgMCAxIDEgMSAxIDE7fQ0NCkBmb250LWZhY2UNDQoJe2ZvbnQtZmFtaWx5OkNlbnR1cnk7DQ0KCXBhbm9zZS0xOjIgNCA2IDQgNSA1IDUgMiAzIDQ7fQ0NCkBmb250LWZhY2UNDQoJe2ZvbnQtZmFtaWx5OiJBbmdzYW5hIE5ldyI7DQ0KCXBhbm9zZS0xOjIgMiA2IDMgNSA0IDUgMiAzIDQ7fQ0NCkBmb250LWZhY2UNDQoJe2ZvbnQtZmFtaWx5OiJDb3JkaWEgTmV3IjsNDQoJcGFub3NlLTE6MiAxMSAzIDQgMiAyIDIgMiAyIDQ7fQ0NCkBmb250LWZhY2UNDQoJe2ZvbnQtZmFtaWx5Ok1hbmdhbDsNDQoJcGFub3NlLTE6MCAwIDQgMCAwIDAgMCAwIDAgMDt9DQ0KQGZvbnQtZmFjZQ0NCgl7Zm9udC1mYW1pbHk6TGF0aGE7DQ0KCXBhbm9zZS0xOjIgMCA0IDAgMCAwIDAgMCAwIDA7fQ0NCkBmb250LWZhY2UNDQoJe2ZvbnQtZmFtaWx5OlN5bGZhZW47DQ0KCXBhbm9zZS0xOjEgMTAgNSAyIDUgMyA2IDMgMyAzO30NDQpAZm9udC1mYWNlDQ0KCXtmb250LWZhbWlseTpWcmluZGE7DQ0KCXBhbm9zZS0xOjAgMCA0IDAgMCAwIDAgMCAwIDA7fQ0NCkBmb250LWZhY2UNDQoJe2ZvbnQtZmFtaWx5OlJhYXZpOw0NCglwYW5vc2UtMToyIDAgNSAwIDAgMCAwIDAgMCAwO30NDQpAZm9udC1mYWNlDQ0KCXtmb250LWZhbWlseTpTaHJ1dGk7DQ0KCXBhbm9zZS0xOjIgMCA1IDAgMCAwIDAgMCAwIDA7fQ0NCkBmb250LWZhY2UNDQoJe2ZvbnQtZmFtaWx5OlNlbmRueWE7DQ0KCXBhbm9zZS0xOjAgMCA0IDAgMCAwIDAgMCAwIDA7fQ0NCkBmb250LWZhY2UNDQoJe2ZvbnQtZmFtaWx5OkdhdXRhbWk7DQ0KCXBhbm9zZS0xOjIgMCA1IDAgMCAwIDAgMCAwIDA7fQ0NCkBmb250LWZhY2UNDQoJe2ZvbnQtZmFtaWx5OlR1bmdhOw0NCglwYW5vc2UtMTowIDAgNCAwIDAgMCAwIDAgMCAwO30NDQpAZm9udC1mYWNlDQ0KCXtmb250LWZhbWlseToiRXN0cmFuZ2VsbyBFZGVzc2EiOw0NCglwYW5vc2UtMTowIDAgMCAwIDAgMCAwIDAgMCAwO30NDQpAZm9udC1mYWNlDQ0KCXtmb250LWZhbWlseToiQ2FtYnJpYSBNYXRoIjsNDQoJcGFub3NlLTE6MiA0IDUgMyA1IDQgNiAzIDIgNDt9DQ0KQGZvbnQtZmFjZQ0NCgl7Zm9udC1mYW1pbHk6Ill1IEdvdGhpYyI7DQ0KCXBhbm9zZS0xOjIgMTEgNCAwIDAgMCAwIDAgMCAwO30NDQpAZm9udC1mYWNlDQ0KCXtmb250LWZhbWlseTpEZW5nWGlhbjsNDQoJcGFub3NlLTE6MiAxIDYgMCAzIDEgMSAxIDEgMTt9DQ0KQGZvbnQtZmFjZQ0NCgl7Zm9udC1mYW1pbHk6Q2FsaWJyaTsNDQoJcGFub3NlLTE6MiAxNSA1IDIgMiAyIDQgMyAyIDQ7fQ0NCkBmb250LWZhY2UNDQoJe2ZvbnQtZmFtaWx5OiJDYWxpYnJpIExpZ2h0IjsNDQoJcGFub3NlLTE6MiAxNSAzIDIgMiAyIDQgMyAyIDQ7fQ0NCkBmb250LWZhY2UNDQoJe2ZvbnQtZmFtaWx5OiJQYWxhdGlubyBMaW5vdHlwZSI7DQ0KCXBhbm9zZS0xOjIgNCA1IDIgNSA1IDUgMyAzIDQ7fQ0NCkBmb250LWZhY2UNDQoJe2ZvbnQtZmFtaWx5OlZlcmRhbmE7DQ0KCXBhbm9zZS0xOjIgMTEgNiA0IDMgNSA0IDQgMiA0O30NDQpAZm9udC1mYWNlDQ0KCXtmb250LWZhbWlseToiQXJpYWwgVW5pY29kZSBNUyI7DQ0KCXBhbm9zZS0xOjIgMTEgNiA0IDIgMiAyIDIgMiA0O30NDQpAZm9udC1mYWNlDQ0KCXtmb250LWZhbWlseToiU2Vnb2UgVUkgRW1vamkiOw0NCglwYW5vc2UtMToyIDExIDUgMiA0IDIgNCAyIDIgMzt9DQ0KQGZvbnQtZmFjZQ0NCgl7Zm9udC1mYW1pbHk6VGFob21hOw0NCglwYW5vc2UtMToyIDExIDYgNCAzIDUgNCA0IDIgNDt9DQ0KQGZvbnQtZmFjZQ0NCgl7Zm9udC1mYW1pbHk6IlNlZ29lIFVJIjsNDQoJcGFub3NlLTE6MiAxMSA1IDIgNCAyIDQgMiAyIDM7fQ0NCkBmb250LWZhY2UNDQoJe2ZvbnQtZmFtaWx5Ok1pbmlvblByby1SZWd1bGFyOw0NCglwYW5vc2UtMTowIDAgMCAwIDAgMCAwIDAgMCAwO30NDQpAZm9udC1mYWNlDQ0KCXtmb250LWZhbWlseToiXEBTaW1TdW4iOw0NCglwYW5vc2UtMToyIDEgNiAwIDMgMSAxIDEgMSAxO30NDQpAZm9udC1mYWNlDQ0KCXtmb250LWZhbWlseToiXEBNaW5pb25Qcm8tUmVndWxhciI7DQ0KCXBhbm9zZS0xOjAgMCAwIDAgMCAwIDAgMCAwIDA7fQ0NCkBmb250LWZhY2UNDQoJe2ZvbnQtZmFtaWx5OiJcQE1TIE1pbmNobyI7DQ0KCXBhbm9zZS0xOjIgMiA2IDkgNCAyIDUgOCAzIDQ7fQ0NCiAvKiBTdHlsZSBEZWZpbml0aW9ucyAqLw0NCiBwLk1zb05vcm1hbCwgbGkuTXNvTm9ybWFsLCBkaXYuTXNvTm9ybWFsDQ0KCXttYXJnaW46MGluOw0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwDQ0KCXttYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tbGVmdDowaW47DQ0KCWZvbnQtc2l6ZToxMi4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLlR0dWxvMSwgbGkuVHR1bG8xLCBkaXYuVHR1bG8xDQ0KCXttc28tc3R5bGUtbmFtZToiVO10dWxvIDEiOw0NCgltc28tc3R5bGUtbGluazoiVO10dWxvIDEgQ2FyIjsNDQoJbWFyZ2luLXRvcDo2LjBwdDsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTo2LjBwdDsNDQoJbWFyZ2luLWxlZnQ6NzAuODVwdDsNDQoJdGV4dC1hbGlnbjpqdXN0aWZ5Ow0NCgl0ZXh0LWp1c3RpZnk6aW50ZXItaWRlb2dyYXBoOw0NCgl0ZXh0LWluZGVudDotNzAuODVwdDsNDQoJcGFnZS1icmVhay1hZnRlcjphdm9pZDsNDQoJZm9udC1zaXplOjEyLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7DQ0KCXRleHQtdHJhbnNmb3JtOnVwcGVyY2FzZTsNDQoJZm9udC13ZWlnaHQ6Ym9sZDt9DQ0KcC5UdHVsbzIsIGxpLlR0dWxvMiwgZGl2LlR0dWxvMg0NCgl7bXNvLXN0eWxlLW5hbWU6IlTtdHVsbyAyIjsNDQoJbXNvLXN0eWxlLWxpbms6IlTtdHVsbyAyIENhciI7DQ0KCW1hcmdpbi10b3A6Ni4wcHQ7DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206Ni4wcHQ7DQ0KCW1hcmdpbi1sZWZ0OjcwLjg1cHQ7DQ0KCXRleHQtYWxpZ246anVzdGlmeTsNDQoJdGV4dC1qdXN0aWZ5OmludGVyLWlkZW9ncmFwaDsNDQoJdGV4dC1pbmRlbnQ6LTcwLjg1cHQ7DQ0KCXBhZ2UtYnJlYWstYWZ0ZXI6YXZvaWQ7DQ0KCWZvbnQtc2l6ZToxMi4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmOw0NCglmb250LXdlaWdodDpib2xkO30NDQpwLlR0dWxvMywgbGkuVHR1bG8zLCBkaXYuVHR1bG8zDQ0KCXttc28tc3R5bGUtbmFtZToiVO10dWxvIDMiOw0NCgltc28tc3R5bGUtbGluazoiVO10dWxvIDMgQ2FyIjsNDQoJbWFyZ2luLXRvcDo2LjBwdDsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTo2LjBwdDsNDQoJbWFyZ2luLWxlZnQ6NzAuODVwdDsNDQoJdGV4dC1hbGlnbjpqdXN0aWZ5Ow0NCgl0ZXh0LWp1c3RpZnk6aW50ZXItaWRlb2dyYXBoOw0NCgl0ZXh0LWluZGVudDotNzAuODVwdDsNDQoJcGFnZS1icmVhay1hZnRlcjphdm9pZDsNDQoJZm9udC1zaXplOjEyLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7DQ0KCWZvbnQtd2VpZ2h0OmJvbGQ7fQ0NCnAuVHR1bG80LCBsaS5UdHVsbzQsIGRpdi5UdHVsbzQNDQoJe21zby1zdHlsZS1uYW1lOiJU7XR1bG8gNCI7DQ0KCW1zby1zdHlsZS1saW5rOiJU7XR1bG8gNCBDYXIiOw0NCgltYXJnaW4tdG9wOjYuMHB0Ow0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjYuMHB0Ow0NCgltYXJnaW4tbGVmdDo3MC44NXB0Ow0NCgl0ZXh0LWFsaWduOmp1c3RpZnk7DQ0KCXRleHQtanVzdGlmeTppbnRlci1pZGVvZ3JhcGg7DQ0KCXRleHQtaW5kZW50Oi03MC44NXB0Ow0NCglwYWdlLWJyZWFrLWFmdGVyOmF2b2lkOw0NCglmb250LXNpemU6MTIuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjsNDQoJZm9udC13ZWlnaHQ6Ym9sZDt9DQ0KcC5UdHVsbzUsIGxpLlR0dWxvNSwgZGl2LlR0dWxvNQ0NCgl7bXNvLXN0eWxlLW5hbWU6IlTtdHVsbyA1IjsNDQoJbXNvLXN0eWxlLWxpbms6IlTtdHVsbyA1IENhciI7DQ0KCW1hcmdpbi10b3A6Ni4wcHQ7DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206Ni4wcHQ7DQ0KCW1hcmdpbi1sZWZ0OjcwLjg1cHQ7DQ0KCXRleHQtaW5kZW50Oi03MC44NXB0Ow0NCglwYWdlLWJyZWFrLWFmdGVyOmF2b2lkOw0NCglmb250LXNpemU6MTIuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjsNDQoJZm9udC13ZWlnaHQ6Ym9sZDt9DQ0KcC5UdHVsbzYsIGxpLlR0dWxvNiwgZGl2LlR0dWxvNg0NCgl7bXNvLXN0eWxlLW5hbWU6IlTtdHVsbyA2IjsNDQoJbXNvLXN0eWxlLWxpbms6IlTtdHVsbyA2IENhciI7DQ0KCW1hcmdpbi10b3A6Ni4wcHQ7DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206Ni4wcHQ7DQ0KCW1hcmdpbi1sZWZ0OjcwLjg1cHQ7DQ0KCXRleHQtaW5kZW50Oi03MC44NXB0Ow0NCglwYWdlLWJyZWFrLWFmdGVyOmF2b2lkOw0NCglmb250LXNpemU6MTIuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjsNDQoJZm9udC13ZWlnaHQ6Ym9sZDt9DQ0KcC5UdHVsbzcsIGxpLlR0dWxvNywgZGl2LlR0dWxvNw0NCgl7bXNvLXN0eWxlLW5hbWU6IlTtdHVsbyA3IjsNDQoJbXNvLXN0eWxlLWxpbms6IlTtdHVsbyA3IENhciI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjYuMHB0Ow0NCgltYXJnaW4tbGVmdDoyMS4yNXB0Ow0NCgl0ZXh0LWluZGVudDotMjEuMjVwdDsNDQoJZm9udC1zaXplOjEyLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuVHR1bG84LCBsaS5UdHVsbzgsIGRpdi5UdHVsbzgNDQoJe21zby1zdHlsZS1uYW1lOiJU7XR1bG8gOCI7DQ0KCW1zby1zdHlsZS1saW5rOiJU7XR1bG8gOCBDYXIiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTo2LjBwdDsNDQoJbWFyZ2luLWxlZnQ6NDIuNXB0Ow0NCgl0ZXh0LWluZGVudDotMjEuMjVwdDsNDQoJZm9udC1zaXplOjEyLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuVHR1bG85LCBsaS5UdHVsbzksIGRpdi5UdHVsbzkNDQoJe21zby1zdHlsZS1uYW1lOiJU7XR1bG8gOSI7DQ0KCW1zby1zdHlsZS1saW5rOiJU7XR1bG8gOSBDYXIiOw0NCgltYXJnaW4tdG9wOjEyLjBwdDsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTozLjBwdDsNDQoJbWFyZ2luLWxlZnQ6MGluOw0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJDYWxpYnJpIExpZ2h0IixzYW5zLXNlcmlmO30NDQpzcGFuLkZ1ZW50ZWRlcHJyYWZvcHJlZGV0ZXINDQoJe21zby1zdHlsZS1uYW1lOiJGdWVudGUgZGUgcOFycmFmbyBwcmVkZXRlclwuIjt9DQ0KcC5QaWVkZXBnaW5hLCBsaS5QaWVkZXBnaW5hLCBkaXYuUGllZGVwZ2luYQ0NCgl7bXNvLXN0eWxlLW5hbWU6IlBpZSBkZSBw4WdpbmEiOw0NCgltc28tc3R5bGUtbGluazoiUGllIGRlIHDhZ2luYSBDYXIiOw0NCgltYXJnaW46MGluOw0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZTo4LjBwdDsNDQoJZm9udC1mYW1pbHk6IkFyaWFsIixzYW5zLXNlcmlmO30NDQpwLkVuY2FiZXphZG8sIGxpLkVuY2FiZXphZG8sIGRpdi5FbmNhYmV6YWRvDQ0KCXttc28tc3R5bGUtbmFtZTpFbmNhYmV6YWRvOw0NCgltc28tc3R5bGUtbGluazoiRW5jYWJlemFkbyBDYXIiOw0NCgltYXJnaW46MGluOw0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMC4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJBcmlhbCIsc2Fucy1zZXJpZjt9DQ0KcC5NZW1vSGVhZGVyU3R5bGUsIGxpLk1lbW9IZWFkZXJTdHlsZSwgZGl2Lk1lbW9IZWFkZXJTdHlsZQ0NCgl7bXNvLXN0eWxlLW5hbWU6TWVtb0hlYWRlclN0eWxlOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjcwLjlwdDsNDQoJdGV4dC1hbGlnbjpqdXN0aWZ5Ow0NCgl0ZXh0LWp1c3RpZnk6aW50ZXItaWRlb2dyYXBoOw0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiQXJpYWwiLHNhbnMtc2VyaWY7DQ0KCWZvbnQtdmFyaWFudDpzbWFsbC1jYXBzOw0NCglmb250LXdlaWdodDpib2xkO30NDQpzcGFuLk5tZXJvZGVwZ2luYQ0NCgl7bXNvLXN0eWxlLW5hbWU6Ik76bWVybyBkZSBw4WdpbmEiO30NDQpwLlRleHRvaW5kZXBlbmRpZW50ZSwgbGkuVGV4dG9pbmRlcGVuZGllbnRlLCBkaXYuVGV4dG9pbmRlcGVuZGllbnRlDQ0KCXttc28tc3R5bGUtbmFtZToiVGV4dG8gaW5kZXBlbmRpZW50ZSI7DQ0KCW1zby1zdHlsZS1saW5rOiJUZXh0byBpbmRlcGVuZGllbnRlIENhciI7DQ0KCW1hcmdpbjowaW47DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmOw0NCgljb2xvcjpncmVlbjsNDQoJZm9udC1zdHlsZTppdGFsaWM7fQ0NCnAuVGV4dG9jb21lbnRhcmlvLCBsaS5UZXh0b2NvbWVudGFyaW8sIGRpdi5UZXh0b2NvbWVudGFyaW8NDQoJe21zby1zdHlsZS1uYW1lOiJUZXh0byBjb21lbnRhcmlvXCwgQ2FyMTdcLCBDYXIxNyBDYXJcLCBDYXIxNyBDYXIgQ2FyXCwgQ2hhcjEzXCwgQ2hhcjEzIENhclwsIENoYXIxMyBDYXIgQ2FyXCxDYXIxN1wsQ2FyMTcgQ2FyXCxDYXIxNyBDYXIgQ2FyXCxDaGFyMTNcLENoYXIxMyBDYXJcLENoYXIxMyBDYXIgQ2FyIjsNDQoJbXNvLXN0eWxlLWxpbms6IlRleHRvIGNvbWVudGFyaW8gQ2FyXCwgQ2FyMTcgQ2FyIENhciBDYXJcLCBDYXIxNyBDYXIgQ2FyMVwsIENhcjE3IENhcjFcLCBDaGFyMTMgQ2FyIENhciBDYXJcLCBDaGFyMTMgQ2FyIENhcjFcLCBDaGFyMTMgQ2FyMVwsQ2FyMTcgQ2FyIENhciBDYXJcLENhcjE3IENhciBDYXIxXCxDYXIxNyBDYXIxXCxDaGFyMTMgQ2FyIENhciBDYXJcLENoYXIxMyBDYXIgQ2FyMVwsQ2hhcjEzIENhcjEiOw0NCgltYXJnaW46MGluOw0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMC4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpzcGFuLkhpcGVydm5jdWxvDQ0KCXttc28tc3R5bGUtbmFtZTpIaXBlcnbtbmN1bG87DQ0KCWNvbG9yOmJsdWU7DQ0KCXRleHQtZGVjb3JhdGlvbjp1bmRlcmxpbmU7fQ0NCnAuRU1FQUVuQm9keVRleHQsIGxpLkVNRUFFbkJvZHlUZXh0LCBkaXYuRU1FQUVuQm9keVRleHQNDQoJe21zby1zdHlsZS1uYW1lOiJFTUVBIEVuIEJvZHkgVGV4dCI7DQ0KCW1hcmdpbi10b3A6Ni4wcHQ7DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206Ni4wcHQ7DQ0KCW1hcmdpbi1sZWZ0OjBpbjsNDQoJdGV4dC1hbGlnbjpqdXN0aWZ5Ow0NCgl0ZXh0LWp1c3RpZnk6aW50ZXItaWRlb2dyYXBoOw0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5UZXh0b2RlZ2xvYm8sIGxpLlRleHRvZGVnbG9ibywgZGl2LlRleHRvZGVnbG9ibw0NCgl7bXNvLXN0eWxlLW5hbWU6IlRleHRvIGRlIGdsb2JvIjsNDQoJbWFyZ2luOjBpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6OC4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUYWhvbWEiLHNhbnMtc2VyaWY7fQ0NCnAuQm9keXRleHRBZ2VuY3ksIGxpLkJvZHl0ZXh0QWdlbmN5LCBkaXYuQm9keXRleHRBZ2VuY3kNDQoJe21zby1zdHlsZS1uYW1lOiJCb2R5IHRleHQgXChBZ2VuY3lcKSI7DQ0KCW1zby1zdHlsZS1saW5rOiJCb2R5IHRleHQgXChBZ2VuY3lcKSBDaGFyIjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206Ny4wcHQ7DQ0KCW1hcmdpbi1sZWZ0OjBpbjsNDQoJbGluZS1oZWlnaHQ6MTQuMHB0Ow0NCglmb250LXNpemU6OS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJWZXJkYW5hIixzYW5zLXNlcmlmO30NDQpzcGFuLkJvZHl0ZXh0QWdlbmN5Q2hhcg0NCgl7bXNvLXN0eWxlLW5hbWU6IkJvZHkgdGV4dCBcKEFnZW5jeVwpIENoYXIiOw0NCgltc28tc3R5bGUtbGluazoiQm9keSB0ZXh0IFwoQWdlbmN5XCkiOw0NCglmb250LWZhbWlseToiVmVyZGFuYSIsc2Fucy1zZXJpZjt9DQ0KcC5EcmFmdGluZ05vdGVzQWdlbmN5LCBsaS5EcmFmdGluZ05vdGVzQWdlbmN5LCBkaXYuRHJhZnRpbmdOb3Rlc0FnZW5jeQ0NCgl7bXNvLXN0eWxlLW5hbWU6IkRyYWZ0aW5nIE5vdGVzIFwoQWdlbmN5XCkiOw0NCgltc28tc3R5bGUtbGluazoiRHJhZnRpbmcgTm90ZXMgXChBZ2VuY3lcKSBDaGFyIjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206Ny4wcHQ7DQ0KCW1hcmdpbi1sZWZ0OjBpbjsNDQoJbGluZS1oZWlnaHQ6MTQuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiQ291cmllciBOZXciOw0NCgljb2xvcjojMzM5OTY2Ow0NCglmb250LXN0eWxlOml0YWxpYzt9DQ0Kc3Bhbi5EcmFmdGluZ05vdGVzQWdlbmN5Q2hhcg0NCgl7bXNvLXN0eWxlLW5hbWU6IkRyYWZ0aW5nIE5vdGVzIFwoQWdlbmN5XCkgQ2hhciI7DQ0KCW1zby1zdHlsZS1saW5rOiJEcmFmdGluZyBOb3RlcyBcKEFnZW5jeVwpIjsNDQoJZm9udC1mYW1pbHk6IkNvdXJpZXIgTmV3IjsNDQoJY29sb3I6IzMzOTk2NjsNDQoJZm9udC1zdHlsZTppdGFsaWM7fQ0NCnAuTm9ybWFsQWdlbmN5LCBsaS5Ob3JtYWxBZ2VuY3ksIGRpdi5Ob3JtYWxBZ2VuY3kNDQoJe21zby1zdHlsZS1uYW1lOiJOb3JtYWwgXChBZ2VuY3lcKSI7DQ0KCW1zby1zdHlsZS1saW5rOiJOb3JtYWwgXChBZ2VuY3lcKSBDaGFyIjsNDQoJbWFyZ2luOjBpbjsNDQoJZm9udC1zaXplOjkuMHB0Ow0NCglmb250LWZhbWlseToiVmVyZGFuYSIsc2Fucy1zZXJpZjt9DQ0KcC5UYWJsZWhlYWRpbmdyb3dzQWdlbmN5LCBsaS5UYWJsZWhlYWRpbmdyb3dzQWdlbmN5LCBkaXYuVGFibGVoZWFkaW5ncm93c0FnZW5jeQ0NCgl7bXNvLXN0eWxlLW5hbWU6IlRhYmxlIGhlYWRpbmcgcm93cyBcKEFnZW5jeVwpIjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206Ny4wcHQ7DQ0KCW1hcmdpbi1sZWZ0OjBpbjsNDQoJbGluZS1oZWlnaHQ6MTQuMHB0Ow0NCglwYWdlLWJyZWFrLWFmdGVyOmF2b2lkOw0NCglmb250LXNpemU6OS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJWZXJkYW5hIixzYW5zLXNlcmlmOw0NCglmb250LXdlaWdodDpib2xkO30NDQpwLlRhYmxldGV4dHJvd3NBZ2VuY3ksIGxpLlRhYmxldGV4dHJvd3NBZ2VuY3ksIGRpdi5UYWJsZXRleHRyb3dzQWdlbmN5DQ0KCXttc28tc3R5bGUtbmFtZToiVGFibGUgdGV4dCByb3dzIFwoQWdlbmN5XCkiOw0NCgltYXJnaW46MGluOw0NCglsaW5lLWhlaWdodDoxNC4wcHQ7DQ0KCWZvbnQtc2l6ZTo5LjBwdDsNDQoJZm9udC1mYW1pbHk6IlZlcmRhbmEiLHNhbnMtc2VyaWY7fQ0NCnNwYW4uTm9ybWFsQWdlbmN5Q2hhcg0NCgl7bXNvLXN0eWxlLW5hbWU6Ik5vcm1hbCBcKEFnZW5jeVwpIENoYXIiOw0NCgltc28tc3R5bGUtbGluazoiTm9ybWFsIFwoQWdlbmN5XCkiOw0NCglmb250LWZhbWlseToiVmVyZGFuYSIsc2Fucy1zZXJpZjt9DQ0Kc3Bhbi5SZWZkZWNvbWVudGFyaW8NDQoJe21zby1zdHlsZS1uYW1lOiJSZWZcLiBkZSBjb21lbnRhcmlvIjt9DQ0KcC5Bc3VudG9kZWxjb21lbnRhcmlvLCBsaS5Bc3VudG9kZWxjb21lbnRhcmlvLCBkaXYuQXN1bnRvZGVsY29tZW50YXJpbw0NCgl7bXNvLXN0eWxlLW5hbWU6IkFzdW50byBkZWwgY29tZW50YXJpbyI7DQ0KCW1zby1zdHlsZS1saW5rOiJBc3VudG8gZGVsIGNvbWVudGFyaW8gQ2FyIjsNDQoJbWFyZ2luOjBpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTAuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjsNDQoJZm9udC13ZWlnaHQ6Ym9sZDt9DQ0Kc3Bhbi5UZXh0b2NvbWVudGFyaW9DYXINDQoJe21zby1zdHlsZS1uYW1lOiJUZXh0byBjb21lbnRhcmlvIENhclwsIENhcjE3IENhciBDYXIgQ2FyXCwgQ2FyMTcgQ2FyIENhcjFcLCBDYXIxNyBDYXIxXCwgQ2hhcjEzIENhciBDYXIgQ2FyXCwgQ2hhcjEzIENhciBDYXIxXCwgQ2hhcjEzIENhcjFcLENhcjE3IENhciBDYXIgQ2FyXCxDYXIxNyBDYXIgQ2FyMVwsQ2FyMTcgQ2FyMVwsQ2hhcjEzIENhciBDYXIgQ2FyXCxDaGFyMTMgQ2FyIENhcjFcLENoYXIxMyBDYXIxIjsNDQoJbXNvLXN0eWxlLWxpbms6IlRleHRvIGNvbWVudGFyaW9cLCBDYXIxN1wsIENhcjE3IENhclwsIENhcjE3IENhciBDYXJcLCBDaGFyMTNcLCBDaGFyMTMgQ2FyXCwgQ2hhcjEzIENhciBDYXJcLENhcjE3XCxDYXIxNyBDYXJcLENhcjE3IENhciBDYXJcLENoYXIxM1wsQ2hhcjEzIENhclwsQ2hhcjEzIENhciBDYXIiOw0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0Kc3Bhbi5Bc3VudG9kZWxjb21lbnRhcmlvQ2FyDQ0KCXttc28tc3R5bGUtbmFtZToiQXN1bnRvIGRlbCBjb21lbnRhcmlvIENhciI7DQ0KCW1zby1zdHlsZS1saW5rOiJBc3VudG8gZGVsIGNvbWVudGFyaW8iOw0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjsNDQoJZm9udC13ZWlnaHQ6Ym9sZDt9DQ0KcC5SZXZpc2luLCBsaS5SZXZpc2luLCBkaXYuUmV2aXNpbg0NCgl7bXNvLXN0eWxlLW5hbWU6UmV2aXNp8247DQ0KCW1hcmdpbjowaW47DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkRlZmF1bHQsIGxpLkRlZmF1bHQsIGRpdi5EZWZhdWx0DQ0KCXttc28tc3R5bGUtbmFtZTpEZWZhdWx0Ow0NCgltYXJnaW46MGluOw0NCgl0ZXh0LWF1dG9zcGFjZTpub25lOw0NCglmb250LXNpemU6MTIuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjsNDQoJY29sb3I6YmxhY2s7fQ0NCnNwYW4uVHR1bG8xQ2FyDQ0KCXttc28tc3R5bGUtbmFtZToiVO10dWxvIDEgQ2FyIjsNDQoJbXNvLXN0eWxlLWxpbms6IlTtdHVsbyAxIjsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7DQ0KCXRleHQtdHJhbnNmb3JtOnVwcGVyY2FzZTsNDQoJZm9udC13ZWlnaHQ6Ym9sZDt9DQ0Kc3Bhbi5UdHVsbzJDYXINDQoJe21zby1zdHlsZS1uYW1lOiJU7XR1bG8gMiBDYXIiOw0NCgltc28tc3R5bGUtbGluazoiVO10dWxvIDIiOw0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjsNDQoJZm9udC13ZWlnaHQ6Ym9sZDt9DQ0Kc3Bhbi5UdHVsbzNDYXINDQoJe21zby1zdHlsZS1uYW1lOiJU7XR1bG8gMyBDYXIiOw0NCgltc28tc3R5bGUtbGluazoiVO10dWxvIDMiOw0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjsNDQoJZm9udC13ZWlnaHQ6Ym9sZDt9DQ0Kc3Bhbi5UdHVsbzRDYXINDQoJe21zby1zdHlsZS1uYW1lOiJU7XR1bG8gNCBDYXIiOw0NCgltc28tc3R5bGUtbGluazoiVO10dWxvIDQiOw0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjsNDQoJZm9udC13ZWlnaHQ6Ym9sZDt9DQ0Kc3Bhbi5UdHVsbzVDYXINDQoJe21zby1zdHlsZS1uYW1lOiJU7XR1bG8gNSBDYXIiOw0NCgltc28tc3R5bGUtbGluazoiVO10dWxvIDUiOw0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjsNDQoJZm9udC13ZWlnaHQ6Ym9sZDt9DQ0Kc3Bhbi5UdHVsbzZDYXINDQoJe21zby1zdHlsZS1uYW1lOiJU7XR1bG8gNiBDYXIiOw0NCgltc28tc3R5bGUtbGluazoiVO10dWxvIDYiOw0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjsNDQoJZm9udC13ZWlnaHQ6Ym9sZDt9DQ0Kc3Bhbi5UdHVsbzdDYXINDQoJe21zby1zdHlsZS1uYW1lOiJU7XR1bG8gNyBDYXIiOw0NCgltc28tc3R5bGUtbGluazoiVO10dWxvIDciOw0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0Kc3Bhbi5UdHVsbzhDYXINDQoJe21zby1zdHlsZS1uYW1lOiJU7XR1bG8gOCBDYXIiOw0NCgltc28tc3R5bGUtbGluazoiVO10dWxvIDgiOw0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5UYWJsZSwgbGkuVGFibGUsIGRpdi5UYWJsZQ0NCgl7bXNvLXN0eWxlLW5hbWU6VGFibGU7DQ0KCW1hcmdpbi10b3A6Ni4wcHQ7DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206Ni4wcHQ7DQ0KCW1hcmdpbi1sZWZ0OjE0MS44cHQ7DQ0KCXRleHQtaW5kZW50Oi01Ni43cHQ7DQ0KCXBhZ2UtYnJlYWstYWZ0ZXI6YXZvaWQ7DQ0KCWZvbnQtc2l6ZToxMi4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmOw0NCglmb250LXdlaWdodDpib2xkO30NDQpwLkRlc2NyaXBjaW4sIGxpLkRlc2NyaXBjaW4sIGRpdi5EZXNjcmlwY2luDQ0KCXttc28tc3R5bGUtbmFtZToiRGVzY3JpcGNp825cLENhcHRpb24gMTJwdFwsQ2FwdGlvbiAxMnB0K1wsQ2FwdGlvbi1GVVNBXCxjYXB0aW9uXCxmaWd1cmUiOw0NCgltYXJnaW4tdG9wOjYuMHB0Ow0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjYuMHB0Ow0NCgltYXJnaW4tbGVmdDowaW47DQ0KCXRleHQtYWxpZ246Y2VudGVyOw0NCglwYWdlLWJyZWFrLWFmdGVyOmF2b2lkOw0NCglmb250LXNpemU6MTAuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjsNDQoJZm9udC13ZWlnaHQ6Ym9sZDt9DQ0KcC5UV05vcm1hbCwgbGkuVFdOb3JtYWwsIGRpdi5UV05vcm1hbA0NCgl7bXNvLXN0eWxlLW5hbWU6IlRXIE5vcm1hbCI7DQ0KCW1hcmdpbi10b3A6MTIuMHB0Ow0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6MGluOw0NCglmb250LXNpemU6MTIuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjsNDQoJY29sb3I6YmxhY2s7fQ0NCnAuUHJyYWZvZGVsaXN0YSwgbGkuUHJyYWZvZGVsaXN0YSwgZGl2LlBycmFmb2RlbGlzdGENDQoJe21zby1zdHlsZS1uYW1lOiJQ4XJyYWZvIGRlIGxpc3RhIjsNDQoJbWFyZ2luLXRvcDo2LjBwdDsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTo2LjBwdDsNDQoJbWFyZ2luLWxlZnQ6LjVpbjsNDQoJZm9udC1zaXplOjEyLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuUHJyYWZvZGVsaXN0YUN4U3BGaXJzdCwgbGkuUHJyYWZvZGVsaXN0YUN4U3BGaXJzdCwgZGl2LlBycmFmb2RlbGlzdGFDeFNwRmlyc3QNDQoJe21zby1zdHlsZS1uYW1lOiJQ4XJyYWZvIGRlIGxpc3RhQ3hTcEZpcnN0IjsNDQoJbWFyZ2luLXRvcDo2LjBwdDsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0Oi41aW47DQ0KCWZvbnQtc2l6ZToxMi4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLlBycmFmb2RlbGlzdGFDeFNwTWlkZGxlLCBsaS5QcnJhZm9kZWxpc3RhQ3hTcE1pZGRsZSwgZGl2LlBycmFmb2RlbGlzdGFDeFNwTWlkZGxlDQ0KCXttc28tc3R5bGUtbmFtZToiUOFycmFmbyBkZSBsaXN0YUN4U3BNaWRkbGUiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0Oi41aW47DQ0KCWZvbnQtc2l6ZToxMi4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLlBycmFmb2RlbGlzdGFDeFNwTGFzdCwgbGkuUHJyYWZvZGVsaXN0YUN4U3BMYXN0LCBkaXYuUHJyYWZvZGVsaXN0YUN4U3BMYXN0DQ0KCXttc28tc3R5bGUtbmFtZToiUOFycmFmbyBkZSBsaXN0YUN4U3BMYXN0IjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206Ni4wcHQ7DQ0KCW1hcmdpbi1sZWZ0Oi41aW47DQ0KCWZvbnQtc2l6ZToxMi4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLlRleHRvbm90YXBpZSwgbGkuVGV4dG9ub3RhcGllLCBkaXYuVGV4dG9ub3RhcGllDQ0KCXttc28tc3R5bGUtbmFtZToiVGV4dG8gbm90YSBwaWUiOw0NCgltc28tc3R5bGUtbGluazoiVGV4dG8gbm90YSBwaWUgQ2FyIjsNDQoJbWFyZ2luOjBpbjsNDQoJZm9udC1zaXplOjEwLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnNwYW4uVGV4dG9ub3RhcGllQ2FyDQ0KCXttc28tc3R5bGUtbmFtZToiVGV4dG8gbm90YSBwaWUgQ2FyIjsNDQoJbXNvLXN0eWxlLWxpbms6IlRleHRvIG5vdGEgcGllIjsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuVGFibGVGb290bm90ZSwgbGkuVGFibGVGb290bm90ZSwgZGl2LlRhYmxlRm9vdG5vdGUNDQoJe21zby1zdHlsZS1uYW1lOiJUYWJsZSBGb290bm90ZSI7DQ0KCW1hcmdpbjowaW47DQ0KCWZvbnQtc2l6ZTo4LjBwdDsNDQoJZm9udC1mYW1pbHk6IkFyaWFsIixzYW5zLXNlcmlmO30NDQpzcGFuLkVuY2FiZXphZG9DYXINDQoJe21zby1zdHlsZS1uYW1lOiJFbmNhYmV6YWRvIENhciI7DQ0KCW1zby1zdHlsZS1saW5rOkVuY2FiZXphZG87DQ0KCWZvbnQtZmFtaWx5OiJBcmlhbCIsc2Fucy1zZXJpZjt9DQ0Kc3Bhbi5IaXBlcnZuY3Vsb3Zpc2l0YWRvDQ0KCXttc28tc3R5bGUtbmFtZToiSGlwZXJ27W5jdWxvIHZpc2l0YWRvIjsNDQoJY29sb3I6cHVycGxlOw0NCgl0ZXh0LWRlY29yYXRpb246dW5kZXJsaW5lO30NDQpwLlRhYmxlVGV4dCwgbGkuVGFibGVUZXh0LCBkaXYuVGFibGVUZXh0DQ0KCXttc28tc3R5bGUtbmFtZToiVGFibGUgVGV4dCI7DQ0KCW1zby1zdHlsZS1saW5rOiJUYWJsZSBUZXh0IENoYXIiOw0NCgltYXJnaW4tdG9wOjYuMHB0Ow0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjYuMHB0Ow0NCgltYXJnaW4tbGVmdDowaW47DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJWZXJkYW5hIixzYW5zLXNlcmlmO30NDQpwLlRhYmxlVGl0bGUsIGxpLlRhYmxlVGl0bGUsIGRpdi5UYWJsZVRpdGxlDQ0KCXttc28tc3R5bGUtbmFtZToiVGFibGUgVGl0bGUiOw0NCgltc28tc3R5bGUtbGluazoiVGFibGUgVGl0bGUgQ2hhciI7DQ0KCW1hcmdpbi10b3A6MTIuMHB0Ow0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjYuMHB0Ow0NCgltYXJnaW4tbGVmdDowaW47DQ0KCXRleHQtYWxpZ246anVzdGlmeTsNDQoJdGV4dC1qdXN0aWZ5OmludGVyLWlkZW9ncmFwaDsNDQoJcGFnZS1icmVhay1hZnRlcjphdm9pZDsNDQoJZm9udC1zaXplOjEyLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7DQ0KCWZvbnQtd2VpZ2h0OmJvbGQ7fQ0NCnNwYW4uVGFibGVUZXh0Q2hhcg0NCgl7bXNvLXN0eWxlLW5hbWU6IlRhYmxlIFRleHQgQ2hhciI7DQ0KCW1zby1zdHlsZS1saW5rOiJUYWJsZSBUZXh0IjsNDQoJZm9udC1mYW1pbHk6IlZlcmRhbmEiLHNhbnMtc2VyaWY7fQ0NCnNwYW4uVGFibGVUaXRsZUNoYXINDQoJe21zby1zdHlsZS1uYW1lOiJUYWJsZSBUaXRsZSBDaGFyIjsNDQoJbXNvLXN0eWxlLWxpbms6IlRhYmxlIFRpdGxlIjsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7DQ0KCWZvbnQtd2VpZ2h0OmJvbGQ7fQ0NCnNwYW4uUGllZGVwZ2luYUNhcg0NCgl7bXNvLXN0eWxlLW5hbWU6IlBpZSBkZSBw4WdpbmEgQ2FyIjsNDQoJbXNvLXN0eWxlLWxpbms6IlBpZSBkZSBw4WdpbmEiOw0NCglmb250LWZhbWlseToiQXJpYWwiLHNhbnMtc2VyaWY7fQ0NCnAuQm9keSwgbGkuQm9keSwgZGl2LkJvZHkNDQoJe21zby1zdHlsZS1uYW1lOkJvZHk7DQ0KCW1zby1zdHlsZS1saW5rOiJCb2R5IENhciI7DQ0KCW1hcmdpbi10b3A6My4wcHQ7DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206My4wcHQ7DQ0KCW1hcmdpbi1sZWZ0OjBpbjsNDQoJdGV4dC1hbGlnbjpqdXN0aWZ5Ow0NCgl0ZXh0LWp1c3RpZnk6aW50ZXItaWRlb2dyYXBoOw0NCglmb250LXNpemU6MTIuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0Kc3Bhbi5Cb2R5Q2FyDQ0KCXttc28tc3R5bGUtbmFtZToiQm9keSBDYXIiOw0NCgltc28tc3R5bGUtbGluazpCb2R5Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5RUkRCb29rbWFyaywgbGkuUVJEQm9va21hcmssIGRpdi5RUkRCb29rbWFyaw0NCgl7bXNvLXN0eWxlLW5hbWU6IlFSRCBCb29rbWFyayI7DQ0KCW1hcmdpbjowaW47DQ0KCXRleHQtYWxpZ246Y2VudGVyOw0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjsNDQoJdGV4dC10cmFuc2Zvcm06dXBwZXJjYXNlOw0NCglmb250LXdlaWdodDpib2xkO30NDQpwLk5vLW51bWhlYWRpbmc0QWdlbmN5LCBsaS5Oby1udW1oZWFkaW5nNEFnZW5jeSwgZGl2Lk5vLW51bWhlYWRpbmc0QWdlbmN5DQ0KCXttc28tc3R5bGUtbmFtZToiTm8tbnVtIGhlYWRpbmcgNCBcKEFnZW5jeVwpIjsNDQoJbWFyZ2luLXRvcDoxNC4wcHQ7DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MTEuMHB0Ow0NCgltYXJnaW4tbGVmdDowaW47DQ0KCXBhZ2UtYnJlYWstYWZ0ZXI6YXZvaWQ7DQ0KCWZvbnQtc2l6ZTo5LjBwdDsNDQoJZm9udC1mYW1pbHk6IlZlcmRhbmEiLHNhbnMtc2VyaWY7DQ0KCWZvbnQtd2VpZ2h0OmJvbGQ7DQ0KCWZvbnQtc3R5bGU6aXRhbGljO30NDQpzcGFuLlRleHRvZW5uZWdyaXRhDQ0KCXttc28tc3R5bGUtbmFtZToiVGV4dG8gZW4gbmVncml0YSI7DQ0KCWZvbnQtd2VpZ2h0OmJvbGQ7fQ0NCnAuTGlzdGFjb252aWV0YXMsIGxpLkxpc3RhY29udmlldGFzLCBkaXYuTGlzdGFjb252aWV0YXMNDQoJe21zby1zdHlsZS1uYW1lOiJMaXN0YSBjb24gdmnxZXRhcyI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjEwLjBwdDsNDQoJbWFyZ2luLWxlZnQ6LjI1aW47DQ0KCXRleHQtaW5kZW50Oi0uMjVpbjsNDQoJbGluZS1oZWlnaHQ6MTE1JTsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IkNhbGlicmkiLHNhbnMtc2VyaWY7fQ0NCnAuQm9keXRleHRFTUEsIGxpLkJvZHl0ZXh0RU1BLCBkaXYuQm9keXRleHRFTUENDQoJe21zby1zdHlsZS1uYW1lOiJCb2R5IHRleHQgXChFTUFcKSI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjcuMHB0Ow0NCgltYXJnaW4tbGVmdDowaW47DQ0KCWxpbmUtaGVpZ2h0OjE0LjBwdDsNDQoJZm9udC1zaXplOjkuMHB0Ow0NCglmb250LWZhbWlseToiVmVyZGFuYSIsc2Fucy1zZXJpZjt9DQ0KcC5UaXR0bGVFTUExLCBsaS5UaXR0bGVFTUExLCBkaXYuVGl0dGxlRU1BMQ0NCgl7bXNvLXN0eWxlLW5hbWU6IlRpdHRsZSBFTUExIjsNDQoJbWFyZ2luOjBpbjsNDQoJdGV4dC1hbGlnbjpjZW50ZXI7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmOw0NCgl0ZXh0LXRyYW5zZm9ybTp1cHBlcmNhc2U7DQ0KCWZvbnQtd2VpZ2h0OmJvbGQ7fQ0NCnAuVGl0dGxlRU1BMiwgbGkuVGl0dGxlRU1BMiwgZGl2LlRpdHRsZUVNQTINDQoJe21zby1zdHlsZS1uYW1lOiJUaXR0bGUgRU1BMiI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6Ni4wcHQ7DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDoyOC4zNXB0Ow0NCgl0ZXh0LWluZGVudDotMjguMzVwdDsNDQoJcGFnZS1icmVhay1hZnRlcjphdm9pZDsNDQoJdGV4dC1hdXRvc3BhY2U6bm9uZTsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7DQ0KCWNvbG9yOmJsYWNrOw0NCglmb250LXdlaWdodDpib2xkO30NDQpwLkJpYmxpb2dyYWZhLCBsaS5CaWJsaW9ncmFmYSwgZGl2LkJpYmxpb2dyYWZhDQ0KCXttc28tc3R5bGUtbmFtZTpCaWJsaW9ncmFm7WE7DQ0KCW1hcmdpbjowaW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuVGV4dG9kZWJsb3F1ZSwgbGkuVGV4dG9kZWJsb3F1ZSwgZGl2LlRleHRvZGVibG9xdWUNDQoJe21zby1zdHlsZS1uYW1lOiJUZXh0byBkZSBibG9xdWUiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjEuMGluOw0NCgltYXJnaW4tYm90dG9tOjYuMHB0Ow0NCgltYXJnaW4tbGVmdDoxLjBpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5UZXh0b2luZGVwZW5kaWVudGUyLCBsaS5UZXh0b2luZGVwZW5kaWVudGUyLCBkaXYuVGV4dG9pbmRlcGVuZGllbnRlMg0NCgl7bXNvLXN0eWxlLW5hbWU6IlRleHRvIGluZGVwZW5kaWVudGUgMiI7DQ0KCW1zby1zdHlsZS1saW5rOiJUZXh0byBpbmRlcGVuZGllbnRlIDIgQ2FyIjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206Ni4wcHQ7DQ0KCW1hcmdpbi1sZWZ0OjBpbjsNDQoJbGluZS1oZWlnaHQ6MjAwJTsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnNwYW4uVGV4dG9pbmRlcGVuZGllbnRlMkNhcg0NCgl7bXNvLXN0eWxlLW5hbWU6IlRleHRvIGluZGVwZW5kaWVudGUgMiBDYXIiOw0NCgltc28tc3R5bGUtbGluazoiVGV4dG8gaW5kZXBlbmRpZW50ZSAyIjsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuVGV4dG9pbmRlcGVuZGllbnRlMywgbGkuVGV4dG9pbmRlcGVuZGllbnRlMywgZGl2LlRleHRvaW5kZXBlbmRpZW50ZTMNDQoJe21zby1zdHlsZS1uYW1lOiJUZXh0byBpbmRlcGVuZGllbnRlIDMiOw0NCgltc28tc3R5bGUtbGluazoiVGV4dG8gaW5kZXBlbmRpZW50ZSAzIENhciI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjYuMHB0Ow0NCgltYXJnaW4tbGVmdDowaW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjguMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0Kc3Bhbi5UZXh0b2luZGVwZW5kaWVudGUzQ2FyDQ0KCXttc28tc3R5bGUtbmFtZToiVGV4dG8gaW5kZXBlbmRpZW50ZSAzIENhciI7DQ0KCW1zby1zdHlsZS1saW5rOiJUZXh0byBpbmRlcGVuZGllbnRlIDMiOw0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5UZXh0b2luZGVwZW5kaWVudGVwcmltZXJhc2FuZ3JhLCBsaS5UZXh0b2luZGVwZW5kaWVudGVwcmltZXJhc2FuZ3JhLCBkaXYuVGV4dG9pbmRlcGVuZGllbnRlcHJpbWVyYXNhbmdyYQ0NCgl7bXNvLXN0eWxlLW5hbWU6IlRleHRvIGluZGVwZW5kaWVudGUgcHJpbWVyYSBzYW5ncu1hIjsNDQoJbXNvLXN0eWxlLWxpbms6IlRleHRvIGluZGVwZW5kaWVudGUgcHJpbWVyYSBzYW5ncu1hIENhciI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjYuMHB0Ow0NCgltYXJnaW4tbGVmdDowaW47DQ0KCXRleHQtaW5kZW50OjEwLjVwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjsNDQoJY29sb3I6Z3JlZW47fQ0NCnNwYW4uVGV4dG9pbmRlcGVuZGllbnRlQ2FyDQ0KCXttc28tc3R5bGUtbmFtZToiVGV4dG8gaW5kZXBlbmRpZW50ZSBDYXIiOw0NCgltc28tc3R5bGUtbGluazoiVGV4dG8gaW5kZXBlbmRpZW50ZSI7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmOw0NCgljb2xvcjpncmVlbjsNDQoJZm9udC1zdHlsZTppdGFsaWM7fQ0NCnNwYW4uVGV4dG9pbmRlcGVuZGllbnRlcHJpbWVyYXNhbmdyYUNhcg0NCgl7bXNvLXN0eWxlLW5hbWU6IlRleHRvIGluZGVwZW5kaWVudGUgcHJpbWVyYSBzYW5ncu1hIENhciI7DQ0KCW1zby1zdHlsZS1saW5rOiJUZXh0byBpbmRlcGVuZGllbnRlIHByaW1lcmEgc2FuZ3LtYSI7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmOw0NCgljb2xvcjpncmVlbjsNDQoJZm9udC1zdHlsZTpub3JtYWw7fQ0NCnAuU2FuZ3JhZGV0ZXh0b25vcm1hbCwgbGkuU2FuZ3JhZGV0ZXh0b25vcm1hbCwgZGl2LlNhbmdyYWRldGV4dG9ub3JtYWwNDQoJe21zby1zdHlsZS1uYW1lOiJTYW5ncu1hIGRlIHRleHRvIG5vcm1hbCI7DQ0KCW1zby1zdHlsZS1saW5rOiJTYW5ncu1hIGRlIHRleHRvIG5vcm1hbCBDYXIiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTo2LjBwdDsNDQoJbWFyZ2luLWxlZnQ6MTQuMTVwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0Kc3Bhbi5TYW5ncmFkZXRleHRvbm9ybWFsQ2FyDQ0KCXttc28tc3R5bGUtbmFtZToiU2FuZ3LtYSBkZSB0ZXh0byBub3JtYWwgQ2FyIjsNDQoJbXNvLXN0eWxlLWxpbms6IlNhbmdy7WEgZGUgdGV4dG8gbm9ybWFsIjsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuVGV4dG9pbmRlcGVuZGllbnRlcHJpbWVyYXNhbmdyYTIsIGxpLlRleHRvaW5kZXBlbmRpZW50ZXByaW1lcmFzYW5ncmEyLCBkaXYuVGV4dG9pbmRlcGVuZGllbnRlcHJpbWVyYXNhbmdyYTINDQoJe21zby1zdHlsZS1uYW1lOiJUZXh0byBpbmRlcGVuZGllbnRlIHByaW1lcmEgc2FuZ3LtYSAyIjsNDQoJbXNvLXN0eWxlLWxpbms6IlRleHRvIGluZGVwZW5kaWVudGUgcHJpbWVyYSBzYW5ncu1hIDIgQ2FyIjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206Ni4wcHQ7DQ0KCW1hcmdpbi1sZWZ0OjE0LjE1cHQ7DQ0KCXRleHQtaW5kZW50OjEwLjVwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0Kc3Bhbi5UZXh0b2luZGVwZW5kaWVudGVwcmltZXJhc2FuZ3JhMkNhcg0NCgl7bXNvLXN0eWxlLW5hbWU6IlRleHRvIGluZGVwZW5kaWVudGUgcHJpbWVyYSBzYW5ncu1hIDIgQ2FyIjsNDQoJbXNvLXN0eWxlLWxpbms6IlRleHRvIGluZGVwZW5kaWVudGUgcHJpbWVyYSBzYW5ncu1hIDIiOw0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5TYW5ncmEyZGV0aW5kZXBlbmRpZW50ZSwgbGkuU2FuZ3JhMmRldGluZGVwZW5kaWVudGUsIGRpdi5TYW5ncmEyZGV0aW5kZXBlbmRpZW50ZQ0NCgl7bXNvLXN0eWxlLW5hbWU6IlNhbmdy7WEgMiBkZSB0XC4gaW5kZXBlbmRpZW50ZSI7DQ0KCW1zby1zdHlsZS1saW5rOiJTYW5ncu1hIDIgZGUgdFwuIGluZGVwZW5kaWVudGUgQ2FyIjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206Ni4wcHQ7DQ0KCW1hcmdpbi1sZWZ0OjE0LjE1cHQ7DQ0KCWxpbmUtaGVpZ2h0OjIwMCU7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpzcGFuLlNhbmdyYTJkZXRpbmRlcGVuZGllbnRlQ2FyDQ0KCXttc28tc3R5bGUtbmFtZToiU2FuZ3LtYSAyIGRlIHRcLiBpbmRlcGVuZGllbnRlIENhciI7DQ0KCW1zby1zdHlsZS1saW5rOiJTYW5ncu1hIDIgZGUgdFwuIGluZGVwZW5kaWVudGUiOw0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5TYW5ncmEzZGV0aW5kZXBlbmRpZW50ZSwgbGkuU2FuZ3JhM2RldGluZGVwZW5kaWVudGUsIGRpdi5TYW5ncmEzZGV0aW5kZXBlbmRpZW50ZQ0NCgl7bXNvLXN0eWxlLW5hbWU6IlNhbmdy7WEgMyBkZSB0XC4gaW5kZXBlbmRpZW50ZSI7DQ0KCW1zby1zdHlsZS1saW5rOiJTYW5ncu1hIDMgZGUgdFwuIGluZGVwZW5kaWVudGUgQ2FyIjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206Ni4wcHQ7DQ0KCW1hcmdpbi1sZWZ0OjE0LjE1cHQ7DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjguMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0Kc3Bhbi5TYW5ncmEzZGV0aW5kZXBlbmRpZW50ZUNhcg0NCgl7bXNvLXN0eWxlLW5hbWU6IlNhbmdy7WEgMyBkZSB0XC4gaW5kZXBlbmRpZW50ZSBDYXIiOw0NCgltc28tc3R5bGUtbGluazoiU2FuZ3LtYSAzIGRlIHRcLiBpbmRlcGVuZGllbnRlIjsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuQ2llcnJlLCBsaS5DaWVycmUsIGRpdi5DaWVycmUNDQoJe21zby1zdHlsZS1uYW1lOkNpZXJyZTsNDQoJbXNvLXN0eWxlLWxpbms6IkNpZXJyZSBDYXIiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjIxMi42cHQ7DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnNwYW4uQ2llcnJlQ2FyDQ0KCXttc28tc3R5bGUtbmFtZToiQ2llcnJlIENhciI7DQ0KCW1zby1zdHlsZS1saW5rOkNpZXJyZTsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuRmVjaGEsIGxpLkZlY2hhLCBkaXYuRmVjaGENDQoJe21zby1zdHlsZS1uYW1lOkZlY2hhOw0NCgltc28tc3R5bGUtbGluazoiRmVjaGEgQ2FyIjsNDQoJbWFyZ2luOjBpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0Kc3Bhbi5GZWNoYUNhcg0NCgl7bXNvLXN0eWxlLW5hbWU6IkZlY2hhIENhciI7DQ0KCW1zby1zdHlsZS1saW5rOkZlY2hhOw0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5NYXBhZGVsZG9jdW1lbnRvLCBsaS5NYXBhZGVsZG9jdW1lbnRvLCBkaXYuTWFwYWRlbGRvY3VtZW50bw0NCgl7bXNvLXN0eWxlLW5hbWU6Ik1hcGEgZGVsIGRvY3VtZW50byI7DQ0KCW1zby1zdHlsZS1saW5rOiJNYXBhIGRlbCBkb2N1bWVudG8gQ2FyIjsNDQoJbWFyZ2luOjBpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6OC4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJTZWdvZSBVSSIsc2Fucy1zZXJpZjt9DQ0Kc3Bhbi5NYXBhZGVsZG9jdW1lbnRvQ2FyDQ0KCXttc28tc3R5bGUtbmFtZToiTWFwYSBkZWwgZG9jdW1lbnRvIENhciI7DQ0KCW1zby1zdHlsZS1saW5rOiJNYXBhIGRlbCBkb2N1bWVudG8iOw0NCglmb250LWZhbWlseToiU2Vnb2UgVUkiLHNhbnMtc2VyaWY7fQ0NCnAuRmlybWFkZWNvcnJlb2VsZWN0cm5pY28sIGxpLkZpcm1hZGVjb3JyZW9lbGVjdHJuaWNvLCBkaXYuRmlybWFkZWNvcnJlb2VsZWN0cm5pY28NDQoJe21zby1zdHlsZS1uYW1lOiJGaXJtYSBkZSBjb3JyZW8gZWxlY3Ry825pY28iOw0NCgltc28tc3R5bGUtbGluazoiRmlybWEgZGUgY29ycmVvIGVsZWN0cvNuaWNvIENhciI7DQ0KCW1hcmdpbjowaW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnNwYW4uRmlybWFkZWNvcnJlb2VsZWN0cm5pY29DYXINDQoJe21zby1zdHlsZS1uYW1lOiJGaXJtYSBkZSBjb3JyZW8gZWxlY3Ry825pY28gQ2FyIjsNDQoJbXNvLXN0eWxlLWxpbms6IkZpcm1hIGRlIGNvcnJlbyBlbGVjdHLzbmljbyI7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLlRleHRvbm90YWFsZmluYWwsIGxpLlRleHRvbm90YWFsZmluYWwsIGRpdi5UZXh0b25vdGFhbGZpbmFsDQ0KCXttc28tc3R5bGUtbmFtZToiVGV4dG8gbm90YSBhbCBmaW5hbCI7DQ0KCW1zby1zdHlsZS1saW5rOiJUZXh0byBub3RhIGFsIGZpbmFsIENhciI7DQ0KCW1hcmdpbjowaW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjEwLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnNwYW4uVGV4dG9ub3RhYWxmaW5hbENhcg0NCgl7bXNvLXN0eWxlLW5hbWU6IlRleHRvIG5vdGEgYWwgZmluYWwgQ2FyIjsNDQoJbXNvLXN0eWxlLWxpbms6IlRleHRvIG5vdGEgYWwgZmluYWwiOw0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5EaXJlY2NpbnNvYnJlLCBsaS5EaXJlY2NpbnNvYnJlLCBkaXYuRGlyZWNjaW5zb2JyZQ0NCgl7bXNvLXN0eWxlLW5hbWU6IkRpcmVjY2nzbiBzb2JyZSI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6Mi4waW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjEyLjBwdDsNDQoJZm9udC1mYW1pbHk6IkNhbGlicmkgTGlnaHQiLHNhbnMtc2VyaWY7fQ0NCnAuUmVtaXRlZGVzb2JyZSwgbGkuUmVtaXRlZGVzb2JyZSwgZGl2LlJlbWl0ZWRlc29icmUNDQoJe21zby1zdHlsZS1uYW1lOiJSZW1pdGUgZGUgc29icmUiOw0NCgltYXJnaW46MGluOw0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMC4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJDYWxpYnJpIExpZ2h0IixzYW5zLXNlcmlmO30NDQpzcGFuLlR0dWxvOUNhcg0NCgl7bXNvLXN0eWxlLW5hbWU6IlTtdHVsbyA5IENhciI7DQ0KCW1zby1zdHlsZS1saW5rOiJU7XR1bG8gOSI7DQ0KCWZvbnQtZmFtaWx5OiJDYWxpYnJpIExpZ2h0IixzYW5zLXNlcmlmO30NDQpwLkRpcmVjY2luSFRNTCwgbGkuRGlyZWNjaW5IVE1MLCBkaXYuRGlyZWNjaW5IVE1MDQ0KCXttc28tc3R5bGUtbmFtZToiRGlyZWNjafNuIEhUTUwiOw0NCgltc28tc3R5bGUtbGluazoiRGlyZWNjafNuIEhUTUwgQ2FyIjsNDQoJbWFyZ2luOjBpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjsNDQoJZm9udC1zdHlsZTppdGFsaWM7fQ0NCnNwYW4uRGlyZWNjaW5IVE1MQ2FyDQ0KCXttc28tc3R5bGUtbmFtZToiRGlyZWNjafNuIEhUTUwgQ2FyIjsNDQoJbXNvLXN0eWxlLWxpbms6IkRpcmVjY2nzbiBIVE1MIjsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7DQ0KCWZvbnQtc3R5bGU6aXRhbGljO30NDQpwLkhUTUxjb25mb3JtYXRvcHJldmlvLCBsaS5IVE1MY29uZm9ybWF0b3ByZXZpbywgZGl2LkhUTUxjb25mb3JtYXRvcHJldmlvDQ0KCXttc28tc3R5bGUtbmFtZToiSFRNTCBjb24gZm9ybWF0byBwcmV2aW8iOw0NCgltc28tc3R5bGUtbGluazoiSFRNTCBjb24gZm9ybWF0byBwcmV2aW8gQ2FyIjsNDQoJbWFyZ2luOjBpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTAuMHB0Ow0NCglmb250LWZhbWlseToiQ291cmllciBOZXciO30NDQpzcGFuLkhUTUxjb25mb3JtYXRvcHJldmlvQ2FyDQ0KCXttc28tc3R5bGUtbmFtZToiSFRNTCBjb24gZm9ybWF0byBwcmV2aW8gQ2FyIjsNDQoJbXNvLXN0eWxlLWxpbms6IkhUTUwgY29uIGZvcm1hdG8gcHJldmlvIjsNDQoJZm9udC1mYW1pbHk6IkNvdXJpZXIgTmV3Ijt9DQ0KcC5uZGljZTEsIGxpLm5kaWNlMSwgZGl2Lm5kaWNlMQ0NCgl7bXNvLXN0eWxlLW5hbWU6Is1uZGljZSAxIjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDoxMS4wcHQ7DQ0KCXRleHQtaW5kZW50Oi0xMS4wcHQ7DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAubmRpY2UyLCBsaS5uZGljZTIsIGRpdi5uZGljZTINDQoJe21zby1zdHlsZS1uYW1lOiLNbmRpY2UgMiI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6MjIuMHB0Ow0NCgl0ZXh0LWluZGVudDotMTEuMHB0Ow0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLm5kaWNlMywgbGkubmRpY2UzLCBkaXYubmRpY2UzDQ0KCXttc28tc3R5bGUtbmFtZToizW5kaWNlIDMiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjMzLjBwdDsNDQoJdGV4dC1pbmRlbnQ6LTExLjBwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5uZGljZTQsIGxpLm5kaWNlNCwgZGl2Lm5kaWNlNA0NCgl7bXNvLXN0eWxlLW5hbWU6Is1uZGljZSA0IjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDo0NC4wcHQ7DQ0KCXRleHQtaW5kZW50Oi0xMS4wcHQ7DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAubmRpY2U1LCBsaS5uZGljZTUsIGRpdi5uZGljZTUNDQoJe21zby1zdHlsZS1uYW1lOiLNbmRpY2UgNSI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6NTUuMHB0Ow0NCgl0ZXh0LWluZGVudDotMTEuMHB0Ow0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLm5kaWNlNiwgbGkubmRpY2U2LCBkaXYubmRpY2U2DQ0KCXttc28tc3R5bGUtbmFtZToizW5kaWNlIDYiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjY2LjBwdDsNDQoJdGV4dC1pbmRlbnQ6LTExLjBwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5uZGljZTcsIGxpLm5kaWNlNywgZGl2Lm5kaWNlNw0NCgl7bXNvLXN0eWxlLW5hbWU6Is1uZGljZSA3IjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDo3Ny4wcHQ7DQ0KCXRleHQtaW5kZW50Oi0xMS4wcHQ7DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAubmRpY2U4LCBsaS5uZGljZTgsIGRpdi5uZGljZTgNDQoJe21zby1zdHlsZS1uYW1lOiLNbmRpY2UgOCI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6ODguMHB0Ow0NCgl0ZXh0LWluZGVudDotMTEuMHB0Ow0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLm5kaWNlOSwgbGkubmRpY2U5LCBkaXYubmRpY2U5DQ0KCXttc28tc3R5bGUtbmFtZToizW5kaWNlIDkiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0Ojk5LjBwdDsNDQoJdGV4dC1pbmRlbnQ6LTExLjBwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5UdHVsb2RlbmRpY2UsIGxpLlR0dWxvZGVuZGljZSwgZGl2LlR0dWxvZGVuZGljZQ0NCgl7bXNvLXN0eWxlLW5hbWU6IlTtdHVsbyBkZSDtbmRpY2UiOw0NCgltYXJnaW46MGluOw0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJDYWxpYnJpIExpZ2h0IixzYW5zLXNlcmlmOw0NCglmb250LXdlaWdodDpib2xkO30NDQpwLkNpdGFkZXN0YWNhZGEsIGxpLkNpdGFkZXN0YWNhZGEsIGRpdi5DaXRhZGVzdGFjYWRhDQ0KCXttc28tc3R5bGUtbmFtZToiQ2l0YSBkZXN0YWNhZGEiOw0NCgltc28tc3R5bGUtbGluazoiQ2l0YSBkZXN0YWNhZGEgQ2FyIjsNDQoJbWFyZ2luLXRvcDouMjVpbjsNDQoJbWFyZ2luLXJpZ2h0Oi42aW47DQ0KCW1hcmdpbi1ib3R0b206LjI1aW47DQ0KCW1hcmdpbi1sZWZ0Oi42aW47DQ0KCXRleHQtYWxpZ246Y2VudGVyOw0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWJvcmRlcjpub25lOw0NCglwYWRkaW5nOjBpbjsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7DQ0KCWNvbG9yOiM1QjlCRDU7DQ0KCWZvbnQtc3R5bGU6aXRhbGljO30NDQpzcGFuLkNpdGFkZXN0YWNhZGFDYXINDQoJe21zby1zdHlsZS1uYW1lOiJDaXRhIGRlc3RhY2FkYSBDYXIiOw0NCgltc28tc3R5bGUtbGluazoiQ2l0YSBkZXN0YWNhZGEiOw0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjsNDQoJY29sb3I6IzVCOUJENTsNDQoJZm9udC1zdHlsZTppdGFsaWM7fQ0NCnAuTGlzdGEsIGxpLkxpc3RhLCBkaXYuTGlzdGENDQoJe21zby1zdHlsZS1uYW1lOkxpc3RhOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjE0LjE1cHQ7DQ0KCXRleHQtaW5kZW50Oi0xNC4xNXB0Ow0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkxpc3RhQ3hTcEZpcnN0LCBsaS5MaXN0YUN4U3BGaXJzdCwgZGl2Lkxpc3RhQ3hTcEZpcnN0DQ0KCXttc28tc3R5bGUtbmFtZTpMaXN0YUN4U3BGaXJzdDsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDoxNC4xNXB0Ow0NCgl0ZXh0LWluZGVudDotMTQuMTVwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5MaXN0YUN4U3BNaWRkbGUsIGxpLkxpc3RhQ3hTcE1pZGRsZSwgZGl2Lkxpc3RhQ3hTcE1pZGRsZQ0NCgl7bXNvLXN0eWxlLW5hbWU6TGlzdGFDeFNwTWlkZGxlOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjE0LjE1cHQ7DQ0KCXRleHQtaW5kZW50Oi0xNC4xNXB0Ow0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkxpc3RhQ3hTcExhc3QsIGxpLkxpc3RhQ3hTcExhc3QsIGRpdi5MaXN0YUN4U3BMYXN0DQ0KCXttc28tc3R5bGUtbmFtZTpMaXN0YUN4U3BMYXN0Ow0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjE0LjE1cHQ7DQ0KCXRleHQtaW5kZW50Oi0xNC4xNXB0Ow0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkxpc3RhMiwgbGkuTGlzdGEyLCBkaXYuTGlzdGEyDQ0KCXttc28tc3R5bGUtbmFtZToiTGlzdGEgMiI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6MjguM3B0Ow0NCgl0ZXh0LWluZGVudDotMTQuMTVwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5MaXN0YTJDeFNwRmlyc3QsIGxpLkxpc3RhMkN4U3BGaXJzdCwgZGl2Lkxpc3RhMkN4U3BGaXJzdA0NCgl7bXNvLXN0eWxlLW5hbWU6Ikxpc3RhIDJDeFNwRmlyc3QiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjI4LjNwdDsNDQoJdGV4dC1pbmRlbnQ6LTE0LjE1cHQ7DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuTGlzdGEyQ3hTcE1pZGRsZSwgbGkuTGlzdGEyQ3hTcE1pZGRsZSwgZGl2Lkxpc3RhMkN4U3BNaWRkbGUNDQoJe21zby1zdHlsZS1uYW1lOiJMaXN0YSAyQ3hTcE1pZGRsZSI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6MjguM3B0Ow0NCgl0ZXh0LWluZGVudDotMTQuMTVwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5MaXN0YTJDeFNwTGFzdCwgbGkuTGlzdGEyQ3hTcExhc3QsIGRpdi5MaXN0YTJDeFNwTGFzdA0NCgl7bXNvLXN0eWxlLW5hbWU6Ikxpc3RhIDJDeFNwTGFzdCI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6MjguM3B0Ow0NCgl0ZXh0LWluZGVudDotMTQuMTVwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5MaXN0YTMsIGxpLkxpc3RhMywgZGl2Lkxpc3RhMw0NCgl7bXNvLXN0eWxlLW5hbWU6Ikxpc3RhIDMiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjQyLjQ1cHQ7DQ0KCXRleHQtaW5kZW50Oi0xNC4xNXB0Ow0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkxpc3RhM0N4U3BGaXJzdCwgbGkuTGlzdGEzQ3hTcEZpcnN0LCBkaXYuTGlzdGEzQ3hTcEZpcnN0DQ0KCXttc28tc3R5bGUtbmFtZToiTGlzdGEgM0N4U3BGaXJzdCI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6NDIuNDVwdDsNDQoJdGV4dC1pbmRlbnQ6LTE0LjE1cHQ7DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuTGlzdGEzQ3hTcE1pZGRsZSwgbGkuTGlzdGEzQ3hTcE1pZGRsZSwgZGl2Lkxpc3RhM0N4U3BNaWRkbGUNDQoJe21zby1zdHlsZS1uYW1lOiJMaXN0YSAzQ3hTcE1pZGRsZSI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6NDIuNDVwdDsNDQoJdGV4dC1pbmRlbnQ6LTE0LjE1cHQ7DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuTGlzdGEzQ3hTcExhc3QsIGxpLkxpc3RhM0N4U3BMYXN0LCBkaXYuTGlzdGEzQ3hTcExhc3QNDQoJe21zby1zdHlsZS1uYW1lOiJMaXN0YSAzQ3hTcExhc3QiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjQyLjQ1cHQ7DQ0KCXRleHQtaW5kZW50Oi0xNC4xNXB0Ow0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkxpc3RhNCwgbGkuTGlzdGE0LCBkaXYuTGlzdGE0DQ0KCXttc28tc3R5bGUtbmFtZToiTGlzdGEgNCI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6NTYuNnB0Ow0NCgl0ZXh0LWluZGVudDotMTQuMTVwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5MaXN0YTRDeFNwRmlyc3QsIGxpLkxpc3RhNEN4U3BGaXJzdCwgZGl2Lkxpc3RhNEN4U3BGaXJzdA0NCgl7bXNvLXN0eWxlLW5hbWU6Ikxpc3RhIDRDeFNwRmlyc3QiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjU2LjZwdDsNDQoJdGV4dC1pbmRlbnQ6LTE0LjE1cHQ7DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuTGlzdGE0Q3hTcE1pZGRsZSwgbGkuTGlzdGE0Q3hTcE1pZGRsZSwgZGl2Lkxpc3RhNEN4U3BNaWRkbGUNDQoJe21zby1zdHlsZS1uYW1lOiJMaXN0YSA0Q3hTcE1pZGRsZSI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6NTYuNnB0Ow0NCgl0ZXh0LWluZGVudDotMTQuMTVwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5MaXN0YTRDeFNwTGFzdCwgbGkuTGlzdGE0Q3hTcExhc3QsIGRpdi5MaXN0YTRDeFNwTGFzdA0NCgl7bXNvLXN0eWxlLW5hbWU6Ikxpc3RhIDRDeFNwTGFzdCI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6NTYuNnB0Ow0NCgl0ZXh0LWluZGVudDotMTQuMTVwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5MaXN0YTUsIGxpLkxpc3RhNSwgZGl2Lkxpc3RhNQ0NCgl7bXNvLXN0eWxlLW5hbWU6Ikxpc3RhIDUiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjcwLjc1cHQ7DQ0KCXRleHQtaW5kZW50Oi0xNC4xNXB0Ow0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkxpc3RhNUN4U3BGaXJzdCwgbGkuTGlzdGE1Q3hTcEZpcnN0LCBkaXYuTGlzdGE1Q3hTcEZpcnN0DQ0KCXttc28tc3R5bGUtbmFtZToiTGlzdGEgNUN4U3BGaXJzdCI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6NzAuNzVwdDsNDQoJdGV4dC1pbmRlbnQ6LTE0LjE1cHQ7DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuTGlzdGE1Q3hTcE1pZGRsZSwgbGkuTGlzdGE1Q3hTcE1pZGRsZSwgZGl2Lkxpc3RhNUN4U3BNaWRkbGUNDQoJe21zby1zdHlsZS1uYW1lOiJMaXN0YSA1Q3hTcE1pZGRsZSI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6NzAuNzVwdDsNDQoJdGV4dC1pbmRlbnQ6LTE0LjE1cHQ7DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuTGlzdGE1Q3hTcExhc3QsIGxpLkxpc3RhNUN4U3BMYXN0LCBkaXYuTGlzdGE1Q3hTcExhc3QNDQoJe21zby1zdHlsZS1uYW1lOiJMaXN0YSA1Q3hTcExhc3QiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjcwLjc1cHQ7DQ0KCXRleHQtaW5kZW50Oi0xNC4xNXB0Ow0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkxpc3RhY29udmlldGFzMiwgbGkuTGlzdGFjb252aWV0YXMyLCBkaXYuTGlzdGFjb252aWV0YXMyDQ0KCXttc28tc3R5bGUtbmFtZToiTGlzdGEgY29uIHZp8WV0YXMgMiI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6MzIuMTVwdDsNDQoJdGV4dC1pbmRlbnQ6LS4yNWluOw0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkxpc3RhY29udmlldGFzMkN4U3BGaXJzdCwgbGkuTGlzdGFjb252aWV0YXMyQ3hTcEZpcnN0LCBkaXYuTGlzdGFjb252aWV0YXMyQ3hTcEZpcnN0DQ0KCXttc28tc3R5bGUtbmFtZToiTGlzdGEgY29uIHZp8WV0YXMgMkN4U3BGaXJzdCI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6MzIuMTVwdDsNDQoJdGV4dC1pbmRlbnQ6LS4yNWluOw0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkxpc3RhY29udmlldGFzMkN4U3BNaWRkbGUsIGxpLkxpc3RhY29udmlldGFzMkN4U3BNaWRkbGUsIGRpdi5MaXN0YWNvbnZpZXRhczJDeFNwTWlkZGxlDQ0KCXttc28tc3R5bGUtbmFtZToiTGlzdGEgY29uIHZp8WV0YXMgMkN4U3BNaWRkbGUiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjMyLjE1cHQ7DQ0KCXRleHQtaW5kZW50Oi0uMjVpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5MaXN0YWNvbnZpZXRhczJDeFNwTGFzdCwgbGkuTGlzdGFjb252aWV0YXMyQ3hTcExhc3QsIGRpdi5MaXN0YWNvbnZpZXRhczJDeFNwTGFzdA0NCgl7bXNvLXN0eWxlLW5hbWU6Ikxpc3RhIGNvbiB2afFldGFzIDJDeFNwTGFzdCI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6MzIuMTVwdDsNDQoJdGV4dC1pbmRlbnQ6LS4yNWluOw0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkxpc3RhY29udmlldGFzMywgbGkuTGlzdGFjb252aWV0YXMzLCBkaXYuTGlzdGFjb252aWV0YXMzDQ0KCXttc28tc3R5bGUtbmFtZToiTGlzdGEgY29uIHZp8WV0YXMgMyI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6NDYuM3B0Ow0NCgl0ZXh0LWluZGVudDotLjI1aW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuTGlzdGFjb252aWV0YXMzQ3hTcEZpcnN0LCBsaS5MaXN0YWNvbnZpZXRhczNDeFNwRmlyc3QsIGRpdi5MaXN0YWNvbnZpZXRhczNDeFNwRmlyc3QNDQoJe21zby1zdHlsZS1uYW1lOiJMaXN0YSBjb24gdmnxZXRhcyAzQ3hTcEZpcnN0IjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDo0Ni4zcHQ7DQ0KCXRleHQtaW5kZW50Oi0uMjVpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5MaXN0YWNvbnZpZXRhczNDeFNwTWlkZGxlLCBsaS5MaXN0YWNvbnZpZXRhczNDeFNwTWlkZGxlLCBkaXYuTGlzdGFjb252aWV0YXMzQ3hTcE1pZGRsZQ0NCgl7bXNvLXN0eWxlLW5hbWU6Ikxpc3RhIGNvbiB2afFldGFzIDNDeFNwTWlkZGxlIjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDo0Ni4zcHQ7DQ0KCXRleHQtaW5kZW50Oi0uMjVpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5MaXN0YWNvbnZpZXRhczNDeFNwTGFzdCwgbGkuTGlzdGFjb252aWV0YXMzQ3hTcExhc3QsIGRpdi5MaXN0YWNvbnZpZXRhczNDeFNwTGFzdA0NCgl7bXNvLXN0eWxlLW5hbWU6Ikxpc3RhIGNvbiB2afFldGFzIDNDeFNwTGFzdCI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6NDYuM3B0Ow0NCgl0ZXh0LWluZGVudDotLjI1aW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuTGlzdGFjb252aWV0YXM0LCBsaS5MaXN0YWNvbnZpZXRhczQsIGRpdi5MaXN0YWNvbnZpZXRhczQNDQoJe21zby1zdHlsZS1uYW1lOiJMaXN0YSBjb24gdmnxZXRhcyA0IjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDo2MC40NXB0Ow0NCgl0ZXh0LWluZGVudDotLjI1aW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuTGlzdGFjb252aWV0YXM0Q3hTcEZpcnN0LCBsaS5MaXN0YWNvbnZpZXRhczRDeFNwRmlyc3QsIGRpdi5MaXN0YWNvbnZpZXRhczRDeFNwRmlyc3QNDQoJe21zby1zdHlsZS1uYW1lOiJMaXN0YSBjb24gdmnxZXRhcyA0Q3hTcEZpcnN0IjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDo2MC40NXB0Ow0NCgl0ZXh0LWluZGVudDotLjI1aW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuTGlzdGFjb252aWV0YXM0Q3hTcE1pZGRsZSwgbGkuTGlzdGFjb252aWV0YXM0Q3hTcE1pZGRsZSwgZGl2Lkxpc3RhY29udmlldGFzNEN4U3BNaWRkbGUNDQoJe21zby1zdHlsZS1uYW1lOiJMaXN0YSBjb24gdmnxZXRhcyA0Q3hTcE1pZGRsZSI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6NjAuNDVwdDsNDQoJdGV4dC1pbmRlbnQ6LS4yNWluOw0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkxpc3RhY29udmlldGFzNEN4U3BMYXN0LCBsaS5MaXN0YWNvbnZpZXRhczRDeFNwTGFzdCwgZGl2Lkxpc3RhY29udmlldGFzNEN4U3BMYXN0DQ0KCXttc28tc3R5bGUtbmFtZToiTGlzdGEgY29uIHZp8WV0YXMgNEN4U3BMYXN0IjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDo2MC40NXB0Ow0NCgl0ZXh0LWluZGVudDotLjI1aW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuTGlzdGFjb252aWV0YXM1LCBsaS5MaXN0YWNvbnZpZXRhczUsIGRpdi5MaXN0YWNvbnZpZXRhczUNDQoJe21zby1zdHlsZS1uYW1lOiJMaXN0YSBjb24gdmnxZXRhcyA1IjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDo3NC42cHQ7DQ0KCXRleHQtaW5kZW50Oi0uMjVpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5MaXN0YWNvbnZpZXRhczVDeFNwRmlyc3QsIGxpLkxpc3RhY29udmlldGFzNUN4U3BGaXJzdCwgZGl2Lkxpc3RhY29udmlldGFzNUN4U3BGaXJzdA0NCgl7bXNvLXN0eWxlLW5hbWU6Ikxpc3RhIGNvbiB2afFldGFzIDVDeFNwRmlyc3QiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0Ojc0LjZwdDsNDQoJdGV4dC1pbmRlbnQ6LS4yNWluOw0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkxpc3RhY29udmlldGFzNUN4U3BNaWRkbGUsIGxpLkxpc3RhY29udmlldGFzNUN4U3BNaWRkbGUsIGRpdi5MaXN0YWNvbnZpZXRhczVDeFNwTWlkZGxlDQ0KCXttc28tc3R5bGUtbmFtZToiTGlzdGEgY29uIHZp8WV0YXMgNUN4U3BNaWRkbGUiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0Ojc0LjZwdDsNDQoJdGV4dC1pbmRlbnQ6LS4yNWluOw0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkxpc3RhY29udmlldGFzNUN4U3BMYXN0LCBsaS5MaXN0YWNvbnZpZXRhczVDeFNwTGFzdCwgZGl2Lkxpc3RhY29udmlldGFzNUN4U3BMYXN0DQ0KCXttc28tc3R5bGUtbmFtZToiTGlzdGEgY29uIHZp8WV0YXMgNUN4U3BMYXN0IjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDo3NC42cHQ7DQ0KCXRleHQtaW5kZW50Oi0uMjVpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5Db250aW51YXJsaXN0YSwgbGkuQ29udGludWFybGlzdGEsIGRpdi5Db250aW51YXJsaXN0YQ0NCgl7bXNvLXN0eWxlLW5hbWU6IkNvbnRpbnVhciBsaXN0YSI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjYuMHB0Ow0NCgltYXJnaW4tbGVmdDoxNC4xNXB0Ow0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkNvbnRpbnVhcmxpc3RhQ3hTcEZpcnN0LCBsaS5Db250aW51YXJsaXN0YUN4U3BGaXJzdCwgZGl2LkNvbnRpbnVhcmxpc3RhQ3hTcEZpcnN0DQ0KCXttc28tc3R5bGUtbmFtZToiQ29udGludWFyIGxpc3RhQ3hTcEZpcnN0IjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDoxNC4xNXB0Ow0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkNvbnRpbnVhcmxpc3RhQ3hTcE1pZGRsZSwgbGkuQ29udGludWFybGlzdGFDeFNwTWlkZGxlLCBkaXYuQ29udGludWFybGlzdGFDeFNwTWlkZGxlDQ0KCXttc28tc3R5bGUtbmFtZToiQ29udGludWFyIGxpc3RhQ3hTcE1pZGRsZSI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6MTQuMTVwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5Db250aW51YXJsaXN0YUN4U3BMYXN0LCBsaS5Db250aW51YXJsaXN0YUN4U3BMYXN0LCBkaXYuQ29udGludWFybGlzdGFDeFNwTGFzdA0NCgl7bXNvLXN0eWxlLW5hbWU6IkNvbnRpbnVhciBsaXN0YUN4U3BMYXN0IjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206Ni4wcHQ7DQ0KCW1hcmdpbi1sZWZ0OjE0LjE1cHQ7DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuQ29udGludWFybGlzdGEyLCBsaS5Db250aW51YXJsaXN0YTIsIGRpdi5Db250aW51YXJsaXN0YTINDQoJe21zby1zdHlsZS1uYW1lOiJDb250aW51YXIgbGlzdGEgMiI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjYuMHB0Ow0NCgltYXJnaW4tbGVmdDoyOC4zcHQ7DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuQ29udGludWFybGlzdGEyQ3hTcEZpcnN0LCBsaS5Db250aW51YXJsaXN0YTJDeFNwRmlyc3QsIGRpdi5Db250aW51YXJsaXN0YTJDeFNwRmlyc3QNDQoJe21zby1zdHlsZS1uYW1lOiJDb250aW51YXIgbGlzdGEgMkN4U3BGaXJzdCI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6MjguM3B0Ow0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkNvbnRpbnVhcmxpc3RhMkN4U3BNaWRkbGUsIGxpLkNvbnRpbnVhcmxpc3RhMkN4U3BNaWRkbGUsIGRpdi5Db250aW51YXJsaXN0YTJDeFNwTWlkZGxlDQ0KCXttc28tc3R5bGUtbmFtZToiQ29udGludWFyIGxpc3RhIDJDeFNwTWlkZGxlIjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDoyOC4zcHQ7DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuQ29udGludWFybGlzdGEyQ3hTcExhc3QsIGxpLkNvbnRpbnVhcmxpc3RhMkN4U3BMYXN0LCBkaXYuQ29udGludWFybGlzdGEyQ3hTcExhc3QNDQoJe21zby1zdHlsZS1uYW1lOiJDb250aW51YXIgbGlzdGEgMkN4U3BMYXN0IjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206Ni4wcHQ7DQ0KCW1hcmdpbi1sZWZ0OjI4LjNwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5Db250aW51YXJsaXN0YTMsIGxpLkNvbnRpbnVhcmxpc3RhMywgZGl2LkNvbnRpbnVhcmxpc3RhMw0NCgl7bXNvLXN0eWxlLW5hbWU6IkNvbnRpbnVhciBsaXN0YSAzIjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206Ni4wcHQ7DQ0KCW1hcmdpbi1sZWZ0OjQyLjQ1cHQ7DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuQ29udGludWFybGlzdGEzQ3hTcEZpcnN0LCBsaS5Db250aW51YXJsaXN0YTNDeFNwRmlyc3QsIGRpdi5Db250aW51YXJsaXN0YTNDeFNwRmlyc3QNDQoJe21zby1zdHlsZS1uYW1lOiJDb250aW51YXIgbGlzdGEgM0N4U3BGaXJzdCI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6NDIuNDVwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5Db250aW51YXJsaXN0YTNDeFNwTWlkZGxlLCBsaS5Db250aW51YXJsaXN0YTNDeFNwTWlkZGxlLCBkaXYuQ29udGludWFybGlzdGEzQ3hTcE1pZGRsZQ0NCgl7bXNvLXN0eWxlLW5hbWU6IkNvbnRpbnVhciBsaXN0YSAzQ3hTcE1pZGRsZSI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6NDIuNDVwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5Db250aW51YXJsaXN0YTNDeFNwTGFzdCwgbGkuQ29udGludWFybGlzdGEzQ3hTcExhc3QsIGRpdi5Db250aW51YXJsaXN0YTNDeFNwTGFzdA0NCgl7bXNvLXN0eWxlLW5hbWU6IkNvbnRpbnVhciBsaXN0YSAzQ3hTcExhc3QiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTo2LjBwdDsNDQoJbWFyZ2luLWxlZnQ6NDIuNDVwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5Db250aW51YXJsaXN0YTQsIGxpLkNvbnRpbnVhcmxpc3RhNCwgZGl2LkNvbnRpbnVhcmxpc3RhNA0NCgl7bXNvLXN0eWxlLW5hbWU6IkNvbnRpbnVhciBsaXN0YSA0IjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206Ni4wcHQ7DQ0KCW1hcmdpbi1sZWZ0OjU2LjZwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5Db250aW51YXJsaXN0YTRDeFNwRmlyc3QsIGxpLkNvbnRpbnVhcmxpc3RhNEN4U3BGaXJzdCwgZGl2LkNvbnRpbnVhcmxpc3RhNEN4U3BGaXJzdA0NCgl7bXNvLXN0eWxlLW5hbWU6IkNvbnRpbnVhciBsaXN0YSA0Q3hTcEZpcnN0IjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDo1Ni42cHQ7DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuQ29udGludWFybGlzdGE0Q3hTcE1pZGRsZSwgbGkuQ29udGludWFybGlzdGE0Q3hTcE1pZGRsZSwgZGl2LkNvbnRpbnVhcmxpc3RhNEN4U3BNaWRkbGUNDQoJe21zby1zdHlsZS1uYW1lOiJDb250aW51YXIgbGlzdGEgNEN4U3BNaWRkbGUiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjU2LjZwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5Db250aW51YXJsaXN0YTRDeFNwTGFzdCwgbGkuQ29udGludWFybGlzdGE0Q3hTcExhc3QsIGRpdi5Db250aW51YXJsaXN0YTRDeFNwTGFzdA0NCgl7bXNvLXN0eWxlLW5hbWU6IkNvbnRpbnVhciBsaXN0YSA0Q3hTcExhc3QiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTo2LjBwdDsNDQoJbWFyZ2luLWxlZnQ6NTYuNnB0Ow0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkNvbnRpbnVhcmxpc3RhNSwgbGkuQ29udGludWFybGlzdGE1LCBkaXYuQ29udGludWFybGlzdGE1DQ0KCXttc28tc3R5bGUtbmFtZToiQ29udGludWFyIGxpc3RhIDUiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTo2LjBwdDsNDQoJbWFyZ2luLWxlZnQ6NzAuNzVwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5Db250aW51YXJsaXN0YTVDeFNwRmlyc3QsIGxpLkNvbnRpbnVhcmxpc3RhNUN4U3BGaXJzdCwgZGl2LkNvbnRpbnVhcmxpc3RhNUN4U3BGaXJzdA0NCgl7bXNvLXN0eWxlLW5hbWU6IkNvbnRpbnVhciBsaXN0YSA1Q3hTcEZpcnN0IjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDo3MC43NXB0Ow0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkNvbnRpbnVhcmxpc3RhNUN4U3BNaWRkbGUsIGxpLkNvbnRpbnVhcmxpc3RhNUN4U3BNaWRkbGUsIGRpdi5Db250aW51YXJsaXN0YTVDeFNwTWlkZGxlDQ0KCXttc28tc3R5bGUtbmFtZToiQ29udGludWFyIGxpc3RhIDVDeFNwTWlkZGxlIjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDo3MC43NXB0Ow0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkNvbnRpbnVhcmxpc3RhNUN4U3BMYXN0LCBsaS5Db250aW51YXJsaXN0YTVDeFNwTGFzdCwgZGl2LkNvbnRpbnVhcmxpc3RhNUN4U3BMYXN0DQ0KCXttc28tc3R5bGUtbmFtZToiQ29udGludWFyIGxpc3RhIDVDeFNwTGFzdCI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjYuMHB0Ow0NCgltYXJnaW4tbGVmdDo3MC43NXB0Ow0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkxpc3RhY29ubm1lcm9zLCBsaS5MaXN0YWNvbm5tZXJvcywgZGl2Lkxpc3RhY29ubm1lcm9zDQ0KCXttc28tc3R5bGUtbmFtZToiTGlzdGEgY29uIG76bWVyb3MiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0Oi4yNWluOw0NCgl0ZXh0LWluZGVudDotLjI1aW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuTGlzdGFjb25ubWVyb3NDeFNwRmlyc3QsIGxpLkxpc3RhY29ubm1lcm9zQ3hTcEZpcnN0LCBkaXYuTGlzdGFjb25ubWVyb3NDeFNwRmlyc3QNDQoJe21zby1zdHlsZS1uYW1lOiJMaXN0YSBjb24gbvptZXJvc0N4U3BGaXJzdCI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6LjI1aW47DQ0KCXRleHQtaW5kZW50Oi0uMjVpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5MaXN0YWNvbm5tZXJvc0N4U3BNaWRkbGUsIGxpLkxpc3RhY29ubm1lcm9zQ3hTcE1pZGRsZSwgZGl2Lkxpc3RhY29ubm1lcm9zQ3hTcE1pZGRsZQ0NCgl7bXNvLXN0eWxlLW5hbWU6Ikxpc3RhIGNvbiBu+m1lcm9zQ3hTcE1pZGRsZSI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6LjI1aW47DQ0KCXRleHQtaW5kZW50Oi0uMjVpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5MaXN0YWNvbm5tZXJvc0N4U3BMYXN0LCBsaS5MaXN0YWNvbm5tZXJvc0N4U3BMYXN0LCBkaXYuTGlzdGFjb25ubWVyb3NDeFNwTGFzdA0NCgl7bXNvLXN0eWxlLW5hbWU6Ikxpc3RhIGNvbiBu+m1lcm9zQ3hTcExhc3QiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0Oi4yNWluOw0NCgl0ZXh0LWluZGVudDotLjI1aW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuTGlzdGFjb25ubWVyb3MyLCBsaS5MaXN0YWNvbm5tZXJvczIsIGRpdi5MaXN0YWNvbm5tZXJvczINDQoJe21zby1zdHlsZS1uYW1lOiJMaXN0YSBjb24gbvptZXJvcyAyIjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDozMi4xNXB0Ow0NCgl0ZXh0LWluZGVudDotLjI1aW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuTGlzdGFjb25ubWVyb3MyQ3hTcEZpcnN0LCBsaS5MaXN0YWNvbm5tZXJvczJDeFNwRmlyc3QsIGRpdi5MaXN0YWNvbm5tZXJvczJDeFNwRmlyc3QNDQoJe21zby1zdHlsZS1uYW1lOiJMaXN0YSBjb24gbvptZXJvcyAyQ3hTcEZpcnN0IjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDozMi4xNXB0Ow0NCgl0ZXh0LWluZGVudDotLjI1aW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuTGlzdGFjb25ubWVyb3MyQ3hTcE1pZGRsZSwgbGkuTGlzdGFjb25ubWVyb3MyQ3hTcE1pZGRsZSwgZGl2Lkxpc3RhY29ubm1lcm9zMkN4U3BNaWRkbGUNDQoJe21zby1zdHlsZS1uYW1lOiJMaXN0YSBjb24gbvptZXJvcyAyQ3hTcE1pZGRsZSI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6MzIuMTVwdDsNDQoJdGV4dC1pbmRlbnQ6LS4yNWluOw0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkxpc3RhY29ubm1lcm9zMkN4U3BMYXN0LCBsaS5MaXN0YWNvbm5tZXJvczJDeFNwTGFzdCwgZGl2Lkxpc3RhY29ubm1lcm9zMkN4U3BMYXN0DQ0KCXttc28tc3R5bGUtbmFtZToiTGlzdGEgY29uIG76bWVyb3MgMkN4U3BMYXN0IjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDozMi4xNXB0Ow0NCgl0ZXh0LWluZGVudDotLjI1aW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuTGlzdGFjb25ubWVyb3MzLCBsaS5MaXN0YWNvbm5tZXJvczMsIGRpdi5MaXN0YWNvbm5tZXJvczMNDQoJe21zby1zdHlsZS1uYW1lOiJMaXN0YSBjb24gbvptZXJvcyAzIjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDo0Ni4zcHQ7DQ0KCXRleHQtaW5kZW50Oi0uMjVpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5MaXN0YWNvbm5tZXJvczNDeFNwRmlyc3QsIGxpLkxpc3RhY29ubm1lcm9zM0N4U3BGaXJzdCwgZGl2Lkxpc3RhY29ubm1lcm9zM0N4U3BGaXJzdA0NCgl7bXNvLXN0eWxlLW5hbWU6Ikxpc3RhIGNvbiBu+m1lcm9zIDNDeFNwRmlyc3QiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjQ2LjNwdDsNDQoJdGV4dC1pbmRlbnQ6LS4yNWluOw0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkxpc3RhY29ubm1lcm9zM0N4U3BNaWRkbGUsIGxpLkxpc3RhY29ubm1lcm9zM0N4U3BNaWRkbGUsIGRpdi5MaXN0YWNvbm5tZXJvczNDeFNwTWlkZGxlDQ0KCXttc28tc3R5bGUtbmFtZToiTGlzdGEgY29uIG76bWVyb3MgM0N4U3BNaWRkbGUiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjQ2LjNwdDsNDQoJdGV4dC1pbmRlbnQ6LS4yNWluOw0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkxpc3RhY29ubm1lcm9zM0N4U3BMYXN0LCBsaS5MaXN0YWNvbm5tZXJvczNDeFNwTGFzdCwgZGl2Lkxpc3RhY29ubm1lcm9zM0N4U3BMYXN0DQ0KCXttc28tc3R5bGUtbmFtZToiTGlzdGEgY29uIG76bWVyb3MgM0N4U3BMYXN0IjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDo0Ni4zcHQ7DQ0KCXRleHQtaW5kZW50Oi0uMjVpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5MaXN0YWNvbm5tZXJvczQsIGxpLkxpc3RhY29ubm1lcm9zNCwgZGl2Lkxpc3RhY29ubm1lcm9zNA0NCgl7bXNvLXN0eWxlLW5hbWU6Ikxpc3RhIGNvbiBu+m1lcm9zIDQiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjYwLjQ1cHQ7DQ0KCXRleHQtaW5kZW50Oi0uMjVpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5MaXN0YWNvbm5tZXJvczRDeFNwRmlyc3QsIGxpLkxpc3RhY29ubm1lcm9zNEN4U3BGaXJzdCwgZGl2Lkxpc3RhY29ubm1lcm9zNEN4U3BGaXJzdA0NCgl7bXNvLXN0eWxlLW5hbWU6Ikxpc3RhIGNvbiBu+m1lcm9zIDRDeFNwRmlyc3QiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjYwLjQ1cHQ7DQ0KCXRleHQtaW5kZW50Oi0uMjVpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5MaXN0YWNvbm5tZXJvczRDeFNwTWlkZGxlLCBsaS5MaXN0YWNvbm5tZXJvczRDeFNwTWlkZGxlLCBkaXYuTGlzdGFjb25ubWVyb3M0Q3hTcE1pZGRsZQ0NCgl7bXNvLXN0eWxlLW5hbWU6Ikxpc3RhIGNvbiBu+m1lcm9zIDRDeFNwTWlkZGxlIjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDo2MC40NXB0Ow0NCgl0ZXh0LWluZGVudDotLjI1aW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuTGlzdGFjb25ubWVyb3M0Q3hTcExhc3QsIGxpLkxpc3RhY29ubm1lcm9zNEN4U3BMYXN0LCBkaXYuTGlzdGFjb25ubWVyb3M0Q3hTcExhc3QNDQoJe21zby1zdHlsZS1uYW1lOiJMaXN0YSBjb24gbvptZXJvcyA0Q3hTcExhc3QiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjYwLjQ1cHQ7DQ0KCXRleHQtaW5kZW50Oi0uMjVpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5MaXN0YWNvbm5tZXJvczUsIGxpLkxpc3RhY29ubm1lcm9zNSwgZGl2Lkxpc3RhY29ubm1lcm9zNQ0NCgl7bXNvLXN0eWxlLW5hbWU6Ikxpc3RhIGNvbiBu+m1lcm9zIDUiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjY3LjU1cHQ7DQ0KCXRleHQtaW5kZW50Oi0uMjVpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5MaXN0YWNvbm5tZXJvczVDeFNwRmlyc3QsIGxpLkxpc3RhY29ubm1lcm9zNUN4U3BGaXJzdCwgZGl2Lkxpc3RhY29ubm1lcm9zNUN4U3BGaXJzdA0NCgl7bXNvLXN0eWxlLW5hbWU6Ikxpc3RhIGNvbiBu+m1lcm9zIDVDeFNwRmlyc3QiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjY3LjU1cHQ7DQ0KCXRleHQtaW5kZW50Oi0uMjVpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5MaXN0YWNvbm5tZXJvczVDeFNwTWlkZGxlLCBsaS5MaXN0YWNvbm5tZXJvczVDeFNwTWlkZGxlLCBkaXYuTGlzdGFjb25ubWVyb3M1Q3hTcE1pZGRsZQ0NCgl7bXNvLXN0eWxlLW5hbWU6Ikxpc3RhIGNvbiBu+m1lcm9zIDVDeFNwTWlkZGxlIjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDo2Ny41NXB0Ow0NCgl0ZXh0LWluZGVudDotLjI1aW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuTGlzdGFjb25ubWVyb3M1Q3hTcExhc3QsIGxpLkxpc3RhY29ubm1lcm9zNUN4U3BMYXN0LCBkaXYuTGlzdGFjb25ubWVyb3M1Q3hTcExhc3QNDQoJe21zby1zdHlsZS1uYW1lOiJMaXN0YSBjb24gbvptZXJvcyA1Q3hTcExhc3QiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjY3LjU1cHQ7DQ0KCXRleHQtaW5kZW50Oi0uMjVpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5UZXh0b21hY3JvLCBsaS5UZXh0b21hY3JvLCBkaXYuVGV4dG9tYWNybw0NCgl7bXNvLXN0eWxlLW5hbWU6IlRleHRvIG1hY3JvIjsNDQoJbXNvLXN0eWxlLWxpbms6IlRleHRvIG1hY3JvIENhciI7DQ0KCW1hcmdpbjowaW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjEwLjBwdDsNDQoJZm9udC1mYW1pbHk6IkNvdXJpZXIgTmV3Ijt9DQ0Kc3Bhbi5UZXh0b21hY3JvQ2FyDQ0KCXttc28tc3R5bGUtbmFtZToiVGV4dG8gbWFjcm8gQ2FyIjsNDQoJbXNvLXN0eWxlLWxpbms6IlRleHRvIG1hY3JvIjsNDQoJZm9udC1mYW1pbHk6IkNvdXJpZXIgTmV3Ijt9DQ0KcC5FbmNhYmV6YWRvZGVtZW5zYWplLCBsaS5FbmNhYmV6YWRvZGVtZW5zYWplLCBkaXYuRW5jYWJlemFkb2RlbWVuc2FqZQ0NCgl7bXNvLXN0eWxlLW5hbWU6IkVuY2FiZXphZG8gZGUgbWVuc2FqZSI7DQ0KCW1zby1zdHlsZS1saW5rOiJFbmNhYmV6YWRvIGRlIG1lbnNhamUgQ2FyIjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDo1Ni43cHQ7DQ0KCXRleHQtaW5kZW50Oi01Ni43cHQ7DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJYmFja2dyb3VuZDojQ0NDQ0NDOw0NCglib3JkZXI6bm9uZTsNDQoJcGFkZGluZzowaW47DQ0KCWZvbnQtc2l6ZToxMi4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJDYWxpYnJpIExpZ2h0IixzYW5zLXNlcmlmO30NDQpzcGFuLkVuY2FiZXphZG9kZW1lbnNhamVDYXINDQoJe21zby1zdHlsZS1uYW1lOiJFbmNhYmV6YWRvIGRlIG1lbnNhamUgQ2FyIjsNDQoJbXNvLXN0eWxlLWxpbms6IkVuY2FiZXphZG8gZGUgbWVuc2FqZSI7DQ0KCWZvbnQtZmFtaWx5OiJDYWxpYnJpIExpZ2h0IixzYW5zLXNlcmlmOw0NCgliYWNrZ3JvdW5kOiNDQ0NDQ0M7fQ0NCnAuU2luZXNwYWNpYWRvLCBsaS5TaW5lc3BhY2lhZG8sIGRpdi5TaW5lc3BhY2lhZG8NDQoJe21zby1zdHlsZS1uYW1lOiJTaW4gZXNwYWNpYWRvIjsNDQoJbWFyZ2luOjBpbjsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuU2FuZ3Jhbm9ybWFsLCBsaS5TYW5ncmFub3JtYWwsIGRpdi5TYW5ncmFub3JtYWwNDQoJe21zby1zdHlsZS1uYW1lOiJTYW5ncu1hIG5vcm1hbCI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6LjVpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5FbmNhYmV6YWRvZGVub3RhLCBsaS5FbmNhYmV6YWRvZGVub3RhLCBkaXYuRW5jYWJlemFkb2Rlbm90YQ0NCgl7bXNvLXN0eWxlLW5hbWU6IkVuY2FiZXphZG8gZGUgbm90YSI7DQ0KCW1zby1zdHlsZS1saW5rOiJFbmNhYmV6YWRvIGRlIG5vdGEgQ2FyIjsNDQoJbWFyZ2luOjBpbjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0Kc3Bhbi5FbmNhYmV6YWRvZGVub3RhQ2FyDQ0KCXttc28tc3R5bGUtbmFtZToiRW5jYWJlemFkbyBkZSBub3RhIENhciI7DQ0KCW1zby1zdHlsZS1saW5rOiJFbmNhYmV6YWRvIGRlIG5vdGEiOw0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5UZXh0b3NpbmZvcm1hdG8sIGxpLlRleHRvc2luZm9ybWF0bywgZGl2LlRleHRvc2luZm9ybWF0bw0NCgl7bXNvLXN0eWxlLW5hbWU6IlRleHRvIHNpbiBmb3JtYXRvIjsNDQoJbXNvLXN0eWxlLWxpbms6IlRleHRvIHNpbiBmb3JtYXRvIENhciI7DQ0KCW1hcmdpbjowaW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjEwLjBwdDsNDQoJZm9udC1mYW1pbHk6IkNvdXJpZXIgTmV3Ijt9DQ0Kc3Bhbi5UZXh0b3NpbmZvcm1hdG9DYXINDQoJe21zby1zdHlsZS1uYW1lOiJUZXh0byBzaW4gZm9ybWF0byBDYXIiOw0NCgltc28tc3R5bGUtbGluazoiVGV4dG8gc2luIGZvcm1hdG8iOw0NCglmb250LWZhbWlseToiQ291cmllciBOZXciO30NDQpwLkNpdGEsIGxpLkNpdGEsIGRpdi5DaXRhDQ0KCXttc28tc3R5bGUtbmFtZTpDaXRhOw0NCgltc28tc3R5bGUtbGluazoiQ2l0YSBDYXIiOw0NCgltYXJnaW4tdG9wOjEwLjBwdDsNDQoJbWFyZ2luLXJpZ2h0Oi42aW47DQ0KCW1hcmdpbi1ib3R0b206OC4wcHQ7DQ0KCW1hcmdpbi1sZWZ0Oi42aW47DQ0KCXRleHQtYWxpZ246Y2VudGVyOw0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmOw0NCgljb2xvcjojNDA0MDQwOw0NCglmb250LXN0eWxlOml0YWxpYzt9DQ0Kc3Bhbi5DaXRhQ2FyDQ0KCXttc28tc3R5bGUtbmFtZToiQ2l0YSBDYXIiOw0NCgltc28tc3R5bGUtbGluazpDaXRhOw0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjsNDQoJY29sb3I6IzQwNDA0MDsNDQoJZm9udC1zdHlsZTppdGFsaWM7fQ0NCnAuU2FsdWRvLCBsaS5TYWx1ZG8sIGRpdi5TYWx1ZG8NDQoJe21zby1zdHlsZS1uYW1lOlNhbHVkbzsNDQoJbXNvLXN0eWxlLWxpbms6IlNhbHVkbyBDYXIiOw0NCgltYXJnaW46MGluOw0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpzcGFuLlNhbHVkb0Nhcg0NCgl7bXNvLXN0eWxlLW5hbWU6IlNhbHVkbyBDYXIiOw0NCgltc28tc3R5bGUtbGluazpTYWx1ZG87DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLkZpcm1hLCBsaS5GaXJtYSwgZGl2LkZpcm1hDQ0KCXttc28tc3R5bGUtbmFtZTpGaXJtYTsNDQoJbXNvLXN0eWxlLWxpbms6IkZpcm1hIENhciI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6MjEyLjZwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0Kc3Bhbi5GaXJtYUNhcg0NCgl7bXNvLXN0eWxlLW5hbWU6IkZpcm1hIENhciI7DQ0KCW1zby1zdHlsZS1saW5rOkZpcm1hOw0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5TdWJ0dHVsbywgbGkuU3VidHR1bG8sIGRpdi5TdWJ0dHVsbw0NCgl7bXNvLXN0eWxlLW5hbWU6U3VidO10dWxvOw0NCgltc28tc3R5bGUtbGluazoiU3VidO10dWxvIENhciI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjMuMHB0Ow0NCgltYXJnaW4tbGVmdDowaW47DQ0KCXRleHQtYWxpZ246Y2VudGVyOw0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMi4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJDYWxpYnJpIExpZ2h0IixzYW5zLXNlcmlmO30NDQpzcGFuLlN1YnR0dWxvQ2FyDQ0KCXttc28tc3R5bGUtbmFtZToiU3VidO10dWxvIENhciI7DQ0KCW1zby1zdHlsZS1saW5rOlN1YnTtdHVsbzsNDQoJZm9udC1mYW1pbHk6IkNhbGlicmkgTGlnaHQiLHNhbnMtc2VyaWY7fQ0NCnAuVGV4dG9jb25zYW5ncmEsIGxpLlRleHRvY29uc2FuZ3JhLCBkaXYuVGV4dG9jb25zYW5ncmENDQoJe21zby1zdHlsZS1uYW1lOiJUZXh0byBjb24gc2FuZ3LtYSI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6MTEuMHB0Ow0NCgl0ZXh0LWluZGVudDotMTEuMHB0Ow0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLlRhYmxhZGVpbHVzdHJhY2lvbmVzLCBsaS5UYWJsYWRlaWx1c3RyYWNpb25lcywgZGl2LlRhYmxhZGVpbHVzdHJhY2lvbmVzDQ0KCXttc28tc3R5bGUtbmFtZToiVGFibGEgZGUgaWx1c3RyYWNpb25lcyI7DQ0KCW1hcmdpbjowaW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuVHR1bG8sIGxpLlR0dWxvLCBkaXYuVHR1bG8NDQoJe21zby1zdHlsZS1uYW1lOlTtdHVsbzsNDQoJbXNvLXN0eWxlLWxpbms6IlTtdHVsbyBDYXIiOw0NCgltYXJnaW4tdG9wOjEyLjBwdDsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTozLjBwdDsNDQoJbWFyZ2luLWxlZnQ6MGluOw0NCgl0ZXh0LWFsaWduOmNlbnRlcjsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTYuMHB0Ow0NCglmb250LWZhbWlseToiQ2FsaWJyaSBMaWdodCIsc2Fucy1zZXJpZjsNDQoJZm9udC13ZWlnaHQ6Ym9sZDt9DQ0Kc3Bhbi5UdHVsb0Nhcg0NCgl7bXNvLXN0eWxlLW5hbWU6IlTtdHVsbyBDYXIiOw0NCgltc28tc3R5bGUtbGluazpU7XR1bG87DQ0KCWZvbnQtZmFtaWx5OiJDYWxpYnJpIExpZ2h0IixzYW5zLXNlcmlmOw0NCglmb250LXdlaWdodDpib2xkO30NDQpwLkVuY2FiZXphZG9kZWxpc3RhLCBsaS5FbmNhYmV6YWRvZGVsaXN0YSwgZGl2LkVuY2FiZXphZG9kZWxpc3RhDQ0KCXttc28tc3R5bGUtbmFtZToiRW5jYWJlemFkbyBkZSBsaXN0YSI7DQ0KCW1hcmdpbi10b3A6Ni4wcHQ7DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDowaW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjEyLjBwdDsNDQoJZm9udC1mYW1pbHk6IkNhbGlicmkgTGlnaHQiLHNhbnMtc2VyaWY7DQ0KCWZvbnQtd2VpZ2h0OmJvbGQ7fQ0NCnAuVERDMSwgbGkuVERDMSwgZGl2LlREQzENDQoJe21zby1zdHlsZS1uYW1lOiJUREMgMSI7DQ0KCW1hcmdpbjowaW47DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuVERDMiwgbGkuVERDMiwgZGl2LlREQzINDQoJe21zby1zdHlsZS1uYW1lOiJUREMgMiI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6MTEuMHB0Ow0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLlREQzMsIGxpLlREQzMsIGRpdi5UREMzDQ0KCXttc28tc3R5bGUtbmFtZToiVERDIDMiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjIyLjBwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5UREM0LCBsaS5UREM0LCBkaXYuVERDNA0NCgl7bXNvLXN0eWxlLW5hbWU6IlREQyA0IjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDozMy4wcHQ7DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuVERDNSwgbGkuVERDNSwgZGl2LlREQzUNDQoJe21zby1zdHlsZS1uYW1lOiJUREMgNSI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6NDQuMHB0Ow0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLlREQzYsIGxpLlREQzYsIGRpdi5UREM2DQ0KCXttc28tc3R5bGUtbmFtZToiVERDIDYiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0OjU1LjBwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5UREM3LCBsaS5UREM3LCBkaXYuVERDNw0NCgl7bXNvLXN0eWxlLW5hbWU6IlREQyA3IjsNDQoJbWFyZ2luLXRvcDowaW47DQ0KCW1hcmdpbi1yaWdodDowaW47DQ0KCW1hcmdpbi1ib3R0b206MGluOw0NCgltYXJnaW4tbGVmdDo2Ni4wcHQ7DQ0KCWxpbmUtaGVpZ2h0OjEzLjBwdDsNDQoJZm9udC1zaXplOjExLjBwdDsNDQoJZm9udC1mYW1pbHk6IlRpbWVzIE5ldyBSb21hbiIsc2VyaWY7fQ0NCnAuVERDOCwgbGkuVERDOCwgZGl2LlREQzgNDQoJe21zby1zdHlsZS1uYW1lOiJUREMgOCI7DQ0KCW1hcmdpbi10b3A6MGluOw0NCgltYXJnaW4tcmlnaHQ6MGluOw0NCgltYXJnaW4tYm90dG9tOjBpbjsNDQoJbWFyZ2luLWxlZnQ6NzcuMHB0Ow0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCWZvbnQtc2l6ZToxMS4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJUaW1lcyBOZXcgUm9tYW4iLHNlcmlmO30NDQpwLlREQzksIGxpLlREQzksIGRpdi5UREM5DQ0KCXttc28tc3R5bGUtbmFtZToiVERDIDkiOw0NCgltYXJnaW4tdG9wOjBpbjsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTowaW47DQ0KCW1hcmdpbi1sZWZ0Ojg4LjBwdDsNDQoJbGluZS1oZWlnaHQ6MTMuMHB0Ow0NCglmb250LXNpemU6MTEuMHB0Ow0NCglmb250LWZhbWlseToiVGltZXMgTmV3IFJvbWFuIixzZXJpZjt9DQ0KcC5UdHVsb1REQywgbGkuVHR1bG9UREMsIGRpdi5UdHVsb1REQw0NCgl7bXNvLXN0eWxlLW5hbWU6IlTtdHVsbyBUREMiOw0NCgltYXJnaW4tdG9wOjEyLjBwdDsNDQoJbWFyZ2luLXJpZ2h0OjBpbjsNDQoJbWFyZ2luLWJvdHRvbTozLjBwdDsNDQoJbWFyZ2luLWxlZnQ6MGluOw0NCglsaW5lLWhlaWdodDoxMy4wcHQ7DQ0KCXBhZ2UtYnJlYWstYWZ0ZXI6YXZvaWQ7DQ0KCWZvbnQtc2l6ZToxNi4wcHQ7DQ0KCWZvbnQtZmFtaWx5OiJDYWxpYnJpIExpZ2h0IixzYW5zLXNlcmlmOw0NCglmb250LXdlaWdodDpib2xkO30NDQpzcGFuLm1zb0lucw0NCgl7bXNvLXN0eWxlLW5hbWU6IiI7DQ0KCXRleHQtZGVjb3JhdGlvbjp1bmRlcmxpbmU7DQ0KCWNvbG9yOnRlYWw7fQ0NCnNwYW4ubXNvRGVsDQ0KCXttc28tc3R5bGUtbmFtZToiIjsNDQoJdGV4dC1kZWNvcmF0aW9uOmxpbmUtdGhyb3VnaDsNDQoJY29sb3I6cmVkO30NDQogLyogUGFnZSBEZWZpbml0aW9ucyAqLw0NCiBAcGFnZSBXb3JkU2VjdGlvbjENDQoJe3NpemU6NTk1LjM1cHQgODQyLjBwdDsNDQoJbWFyZ2luOjU2LjdwdCA3MC45cHQgNTYuN3B0IDcwLjlwdDt9DQ0KZGl2LldvcmRTZWN0aW9uMQ0NCgl7cGFnZTpXb3JkU2VjdGlvbjE7fQ0NCiAvKiBMaXN0IERlZmluaXRpb25zICovDQ0KIG9sDQ0KCXttYXJnaW4tYm90dG9tOjBpbjt9DQ0KdWwNDQoJe21hcmdpbi1ib3R0b206MGluO30NDQotLT4NDQo8L3N0eWxlPg==" />
                    </Binary>
                </contained>
                <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                    <valueReference>
                        <reference value="#stylesheet0" />
                    </valueReference>
                </extension>
                <status value="final" />
                <type>
                    <coding>
                        <system value="http://spor.ema.europa.eu/v1/lists/100000155531" />
                        <code value="100000155532" />
                        <display value="SUMMARY OF PRODUCT CHARACTERISTICS" />
                    </coding>
                </type>
                <subject>
                    <reference value="[]" />
                </subject>
                <date value="2021-02-01" />
                <author>
                    <identifier>
                        <system value="[]" />
                    </identifier>
                </author>
                <title value="Acme Product" />
                <relatesTo>
                    <code value="appends" />
                    <targetReference>
                        <reference value="${document[n].relatesTo}" />
                    </targetReference>
                </relatesTo>
                <section id="fe90a14e-4030-46e8-865e-2f2605b26c4c">
                    <title value="SUMMARY OF PRODUCT CHARACTERISTICS" />
                    <code>
                        <coding>
                            <system value="http://spor.ema.europa.eu/v1/example-sections" />
                            <code value="1" />
                            <display value="SUMMARY OF PRODUCT CHARACTERISTICS" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <span lang="EN-GB" style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;,serif;  color:green">
                                <br clear="all" style="page-break-before:always" />
                            </span>
                            <br clear="all" style="page-break-before:always" />
                        </div>
                    </text>
                    <section id="307ef8dd-16df-48e5-86de-2f6c967d0025">
                        <title value="1.       NAME OF THE MEDICINAL PRODUCT" />
                        <code>
                            <coding>
                                <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                <code value="3" />
                                <display value="1. NAME OF THE MEDICINAL PRODUCT" />
                            </coding>
                        </code>
                        <text>
                            <status value="additional" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                    <span lang="EN-GB">Acme Product 30 mg gastro‑resistant tablets</span>
                                </p>
                                <p class="MsoNormal" style="line-height:normal">
                                    <span lang="EN-GB">Acme Product 120 mg </span>
                                    <span lang="EN-GB">gastro‑resistant tablets</span>
                                </p>
                                <p class="MsoNormal" style="line-height:normal"></p>
                                <p class="MsoNormal" style="line-height:normal"></p>
                            </div>
                        </text>
                    </section>
                    <section id="1fe066ba-bb1a-446c-ab2f-6ed62f66b371">
                        <title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION" />
                        <code>
                            <coding>
                                <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                <code value="4" />
                                <display value="2. QUALITATIVE AND QUANTITATIVE COMPOSITION" />
                            </coding>
                        </code>
                        <text>
                            <status value="additional" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                    <u>
                                        <span lang="EN-GB">Acme Product 30 mg</span>
                                    </u>
                                </p>
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                    <span lang="EN-GB">Each </span>
                                    <span lang="EN-GB">gastro‑resistant tablet</span>
                                    <span lang="EN-GB">contains 30 mg dimethyl fumarate.</span>
                                </p>
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                    <u>
                                        <span lang="EN-GB">Acme Product 120 mg</span>
                                    </u>
                                </p>
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                    <span lang="EN-GB">Each </span>
                                    <span lang="EN-GB">gastro‑resistant tablet</span>
                                    <span lang="EN-GB">contains 120 mg dimethyl fumarate.</span>
                                </p>
                                <p class="MsoNormal" style="line-height:normal"></p>
                            </div>
                        </text>
                        <section id="12ef092e-11a7-4a2b-bb69-16beea26c8b9">
                            <title value="Excipient with known effect" />
                            <code>
                                <coding>
                                    <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                    <code value="7" />
                                    <display value="Excipient(s) with known effect" />
                                </coding>
                            </code>
                            <text>
                                <status value="additional" />
                                <div xmlns="http://www.w3.org/1999/xhtml">
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="EN-GB">Acme Product 30 mg</span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Each </span>
                                        <span lang="EN-GB">gastro‑resistant tablet</span>
                                        <span lang="EN-GB">contains 34.2 mg lactose (as </span>
                                        <span lang="EN-GB">monohydrate)</span>
                                        <span lang="EN-GB">.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="EN-GB">Acme Product 120 mg</span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Each </span>
                                        <span lang="EN-GB">gastro‑resistant tablet</span>
                                        <span lang="EN-GB">contains 136.8 mg lactose (as monohydrate).</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">For the full list of excipients, see section 6.1.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                </div>
                            </text>
                        </section>
                    </section>
                    <section id="248e1319-4e22-4c97-bee3-8ba8fa5eca0b">
                        <title value="3.       PHARMACEUTICAL FORM" />
                        <code>
                            <coding>
                                <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                <code value="8" />
                                <display value="3. PHARMACEUTICAL FORM" />
                            </coding>
                        </code>
                        <text>
                            <status value="additional" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                    <span lang="EN-GB">Gastro‑resistant tablet.</span>
                                </p>
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                    <u>
                                        <span lang="EN-GB">Acme Product 30 mg</span>
                                    </u>
                                </p>
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                    <span lang="EN-GB">White, film-coated, round, biconvex </span>
                                    <span lang="EN-GB">tablet</span>
                                    <span lang="EN-GB">with a diameter of approximately 6.8 mm.</span>
                                </p>
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                    <u>
                                        <span lang="EN-GB">Acme Product 120 mg</span>
                                    </u>
                                </p>
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                    <span lang="EN-GB">Blue, film-coated, round, biconvex </span>
                                    <span lang="EN-GB">tablet with a diameter of approximately 11.6 mm.</span>
                                </p>
                                <p class="MsoNormal" style="line-height:normal"></p>
                                <p class="MsoNormal" style="line-height:normal"></p>
                            </div>
                        </text>
                    </section>
                    <section id="edee7185-44da-41cb-9143-a1c0753cfecf">
                        <title value="4.       CLINICAL PARTICULARS" />
                        <code>
                            <coding>
                                <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                <code value="9" />
                                <display value="4. CLINICAL PARTICULARS" />
                            </coding>
                        </code>
                        <text>
                            <status value="additional" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                            </div>
                        </text>
                        <section id="629e8aa5-3958-4910-8794-dc506c61331a">
                            <title value="4.1     Therapeutic indications" />
                            <code>
                                <coding>
                                    <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                    <code value="10" />
                                    <display value="4.1 Therapeutic indications" />
                                </coding>
                            </code>
                            <text>
                                <status value="additional" />
                                <div xmlns="http://www.w3.org/1999/xhtml">
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Acme Product is indicated for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                </div>
                            </text>
                        </section>
                        <section id="ac695909-94e0-4904-b112-314b67beac99">
                            <title value="4.2     Posology and method of administration" />
                            <code>
                                <coding>
                                    <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                    <code value="11" />
                                    <display value="4.2 Posology and method of administration" />
                                </coding>
                            </code>
                            <text>
                                <status value="additional" />
                                <div xmlns="http://www.w3.org/1999/xhtml">
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="EN-GB"></span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Acme Product is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of psoriasis.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <u>
                                            <span lang="EN-GB"></span>
                                        </u>
                                    </p>
                                </div>
                            </text>
                            <section id="3cd4f0da-98e4-4648-ac69-2331e2e6fc08">
                                <title value="Posology" />
                                <code>
                                    <coding>
                                        <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                        <code value="12" />
                                        <display value="Posology" />
                                    </coding>
                                </code>
                                <text>
                                    <status value="additional" />
                                    <div xmlns="http://www.w3.org/1999/xhtml">
                                        <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                            <span lang="EN-GB">To improve tolerability, it is recommended to begin treatment with a low initial dose with subsequent gradual increases. In the first week, Acme Product 30 mg is taken once daily (1 tablet in the evening). In the second week, Acme Product 30 mg is taken twice daily (1 tablet in the morning and 1 in the evening). In the third week, Acme Product 30 mg is taken three times daily (1 tablet in the morning, 1 at midday, and 1 in the evening). From the fourth week, treatment is switched to only 1 tablet of Acme Product 120 mg in the evening. This dose is then increased by 1 Acme Product 120 mg tablet per week at different times of day for the subsequent 5 weeks, as shown in the table below. The maximum daily dose allowed is 720 mg (3 x 2 tablets of Acme Product 120 mg).</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                        <table border="0" cellpadding="0" cellspacing="0" class="Tablanormal" style="width:100.0%;border-collapse:collapse" width="100%">
                                            <tr>
                                                <td style="width:10.42%;border:solid windowtext 1.0pt;    border-bottom:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="10%">
                                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                                        <b>
                                                            <span lang="EN-GB">Week</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td colspan="3" style="width:62.5%;border:solid windowtext 1.0pt;    border-left:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="62%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <b>
                                                            <span lang="EN-GB">Number of tablets</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td style="width:27.08%;border-top:solid windowtext 1.0pt;    border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="27%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <b>
                                                            <span lang="EN-GB">Total daily dose (mg)</span>
                                                        </b>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="width:10.42%;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="10%">
                                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                                </td>
                                                <td style="width:20.84%;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <b>
                                                            <span lang="EN-GB">Morning</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:solid windowtext 1.0pt;    border-left:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <b>
                                                            <span lang="EN-GB">Midday</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:solid windowtext 1.0pt;    border-left:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <b>
                                                            <span lang="EN-GB">Evening</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td style="width:27.08%;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="27%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <b>
                                                            <span lang="EN-GB">of dimethyl fumarate </span>
                                                        </b>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="4" style="width:72.92%;border-top:none;    border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;    border-right:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="72%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <b>
                                                            <span lang="EN-GB">Acme Product 30 mg</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td style="width:27.08%;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="27%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid"></p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" width="10%">
                                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                                        <span lang="EN-GB">1</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">0</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">0</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">1</span>
                                                    </p>
                                                </td>
                                                <td style="width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" width="27%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">30</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" width="10%">
                                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                                        <span lang="EN-GB">2</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">1</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">0</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">1</span>
                                                    </p>
                                                </td>
                                                <td style="width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" width="27%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">60</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="width:10.42%;border:solid windowtext 1.0pt;border-top:    none;padding:1.4pt 5.4pt 1.4pt 5.4pt" width="10%">
                                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                                        <span lang="EN-GB">3</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">1</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">1</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">1</span>
                                                    </p>
                                                </td>
                                                <td style="width:27.08%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" width="27%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">90</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="4" style="width:72.92%;border-top:none;border-left:    solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:    none;padding:1.4pt 5.4pt 1.4pt 5.4pt" width="72%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <b>
                                                            <span lang="EN-GB">Acme Product 120 mg</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td style="width:27.08%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" width="27%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid"></p>
                                                </td>
                                            </tr>
                                            <tr style="height:11.55pt">
                                                <td style="width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt;    height:11.55pt" width="10%">
                                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                                        <span lang="EN-GB">4</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:11.55pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">0</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:11.55pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">0</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:11.55pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">1</span>
                                                    </p>
                                                </td>
                                                <td style="width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:11.55pt" width="27%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">120</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr style="height:12.65pt">
                                                <td style="width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt;    height:12.65pt" width="10%">
                                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                                        <span lang="EN-GB">5</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.65pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">1</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.65pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">0</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.65pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">1</span>
                                                    </p>
                                                </td>
                                                <td style="width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.65pt" width="27%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">240</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr style="height:16.15pt">
                                                <td style="width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt;    height:16.15pt" width="10%">
                                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                                        <span lang="EN-GB">6</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:16.15pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">1</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:16.15pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">1</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:16.15pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">1</span>
                                                    </p>
                                                </td>
                                                <td style="width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:16.15pt" width="27%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">360</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr style="height:12.1pt">
                                                <td style="width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt;    height:12.1pt" width="10%">
                                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                                        <span lang="EN-GB">7</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.1pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">1</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.1pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">1</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.1pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">2</span>
                                                    </p>
                                                </td>
                                                <td style="width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.1pt" width="27%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">480</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr style="height:13.25pt">
                                                <td style="width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt;    height:13.25pt" width="10%">
                                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                                        <span lang="EN-GB">8</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:13.25pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">2</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:13.25pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">1</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:13.25pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">2</span>
                                                    </p>
                                                </td>
                                                <td style="width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:13.25pt" width="27%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">600</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr style="height:15.85pt">
                                                <td style="width:10.42%;border:solid windowtext 1.0pt;border-top:    none;padding:1.4pt 5.4pt 1.4pt 5.4pt;height:15.85pt" width="10%">
                                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                                        <span lang="EN-GB">9+</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:15.85pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">2</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:15.85pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">2</span>
                                                    </p>
                                                </td>
                                                <td style="width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:15.85pt" width="20%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">2</span>
                                                    </p>
                                                </td>
                                                <td style="width:27.08%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:15.85pt" width="27%">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="EN-GB">720</span>
                                                    </p>
                                                </td>
                                            </tr>
                                        </table>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                        <p class="MsoNormal" style="line-height:normal">
                                            <span lang="EN-GB">If a particular dose increase is not tolerated, it may</span>
                                            <span lang="EN-GB">be temporarily reduced to the last tolerated dose.</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                        <p class="MsoNormal" style="line-height:normal">
                                            <span lang="EN-GB">If treatment success is observed before the maximum dose is reached, no further increase of dose is necessary. After clinically relevant improvement of the skin lesions has been achieved, consideration should be given to gradual reduction of the daily dose of Acme Product to the maintenance dose required by the individual.</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                        <p class="MsoNormal" style="line-height:normal">
                                            <span lang="EN-GB">Dosage modifications may also be necessary if</span>
                                            <span lang="EN-GB">abnormalities in laboratory parameters are observed </span>
                                            <span lang="EN-GB">(see section 4.4).</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                        <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                            <i>
                                                <span lang="EN-GB">Elderly patients</span>
                                            </i>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                            <span lang="EN-GB">Clinical studies of Acme Product did not include sufficient numbers of patients aged 65 years and above to determine whether they respond differently compared to patients under 65 years (see section 5.2). Based on the pharmacology of dimethyl fumarate, a need for dose adjustment in the elderly is not expected.</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                        <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                            <i>
                                                <span lang="EN-GB">Renal impairment</span>
                                            </i>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                            <span lang="EN-GB">No dose adjustment is needed in patients </span>
                                            <span lang="EN-GB">with mild to moderate renal impairment (see section 5.2).</span>
                                            <span lang="EN-GB">Acme Product has not been studied in patients with severe renal impairment, and use of Acme Product is contraindicated in these patients (see section 4.3).</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                        <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                            <i>
                                                <span lang="EN-GB">Hepatic impairment</span>
                                            </i>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                            <span lang="EN-GB">No dose adjustment is needed in patients </span>
                                            <span lang="EN-GB">with mild to moderate hepatic impairment (see section 5.2).</span>
                                            <span lang="EN-GB">Acme Product has not been studied in patients with severe hepatic impairment, and use of Acme Product is contraindicated in these patients (see section 4.3).</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                    </div>
                                </text>
                                <section id="f3544eb5-1cdd-4a65-a815-2c9119be0504">
                                    <title value="Paediatric population" />
                                    <code>
                                        <coding>
                                            <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                            <code value="13" />
                                            <display value="Paediatric population" />
                                        </coding>
                                    </code>
                                    <text>
                                        <status value="additional" />
                                        <div xmlns="http://www.w3.org/1999/xhtml">
                                            <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                                <span lang="EN-GB">The safety and efficacy of Acme Product in paediatric population below the age of 18 years have not been established. There are no data available with Acme Product in paediatric population.</span>
                                            </p>
                                            <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p>
                                        </div>
                                    </text>
                                </section>
                            </section>
                            <section id="9604c7e5-77de-4c81-8b69-2c6eb88de9be">
                                <title value="Method of administration" />
                                <code>
                                    <coding>
                                        <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                        <code value="14" />
                                        <display value="Method of administration" />
                                    </coding>
                                </code>
                                <text>
                                    <status value="additional" />
                                    <div xmlns="http://www.w3.org/1999/xhtml">
                                        <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                            <span lang="EN-GB">Acme Product is for oral use.</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal">
                                            <span lang="EN-GB">Acme Product tablets must be swallowed whole with fluid during or immediately after a meal.</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal">
                                            <span lang="EN-GB">The coating of the gastro‑resistant tablets is designed to prevent gastric irritation. Therefore, the tablets should not be crushed, divided, dissolved or chewed.</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                    </div>
                                </text>
                            </section>
                        </section>
                        <section id="2bf255a3-aab0-48cf-aa70-41bc28641ae0">
                            <title value="4.3     Contraindications" />
                            <code>
                                <coding>
                                    <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                    <code value="16" />
                                    <display value="4.3 Contraindications" />
                                </coding>
                            </code>
                            <text>
                                <status value="additional" />
                                <div xmlns="http://www.w3.org/1999/xhtml">
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                    <p class="Prrafodelista" style="margin-top:0in;margin-right:0in;margin-bottom:  0in;margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid">
                                        <span lang="EN-GB" style="font-size:11.0pt;font-family:&quot;Calibri&quot;,sans-serif">‒</span>
                                        <span lang="EN-GB" style="font-size:11.0pt">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span>
                                    </p>
                                    <p class="Prrafodelista" style="margin-top:0in;margin-right:0in;margin-bottom:  0in;margin-left:28.35pt;text-indent:-28.35pt">
                                        <span lang="EN-GB" style="font-size:11.0pt;font-family:&quot;Calibri&quot;,sans-serif">‒</span>
                                        <span lang="EN-GB" style="font-size:11.0pt">Severe gastrointestinal disorders.</span>
                                    </p>
                                    <p class="Prrafodelista" style="margin-top:0in;margin-right:0in;margin-bottom:  0in;margin-left:28.35pt;text-indent:-28.35pt">
                                        <span lang="EN-GB" style="font-size:11.0pt;font-family:&quot;Calibri&quot;,sans-serif">‒</span>
                                        <span lang="EN-GB" style="font-size:11.0pt">Severe hepatic or renal impairment.</span>
                                    </p>
                                    <p class="PrrafodelistaCxSpLast" style="margin-top:0in;margin-right:0in;  margin-bottom:0in;margin-left:28.35pt;text-indent:-28.35pt">
                                        <span lang="EN-GB" style="font-size:11.0pt;font-family:&quot;Calibri&quot;,sans-serif">‒</span>
                                        <span lang="EN-GB" style="font-size:11.0pt">Pregnancy and breast-feeding.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                </div>
                            </text>
                        </section>
                        <section id="52fbef30-5b80-4ece-8b05-772b36916b89">
                            <title value="4.4     Special warnings and precautions for use" />
                            <code>
                                <coding>
                                    <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                    <code value="17" />
                                    <display value="4.4 Special warnings and precautions for use" />
                                </coding>
                            </code>
                            <text>
                                <status value="additional" />
                                <div xmlns="http://www.w3.org/1999/xhtml">
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="EN-GB"></span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="EN-GB">Haematology</span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Acme Product may decrease leukocyte and lymphocyte counts (see section 4.8). It has not been studied in patients with pre-existing low leukocyte or lymphocyte counts.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <i>
                                            <span lang="EN-GB">Before treatment</span>
                                        </i>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Prior to initiating treatment with </span>
                                        <span lang="EN-GB">Acme Product, a current complete blood count (including differential blood count and platelet count) should be available. Treatment should not be initiated if</span>
                                        <span lang="EN-GB">leukopenia</span>
                                        <span lang="EN-GB">below 3.0x10
                                            <sup>9</sup>/L,
                                        </span>
                                        <span lang="EN-GB">lymphopenia below </span>
                                        <span lang="EN-GB">1.0x10
                                            <sup>9</sup>/L
                                        </span>
                                        <span lang="EN-GB">or other pathological results are identified.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <i>
                                            <span lang="EN-GB">During treatment</span>
                                        </i>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">During treatment a complete blood count with differential should be performed every 3 months. Action is needed in the following circumstances:</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" id="3de69782-1a9a-4ad4-895d-e8578e4f0ffa" style="line-height:normal"></p>
                                    <i>
                                        <span lang="EN-GB">Leukopenia:</span>
                                    </i>
                                    <none></none>
                                    <p class="MsoNormal" id="3de69782-1a9a-4ad4-895d-e8578e4f0ffa" style="line-height:normal">
                                        <span lang="EN-GB">If a marked decrease in the total number of white blood cells isfound, the situation should be monitored carefully and treatment withAcme Product should be discontinued at levels below 3.0x10
                                            <sup>9</sup>/L.
                                        </span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" id="ca0bf9c4-c58f-40b6-8adc-462ad91e700d" style="line-height:normal"></p>
                                    <i>
                                        <span lang="EN-GB">Lymphopenia:</span>
                                    </i>
                                    <none></none>
                                    <p class="MsoNormal" id="ca0bf9c4-c58f-40b6-8adc-462ad91e700d" style="line-height:normal">
                                        <span lang="EN-GB">If the lymphocyte count falls below 1.0x10
                                            <sup>9</sup>/L
                                        </span>
                                        <span lang="EN-GB" style="color:black">but is ≥0.7 x10
                                            <sup>9</sup>/L
                                        </span>
                                        <span lang="EN-GB">, blood monitoring should be performed monthly until levels returnto 1.0x10
                                            <sup>9</sup>/L or higher for two consecutive blood tests at whichpoint monitoring can again be performed every 3 months.
                                        </span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">If the
lymphocyte count falls below 0.7x10
                                            <sup>9</sup>/L, the blood test must be
repeated and if the levels are confirmed to be below 0.7x10
                                            <sup>9</sup>/L, then
treatment must be stopped immediately. Patients developing lymphopenia should
be monitored after stopping treatment until their lymphocyte count has returned
to the normal range (see section 4.8).
                                        </span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <i>
                                            <span lang="EN-GB">Other haematological disorders</span>
                                        </i>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Therapy should be discontinued and caution is advised if other pathological results occur. In any case blood counts should be monitored until values have returned to the normal range.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <u>
                                            <span lang="EN-GB"></span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="EN-GB">Infections</span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Acme Product is an immunomodulator and may affect the way the immune system responds to infection. For p</span>
                                        <span lang="EN-GB">atients with pre‑existing infections of clinical relevance, the physician should decide if treatment with Acme Product should only be initiated once the infection has resolved. If a patient develops an infection during treatment with Acme Product, suspension of treatment should be considered and the benefits and risks should be reassessed prior to re-initiation of therapy. Patients receiving Acme Product should be instructed to report symptoms of infection to a physician.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <i>
                                            <span lang="EN-GB">Opportunistic infections/progressive multifocal leukoencephalopathy (PML)</span>
                                        </i>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Cases of opportunistic infections, particularly of progressive multifocal leukoencephalopathy (PML) have been reported with other dimethyl fumarate-containing products (see section 4.8). PML is an opportunistic infection caused by the John‑Cunningham virus (JCV) that can be fatal or cause severe disabilities. PML is probably caused by a combination of factors.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">A previous infection with JCV is considered a prerequisite for the development of PML. Risk factors can include previous immunosuppressive treatment and the existence of certain concomitant disorders (such as some autoimmune disorders or malignant haematological conditions). A modified or weakened immune system as well as genetic or environmental factors can also constitute risk factors.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">Persistent moderate or severe lymphopenia during treatment with dimethyl fumarate is also considered a risk factor for PML. Patients who develop lymphopenia should be monitored for signs and symptoms of opportunistic infections, particularly for symptoms indicative of PML. Typical symptoms associated with PML are diverse, become worse over days to weeks and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision and changes in thinking, memory and orientation leading to confusion and personality changes. If PML is suspected, treatment with Acme Product should be stopped immediately and further appropriate neurological and radiological examinations performed.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <u>
                                            <span lang="EN-GB"></span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="EN-GB">Prior </span>
                                            <span lang="EN-GB">and concomitant </span>
                                        </u>
                                        <u>
                                            <span lang="EN-GB">treatment with immunosuppressive or immunomodulating therapies</span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Limited</span>
                                        <span lang="EN-GB">data are available on the efficacy and safety of Acme Product in patients who have been previously treated with other immunosuppressive or immunomodulating therapies. When switching patients from such therapies to Acme Product, the half-life and mode of action of the other therapy should be considered in order to avoid additive effects on the immune system.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <u>
                                            <span lang="EN-GB"></span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">No data are available on the efficacy and safety of Acme Product when taken concomitantly with other immunosuppressive or immunomodulating therapies (see section 4.5).</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <u>
                                            <span lang="EN-GB"></span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="EN-GB">Pre‑existing gastrointestinal disease</span>
                                        </u>
                                    </p>
                                    <p class="Default" style="page-break-after:avoid;text-autospace:ideograph-numeric ideograph-other">
                                        <span lang="EN-GB" style="font-size:11.0pt;color:windowtext">Acme Product has not been studied in patients with pre-existing gastrointestinal disease.</span>
                                        <span lang="EN-GB" style="font-size:11.0pt">Acme Product is contraindicated in patients with severe </span>
                                        <span lang="EN-GB" style="font-size:11.0pt">gastrointestinal disease </span>
                                        <span lang="EN-GB" style="font-size:11.0pt;color:windowtext">(see sections 4.3)</span>
                                        <span lang="EN-GB" style="font-size:11.0pt">. Gastrointestinal tolerability can be improved by following the </span>
                                        <span lang="EN-GB" style="font-size:11.0pt;color:windowtext">dose titration schedule on initiating Acme Product treatment and by taking Acme Product with food (see sections 4.2 and 4.8).</span>
                                    </p>
                                    <p class="Default"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="EN-GB">Renal function</span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Since renal elimination plays a minor role in the clearance of Acme Product from plasma, it is unlikely that renal impairment would affect the pharmacokinetic characteristics, and so a need for dose adjustment in patients with mild to moderate renal impairment is not expected (see sections 4.2 and 5.2).</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">During the Phase III placebo-controlled clinical trial, renal function was not seen to deteriorate during therapy across treatment groups. However, Acme Product has not been studied in patients with severe renal impairment, and some cases of renal toxicity have been reported during post-marketing surveillance with fumaric acid esters. Hence, Acme Product is contraindicated in patients with severe renal impairment (see section 4.3).</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">Renal function (e.g. creatinine, blood urea nitrogen and urinalysis) should be checked prior to initiation of treatment and every 3 months thereafter. In the event of a clinically relevant change in renal function, particularly in the absence of alternative explanations, consideration should be given to dosage reduction or treatment discontinuation.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <i>
                                            <span lang="EN-GB">Fanconi syndrome</span>
                                        </i>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Early diagnosis of Fanconi syndrome and discontinuation of Acme Product treatment are important to prevent the onset of renal impairment and osteomalacia, as the syndrome is usually reversible. The most important signs are: proteinuria, glucosuria (with normal blood sugar levels), hyperaminoaciduria and phosphaturia (possibly concurrent with hypophosphatemia). Progression might involve symptoms such as polyuria, polydipsia and proximal muscle weakness. In rare cases hypophosphataemic osteomalacia with non-localised bone pain, elevated alkaline phosphatase in serum and stress fractures may occur. Importantly, Fanconi syndrome can occur without elevated creatinine levels or low glomerular filtration rate. In case of unclear symptoms Fanconi syndrome should be considered and appropriate examinations should be performed.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="EN-GB">Hepatic function</span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Acme Product has not been studied in patients with severe hepatic impairment and is contraindicated in these patients (see section 4.3). </span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">It is recommended to monitor hepatic function (SGOT, SGPT, gamma‑GT, AP) prior to initiation of treatment and every 3 months thereafter, since elevation of hepatic enzymes has been observed in some patients in the Phase III study. In the event of a clinically relevant change in hepatic parameters, particularly in the absence of alternative explanations, consideration should be given to dose reduction or treatment discontinuation.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="EN-GB">Flushing</span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Patients should be made aware that they are likely to experience flushing in the first few weeks of taking Acme Product (see section 4.8).</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="EN-GB">Lactose</span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Acme Product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                </div>
                            </text>
                        </section>
                        <section id="82ef2852-a680-4c3b-9076-f08c351005a9">
                            <title value="4.5     Interaction with other medicinal products and other forms of interaction" />
                            <code>
                                <coding>
                                    <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                    <code value="20" />
                                    <display value="4.5 Interaction with other medicinal products and other forms of interaction" />
                                </coding>
                            </code>
                            <text>
                                <status value="additional" />
                                <div xmlns="http://www.w3.org/1999/xhtml">
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">No interaction studies have been performed.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">Acme Product should </span>
                                        <span lang="EN-GB">be used cautiously in combination </span>
                                        <span lang="EN-GB">with other</span>
                                        <span lang="EN-GB">systemic antipsoriatic therapy (e.g. methotrexate, retinoids, psoralens, ciclosporin, immunosuppressants or cytostatics) (see section 4.4). </span>
                                        <span lang="EN-GB">During treatment with Acme Product, simultaneous use of other fumaric acid derivatives (topical or systemic) should be avoided.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">Concurrent therapy with nephrotoxic substances (e.g. methotrexate, ciclosporin, aminoglycosides, diuretics, NSAIDs or lithium) may increase the potential for renal adverse reactions (e.g. proteinuria) in patients taking Acme Product.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">In cases of severe or prolonged diarrhoea during treatment with Acme Product, absorption of other medicinal products may be affected. Caution should be exercised when prescribing medicinal products with a narrow therapeutic index that require absorption in the intestinal tract.</span>
                                        <span lang="EN-GB">The efficacy of oral contraceptives may be reduced and the use of an alternative barrier contraceptive method is recommended to prevent possible failure of contraception (see the prescribing information of the oral contraceptive).</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">Consumption of large quantities of strong alcoholic drinks (more than 30% alcohol by volume) should be avoided because it may lead to increased dissolution rates of Acme Product and, therefore, may increase the frequency of gastrointestinal adverse reactions.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">Vaccination during treatment with Acme Product has not been studied. Immunosuppression is a risk factor for the use of live vaccines. The risk of vaccination should be weighed against the benefit.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">There is no evidence for Acme Product interaction with cytochrome P450 and the most common efflux and uptake transporters, thus no interactions are expected with medicinal products metabolised or transported by these systems (see section 5.2).</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                </div>
                            </text>
                        </section>
                        <section id="eb10e9ba-bf7d-43f3-bce8-14d2bdf5d325">
                            <title value="4.6     Fertility, pregnancy and lactation" />
                            <code>
                                <coding>
                                    <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                    <code value="22" />
                                    <display value="4.6 Fertility, pregnancy and lactation" />
                                </coding>
                            </code>
                            <text>
                                <status value="additional" />
                                <div xmlns="http://www.w3.org/1999/xhtml">
                                    <p class="Textocomentario" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="X-NONE" style="font-size:11.0pt"></span>
                                        </u>
                                    </p>
                                    <p class="Textocomentario" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="X-NONE" style="font-size:11.0pt">Women of child-bearing potential</span>
                                        </u>
                                    </p>
                                    <p class="Textocomentario" style="line-height:normal;page-break-after:avoid">
                                        <span lang="X-NONE" style="font-size:11.0pt">Acme Product is not recommended in women of child-bearing potential not using appropriate contraception. In patients experiencing diarrhoea during Acme Product treatment, the effect of oral contraceptives may be reduced and additional barrier methods of contraception may be necessary (see section 4.5).</span>
                                    </p>
                                    <p class="Textocomentario" style="line-height:normal">
                                        <u>
                                            <span lang="X-NONE" style="font-size:11.0pt"></span>
                                        </u>
                                    </p>
                                </div>
                            </text>
                            <section id="2d5a87fc-ba92-4fe3-962e-4c6dd1067255">
                                <title value="Pregnancy" />
                                <code>
                                    <coding>
                                        <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                        <code value="23" />
                                        <display value="Pregnancy" />
                                    </coding>
                                </code>
                                <text>
                                    <status value="additional" />
                                    <div xmlns="http://www.w3.org/1999/xhtml">
                                        <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                            <span lang="EN-GB">There are limited</span>
                                            <span lang="EN-GB">data from the use of dimethyl fumarate in pregnant women. Animal studies have shown reproductive toxicity (see section 5.3). </span>
                                            <span lang="EN-GB">Acme Product is contraindicated during pregnancy (see section 4.3).</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal">
                                            <u>
                                                <span lang="EN-GB"></span>
                                            </u>
                                        </p>
                                    </div>
                                </text>
                            </section>
                            <section id="e5373e86-6286-4cec-869d-45cdce554587">
                                <title value="Breast‑feeding" />
                                <code>
                                    <coding>
                                        <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                        <code value="24" />
                                        <display value="Breast-feeding" />
                                    </coding>
                                </code>
                                <text>
                                    <status value="additional" />
                                    <div xmlns="http://www.w3.org/1999/xhtml">
                                        <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                            <span lang="EN-GB" style="color:black">It is unknown whether </span>
                                            <span lang="EN-GB">dimethyl </span>
                                            <span lang="EN-GB">fumarate
                                                <span style="color:black">or its metabolites are excreted in human milk. A risk to newborns or infants cannot be </span>excluded
                                                <span style="color:black">.</span>
                                            </span>
                                            <span lang="EN-GB">Therefore, Acme Product is contraindicated during breast-feeding </span>
                                            <span lang="EN-GB">(</span>
                                            <span lang="EN-GB">see section 4.3).</span>
                                        </p>
                                        <p class="Textocomentario" style="line-height:normal"></p>
                                    </div>
                                </text>
                            </section>
                            <section id="8c5f5d68-ad92-4b71-8790-80fc716af60d">
                                <title value="Fertility" />
                                <code>
                                    <coding>
                                        <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                        <code value="25" />
                                        <display value="Fertility" />
                                    </coding>
                                </code>
                                <text>
                                    <status value="additional" />
                                    <div xmlns="http://www.w3.org/1999/xhtml">
                                        <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                            <span lang="EN-GB">There are no human or animal data on the effects of Acme Product on fertility.</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                    </div>
                                </text>
                            </section>
                        </section>
                        <section id="20df1935-92c7-416f-a820-4faf30d9bf78">
                            <title value="4.7     Effects on ability to drive and use machines" />
                            <code>
                                <coding>
                                    <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                    <code value="26" />
                                    <display value="4.7 Effects on ability to drive and use machines" />
                                </coding>
                            </code>
                            <text>
                                <status value="additional" />
                                <div xmlns="http://www.w3.org/1999/xhtml">
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">No studies on the ability to drive and use machines have been conducted. Acme Product may have a minor influence on the ability to drive and use machines. Dizziness and fatigue may occur following administration of Acme Product (see section 4.8).</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                </div>
                            </text>
                        </section>
                        <section id="1e27f2ed-048a-4f89-9b59-dddd00145fa2">
                            <title value="4.8     Undesirable effects" />
                            <code>
                                <coding>
                                    <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                    <code value="27" />
                                    <display value="4.8 Undesirable effects" />
                                </coding>
                            </code>
                            <text>
                                <status value="additional" />
                                <div xmlns="http://www.w3.org/1999/xhtml">
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="EN-GB"></span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="EN-GB">Summary of the safety profile</span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">The most common adverse reactions observed with Acme Product in the Phase III clinical study (1102) in psoriasis patients were gastrointestinal events (62.7%), flushing (20.8%) and lymphopenia (10.0%). Most adverse reactions were considered mild and did not lead to discontinuation of study treatment. The only adverse reactions that led to discontinuation of treatment in &gt;5% of patients were gastrointestinal reactions. For monitoring recommendations and clinical management of adverse reactions, see section 4.4.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="EN-GB">Tabulated list of adverse reactions</span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">The following is a list of adverse reactions experienced by patients treated with Acme Product during the clinical study and with Fumaderm, a related </span>
                                        <span lang="EN-GB">medicinal product containing dimethyl fumarate along with other fumaric acid esters</span>
                                        <span lang="EN-GB">.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">The frequency of adverse reactions is defined using the following convention: very common (≥1/10); common (≥1/100 to &lt;1/10); uncommon (≥1/1,000 to &lt;1/100); rare (≥1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); and not known (cannot be estimated from available data).</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <table border="1" cellpadding="0" cellspacing="0" class="Tablanormal" style="border-collapse:   collapse;border:none">
                                        <thead>
                                            <tr>
                                                <td style="width:155.35pt;border:solid windowtext 1.0pt;     padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="207">
                                                    <p class="MsoNormal" style="line-height:normal">
                                                        <b>
                                                            <span lang="EN-GB">System    organ class</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td style="width:218.6pt;border:solid windowtext 1.0pt;     border-left:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="291">
                                                    <p class="MsoNormal" style="line-height:normal">
                                                        <b>
                                                            <span lang="EN-GB">Adverse reactions</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td style="width:90.4pt;border:solid windowtext 1.0pt;     border-left:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="121">
                                                    <p class="MsoNormal" style="line-height:normal">
                                                        <b>
                                                            <span lang="EN-GB">Frequency</span>
                                                        </b>
                                                    </p>
                                                </td>
                                            </tr>
                                        </thead>
                                        <tr>
                                            <td style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="207">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Infections and   infestations</span>
                                                </p>
                                            </td>
                                            <td style="width:218.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="291">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Herpes zoster</span>
                                                </p>
                                            </td>
                                            <td style="width:90.4pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="121">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Not known**</span>
                                                </p>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="207">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Blood and   lymphatic system disorders</span>
                                                </p>
                                            </td>
                                            <td style="width:218.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="291">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Lymphopenia</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Leukopenia</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Eosinophilia</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Leukocytosis</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Acute   lymphatic leukaemia*</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Irreversible   pancytopenia*</span>
                                                </p>
                                            </td>
                                            <td style="width:90.4pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="121">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Very common</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Very common</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Common</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Common</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Very rare</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Very rare</span>
                                                </p>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="207">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Metabolism and   nutrition disorders</span>
                                                </p>
                                            </td>
                                            <td style="width:218.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="291">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Decreased   appetite</span>
                                                </p>
                                            </td>
                                            <td style="width:90.4pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="121">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Common</span>
                                                </p>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="207">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Nervous system   disorders</span>
                                                </p>
                                            </td>
                                            <td style="width:218.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="291">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Headache</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Paraesthesia</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Dizziness*</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Progressive   multifocal leukoencephalopathy</span>
                                                </p>
                                            </td>
                                            <td style="width:90.4pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="121">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Common</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Common</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Uncommon</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Not known</span>
                                                </p>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="207">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Vascular   disorders</span>
                                                </p>
                                            </td>
                                            <td style="width:218.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="291">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Flushing</span>
                                                </p>
                                            </td>
                                            <td style="width:90.4pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="121">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Very common</span>
                                                </p>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="207">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Gastrointestinal   disorders</span>
                                                </p>
                                            </td>
                                            <td style="width:218.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="291">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="IT">Diarrhoea</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="IT">Abdominal   distension</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="IT">Abdominal pain</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="IT">Nausea</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="IT">Vomiting</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="IT">Dyspepsia</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Constipation</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Abdominal   discomfort</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Flatulence</span>
                                                </p>
                                            </td>
                                            <td style="width:90.4pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="121">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Very common</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Very common</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Very common</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Very common</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Common</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Common</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Common</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Common</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Common</span>
                                                </p>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="207">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Skin and   subcutaneous tissue disorders</span>
                                                </p>
                                            </td>
                                            <td style="width:218.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="291">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Erythema</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Skin burning   sensation</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Pruritus</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Allergic skin   reaction</span>
                                                </p>
                                            </td>
                                            <td style="width:90.4pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="121">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Common</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Common</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Common</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Rare</span>
                                                </p>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="207">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Renal and   urinary disorders</span>
                                                </p>
                                            </td>
                                            <td style="width:218.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="291">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Proteinuria</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Renal failure</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Fanconi   syndrome</span>
                                                    <span lang="EN-GB">*</span>
                                                </p>
                                            </td>
                                            <td style="width:90.4pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="121">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Uncommon</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Not known</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Not known</span>
                                                </p>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="207">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">General   disorders and administration site conditions </span>
                                                </p>
                                            </td>
                                            <td style="width:218.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="291">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Fatigue</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Feeling hot</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Asthenia</span>
                                                </p>
                                            </td>
                                            <td style="width:90.4pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="121">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Common</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Common</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Common</span>
                                                </p>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="207">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Investigations</span>
                                                </p>
                                            </td>
                                            <td style="width:218.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="291">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Hepatic   enzymes increased</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Serum   creatinine increased</span>
                                                </p>
                                            </td>
                                            <td style="width:90.4pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="121">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Common</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB">Uncommon</span>
                                                </p>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td colspan="3" style="width:464.35pt;border:none;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="619">
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB" style="font-size:9.0pt">*Additional adverse reactions reported with Fumaderm,   a related medicinal product containing dimethyl fumarate along with other   fumaric acid esters.</span>
                                                </p>
                                                <p class="MsoNormal" style="line-height:normal">
                                                    <span lang="EN-GB" style="font-size:9.0pt">**Adverse reactions reported during post marketing   experience.</span>
                                                </p>
                                            </td>
                                        </tr>
                                    </table>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="EN-GB">Description of selected adverse reactions</span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <i>
                                            <span lang="EN-GB">Gastrointestinal disturbances</span>
                                        </i>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Data from the Phase III clinical study as well as from the literature show that gastrointestinal disorders with dimethyl fumarate‑containing products are most likely to occur during the first 2 to 3 months after starting treatment. No apparent dose relationship and no risk factors for the occurrence of these adverse reactions could be identified. Diarrhoea was a common adverse reaction (36.9%) among patients taking Acme Product, leading to medicinal product withdrawal in about 10% of patients. More than 90% of these diarrhoea events were of mild to moderate severity (see section 4.4).</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <i>
                                            <span lang="EN-GB">Flushing</span>
                                        </i>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Based on observations in the Phase III clinical study as well as on literature data, flushing is most likely to occur during the early weeks of treatment and tends to lessen with time. In the clinical study a total of 20.8% of patients receiving Acme Product </span>
                                        <span lang="EN-GB">experienced flushing, which was mild in the majority of cases (see section 4.4). Published clinical experience with dimethyl fumarate-containing products shows that individual episodes of flushing usually begin shortly after taking the tablets and resolve within a few hours.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <i>
                                            <span lang="EN-GB">Haematological changes</span>
                                        </i>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Data from the Phase III clinical study as well as from the
literature show that changes in haematological parameters are most likely to
occur during the first 3 months after starting treatment with dimethyl
fumarate. In particular, in the clinical study there was a slight decrease in
mean lymphocyte counts starting between weeks 3 and 5 and reaching a
maximum in week 12 where approximately one third of patients had
lymphocyte values below 1.0x10
                                            <sup>9</sup>/L. The mean and median values of
lymphocytes remained within the normal range during the clinical study. At week 16
(end of treatment), there was no further decline in lymphocyte counts. At week
16
                                        </span>
                                        <span lang="EN-GB">of treatment</span>
                                        <span lang="EN-GB">, 13/175 (7.4%) </span>
                                        <span lang="EN-GB">of patients were noted to have lymphocyte levels &lt;0.7x 10
                                            <sup>9</sup>/L.
Blood sampling for safety clinical laboratory tests at follow-up visits was
only performed in case of abnormalities at the preceeding visit. During the
treatment free follow up, lymphocyte levels of &lt;0.7x 10
                                            <sup>9</sup>/L were
observed in 1/29 (3.5%) patient at 6 months and 0/28 (0%) at 12 months after
stopping treatment.
                                        </span>
                                        <span lang="EN-GB">At 12 months after stopping treatment
3/28 (10.7%) of patients had lymphocyte values below 1.0x10
                                            <sup>9</sup>/L,
which would represent 3/279 (1.1%) of the patients started on Acme Product.
                                        </span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">For the total
leukocyte count, a decline became apparent at week 12 of treatment; it
slowly increased again at week 16 (end of treatment); and 12 months
after stopping treatment all patients had values above 3.0x10
                                            <sup>9</sup>/L.
                                        </span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">A transient increase in mean values of eosinophils was noted as early as week 3, reached a maximum at week 5 and 8, and had returned to baseline values at week 16. </span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">For monitoring recommendations and clinical management of haematological adverse reactions, see section 4.4.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                </div>
                            </text>
                            <section id="c0d1136e-e986-4ce9-a747-16f227e8a02f">
                                <title value="Reporting of suspected adverse reactions" />
                                <code>
                                    <coding>
                                        <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                        <code value="29" />
                                        <display value="Reporting of suspected adverse reactions" />
                                    </coding>
                                </code>
                                <text>
                                    <status value="additional" />
                                    <div xmlns="http://www.w3.org/1999/xhtml">
                                        <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                            <span lang="EN-GB">Reporting suspected adverse reactions after </span>
                                            <span lang="EN-GB">authorisation</span>
                                            <span lang="EN-GB">of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via 
                                                <span style="background:lightgrey">the national reporting system listed in </span>
                                            </span>
                                            <span lang="EN-GB">
                                                <a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">
                                                    <span class="Hipervnculo">
                                                        <span style="background:lightgrey">Appendix V</span>
                                                    </span>
                                                </a>
                                            </span>
                                            <span lang="EN-GB">.</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                    </div>
                                </text>
                            </section>
                        </section>
                        <section id="627d26c9-ebe7-4518-a6b7-e7264a1d0f6a">
                            <title value="4.9     Overdose" />
                            <code>
                                <coding>
                                    <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                    <code value="30" />
                                    <display value="4.9 Overdose" />
                                </coding>
                            </code>
                            <text>
                                <status value="additional" />
                                <div xmlns="http://www.w3.org/1999/xhtml">
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Symptomatic treatment is indicated in the case of an overdose. No specific antidote is known.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                </div>
                            </text>
                        </section>
                    </section>
                    <section id="cb0ae994-0435-4812-9a5c-ff150014510a">
                        <title value="5.       PHARMACOLOGICAL PROPERTIES" />
                        <code>
                            <coding>
                                <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                <code value="32" />
                                <display value="5. PHARMACOLOGICAL PROPERTIES" />
                            </coding>
                        </code>
                        <text>
                            <status value="additional" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                            </div>
                        </text>
                        <section id="a91b5286-b5f8-442d-8579-cf5477337aa2">
                            <title value="5.1     Pharmacodynamic properties" />
                            <code>
                                <coding>
                                    <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                    <code value="33" />
                                    <display value="5.1 Pharmacodynamic properties" />
                                </coding>
                            </code>
                            <text>
                                <status value="additional" />
                                <div xmlns="http://www.w3.org/1999/xhtml">
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Pharmacotherapeutic group: </span>
                                        <span lang="EN-GB">Other immunosuppressants,</span>
                                        <span lang="EN-GB">ATC code: </span>
                                        <span lang="EN-GB">L04AX07</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <u>
                                            <span lang="EN-GB"></span>
                                        </u>
                                    </p>
                                </div>
                            </text>
                            <section id="98bc7dbb-bac6-440c-a5f9-a012d496b8ef">
                                <title value="Mechanism of action" />
                                <code>
                                    <coding>
                                        <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                        <code value="34" />
                                        <display value="Mechanism of action" />
                                    </coding>
                                </code>
                                <text>
                                    <status value="additional" />
                                    <div xmlns="http://www.w3.org/1999/xhtml">
                                        <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                            <span lang="EN-GB">The anti-inflammatory and immunomodulating effects of dimethyl fumarate and its metabolite monomethyl fumarate are not fully elucidated but are thought to be mainly due to the interaction with the intracellular reduced glutathione of cells directly involved in the pathogenesis of psoriasis. This interaction with glutathione leads to the inhibition of translocation into the nucleus and the transcriptional activity of the nuclear factor kappa‑light‑chain‑enhancer of activated B‑cells (NF‑κB).</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                        <p class="MsoNormal" style="line-height:normal">
                                            <span lang="EN-GB">The main activity of dimethyl fumarate and monomethyl fumarate is considered to be immunomodulatory, resulting in a shift in T helper cells (Th) from the Th1 and Th17 profile to a Th2 phenotype. The inflammatory cytokine production is reduced with induction of proapoptotic events, inhibition of keratinocyte proliferation, reduced expression of adhesion molecules, and diminished inflammatory infiltrate within psoriatic plaques.</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal">
                                            <u>
                                                <span lang="EN-GB"></span>
                                            </u>
                                        </p>
                                    </div>
                                </text>
                            </section>
                            <section id="287a0ff0-769c-4b91-90b3-83db1a79dd2d">
                                <title value="Clinical efficacy and safety" />
                                <code>
                                    <coding>
                                        <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                        <code value="36" />
                                        <display value="Clinical efficacy and safety" />
                                    </coding>
                                </code>
                                <text>
                                    <status value="additional" />
                                    <div xmlns="http://www.w3.org/1999/xhtml">
                                        <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                            <span lang="EN-GB">The safety and efficacy of Acme Product was assessed in one double‑blind, </span>
                                            <span lang="EN-GB">3‑arm, placebo‑ and active comparator-controlled Phase III study (1102) in patients with moderate to severe plaque psoriasis (Study 1102). 704 patients were randomised to receive Acme Product, an active comparator (Fumaderm, a combination product with the same content of </span>
                                            <span lang="EN-GB">dimethyl fumarate plus</span>
                                            <span lang="EN-GB">3 monoethyl fumarate salts) and placebo in a ratio of 2:2:1. Patients began treatment with tablets containing 30 mg/day </span>
                                            <span lang="EN-GB">dimethyl fumarate</span>
                                            <span lang="EN-GB">or placebo, titrating up to a maximum of 720 mg/day in both active treatment arms as described in section 4.2. </span>
                                            <span lang="EN-GB">If treatment success was observed before the maximum dose of 720 mg/day of dimethyl fumarate was reached, no further increase of dosage was necessary and the dosage was to be steadily reduced to an individual maintenance dose. In case of individual intolerability of the increased dosage during weeks 4 to 16, the patient was to return to the last tolerated dose taken since the start of week 4, which was to be maintained until end of the treatment period (week 16). </span>
                                            <span lang="EN-GB">Patients received treatment for up to 16 weeks and follow-up visits were planned for up to 12 months after treatment was stopped.</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                        <p class="MsoNormal" style="line-height:normal">
                                            <span lang="EN-GB">The demographic and baseline characteristics were well balanced between the treatment </span>
                                            <span lang="EN-GB">groups</span>
                                            <span lang="EN-GB">. Of the 699 patients, most were Caucasian (99%) and male (65%), and the mean age was 44 years. Most patients (91%) were &lt;65 years of age. Most patients had moderate psoriasis based on Psoriasis Area and Severity Index (PASI) and Physician’s Global Assessment (PGA) scores at baseline: the mean PASI score at baseline was 16.35 and 60% of patients scored as moderate on the PGA. The majority of patients reported a “very large” or “extremely large” effect of psoriasis on their life based on the Dermatology Life Quality Index (DLQI), with a mean DLQI score of 11.5.</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                        <p class="MsoNormal" style="line-height:normal;text-autospace:none">
                                            <a name="_Ref431313822">
                                                <span lang="EN-GB">After 16 weeks of treatment, Acme Product was found to be superior to placebo (p&lt;0.0001) based on PASI 75 and PGA score clear or almost clear and non‑inferior (using a non-inferiority margin of ‑15%) to the active comparator (p&lt;0.0003) based on PASI 75. </span>
                                            </a>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                        <table border="0" cellpadding="0" cellspacing="0" class="Tablanormal" style="border-collapse:collapse" width="612">
                                            <tr>
                                                <td colspan="7" style="width:459.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="612">
                                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                                        <b>
                                                            <span lang="EN-GB" style="font-size:10.0pt">Summary of clinical efficacy after   16 weeks treatment in Study 1102</span>
                                                        </b>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="width:203.85pt;border:none;border-top:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="272">
                                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                                        <b>
                                                            <span lang="NL-BE" style="font-size:10.0pt">Assessment</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td colspan="2" style="width:92.15pt;border:none;    border-top:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="123">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <b>
                                                            <span lang="NL-BE" style="font-size:10.0pt">Acme Product</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td colspan="3" style="width:70.9pt;border:none;border-top:    solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="95">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <b>
                                                            <span lang="NL-BE" style="font-size:10.0pt">Placebo</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td style="width:92.1pt;border:none;border-top:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="123">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <b>
                                                            <span lang="NL-BE" style="font-size:10.0pt">Fumaderm</span>
                                                        </b>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="width:203.85pt;border:none;border-bottom:    solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="272">
                                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                                </td>
                                                <td colspan="2" style="width:92.15pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="123">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <b>
                                                            <span lang="NL-BE" style="font-size:10.0pt">N=267</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td colspan="3" style="width:70.9pt;border:none;border-bottom:    solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="95">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <b>
                                                            <span lang="NL-BE" style="font-size:10.0pt">N=131</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td style="width:92.1pt;border:none;border-bottom:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="123">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <b>
                                                            <span lang="NL-BE" style="font-size:10.0pt">N=273</span>
                                                        </b>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="7" style="width:459.0pt;border:none;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="612">
                                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                                        <b>
                                                            <span lang="NL-BE" style="font-size:10.0pt">Superiority testing vs placebo</span>
                                                        </b>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="width:203.85pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="272">
                                                    <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;    line-height:normal;page-break-after:avoid">
                                                        <b>
                                                            <span lang="NL-BE" style="font-size:10.0pt">PASI 75</span>
                                                        </b>
                                                        <span lang="NL-BE" style="font-size:    10.0pt">, n (%)</span>
                                                    </p>
                                                </td>
                                                <td colspan="2" style="width:92.15pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" width="123">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">100 (37.5)</span>
                                                    </p>
                                                </td>
                                                <td colspan="3" style="width:70.9pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" width="95">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">20 (15.3)</span>
                                                    </p>
                                                </td>
                                                <td style="width:92.1pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" width="123">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">110 (40.3)</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="width:203.85pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="272">
                                                    <p class="MsoNormal" style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">p-value</span>
                                                    </p>
                                                </td>
                                                <td colspan="3" style="width:127.6pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="170">
                                                    <p align="right" class="MsoNormal" style="margin-right:15.85pt;text-align:right;    line-height:normal;page-break-after:avoid">
                                                        <span lang="NL-BE" style="font-size:    10.0pt">&lt;0.0001
                                                            <sup>a</sup>
                                                        </span>
                                                    </p>
                                                </td>
                                                <td colspan="3" style="width:127.55pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="170">
                                                    <p class="MsoNormal" style="margin-left:15.85pt;line-height:normal;page-break-after:    avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">&lt;0.0001
                                                            <sup>a</sup>
                                                        </span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="width:203.85pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="272">
                                                    <p class="MsoNormal" style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">Two-sided 99.24% CI</span>
                                                    </p>
                                                </td>
                                                <td colspan="3" style="width:127.6pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="170">
                                                    <p align="right" class="MsoNormal" style="margin-right:14.2pt;text-align:right;    line-height:normal;page-break-after:avoid">
                                                        <span lang="NL-BE" style="font-size:    10.0pt">10.7, 33.7</span>
                                                        <sup>
                                                            <span lang="NL-BE" style="font-size:10.0pt">a</span>
                                                        </sup>
                                                    </p>
                                                </td>
                                                <td colspan="3" style="width:127.55pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="170">
                                                    <p class="MsoNormal" style="margin-left:8.75pt;line-height:normal;page-break-after:    avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">13.5, 36.6</span>
                                                        <sup>
                                                            <span lang="NL-BE" style="font-size:10.0pt">a</span>
                                                        </sup>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="width:203.85pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="272">
                                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                                        <b>
                                                            <span lang="EN-GB" style="font-size:10.0pt">PGA score clear or almost clear,</span>
                                                        </b>
                                                        <span lang="EN-GB" style="font-size:10.0pt">n (%)</span>
                                                    </p>
                                                </td>
                                                <td colspan="2" style="width:92.15pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="123">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">88 (33.0)</span>
                                                    </p>
                                                </td>
                                                <td colspan="3" style="width:70.9pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="95">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">17 (13.0)</span>
                                                    </p>
                                                </td>
                                                <td style="width:92.1pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="123">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">102 (37.4)</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="width:203.85pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="272">
                                                    <p class="MsoNormal" style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">p-value</span>
                                                    </p>
                                                </td>
                                                <td colspan="3" style="width:127.6pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="170">
                                                    <p align="right" class="MsoNormal" style="margin-right:15.85pt;text-align:right;    line-height:normal;page-break-after:avoid">
                                                        <span lang="NL-BE" style="font-size:    10.0pt">&lt;0.0001
                                                            <sup>a</sup>
                                                        </span>
                                                    </p>
                                                </td>
                                                <td colspan="3" style="width:127.55pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="170">
                                                    <p class="MsoNormal" style="margin-left:15.85pt;line-height:normal;page-break-after:    avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">&lt;0.0001
                                                            <sup>a</sup>
                                                        </span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td style="width:203.85pt;border:none;border-bottom:    solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="272">
                                                    <p class="MsoNormal" style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">Two-sided 99.24% CI</span>
                                                    </p>
                                                </td>
                                                <td colspan="3" style="width:127.6pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="170">
                                                    <p align="right" class="MsoNormal" style="margin-right:14.2pt;text-align:right;    line-height:normal;page-break-after:avoid">
                                                        <span lang="NL-BE" style="font-size:    10.0pt">9.0, 31.0</span>
                                                        <sup>
                                                            <span lang="NL-BE" style="font-size:10.0pt">a</span>
                                                        </sup>
                                                    </p>
                                                </td>
                                                <td colspan="3" style="width:127.55pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="170">
                                                    <p class="MsoNormal" style="margin-left:8.75pt;line-height:normal;page-break-after:    avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">13.3, 35.5</span>
                                                        <sup>
                                                            <span lang="NL-BE" style="font-size:10.0pt">a</span>
                                                        </sup>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="2" style="width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="319">
                                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                                </td>
                                                <td colspan="3" style="width:106.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="142">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <b>
                                                            <span lang="NL-BE" style="font-size:10.0pt">Acme Product</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td colspan="2" style="width:113.4pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="151">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <b>
                                                            <span lang="NL-BE" style="font-size:10.0pt">Fumaderm</span>
                                                        </b>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="2" style="width:239.3pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="319">
                                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                                </td>
                                                <td colspan="3" style="width:106.3pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="142">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <b>
                                                            <span lang="NL-BE" style="font-size:10.0pt">N=267</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td colspan="2" style="width:113.4pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="151">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <b>
                                                            <span lang="NL-BE" style="font-size:10.0pt">N=273</span>
                                                        </b>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="2" style="width:239.3pt;border:none;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="319">
                                                    <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;    line-height:normal;page-break-after:avoid">
                                                        <b>
                                                            <span lang="EN-GB" style="font-size:10.0pt">Non-inferiority of Acme Product vs. Fumaderm</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td colspan="3" style="width:106.3pt;border:none;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="142">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid"></p>
                                                </td>
                                                <td colspan="2" style="width:113.4pt;border:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" width="151">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid"></p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="2" style="width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="319">
                                                    <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;    line-height:normal;page-break-after:avoid">
                                                        <b>
                                                            <span lang="NL-BE" style="font-size:10.0pt">PASI 75</span>
                                                        </b>
                                                        <span lang="NL-BE" style="font-size:    10.0pt">, n (%)</span>
                                                    </p>
                                                </td>
                                                <td colspan="3" style="width:106.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="142">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">100 (37.5)</span>
                                                    </p>
                                                </td>
                                                <td colspan="2" style="width:113.4pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" width="151">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">110 (40.3)</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="2" style="width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="319">
                                                    <p class="MsoNormal" style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">p-value</span>
                                                    </p>
                                                </td>
                                                <td colspan="5" style="width:219.7pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="293">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">0.0003
                                                            <sup>b</sup>
                                                        </span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="2" style="width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="319">
                                                    <p class="MsoNormal" style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid">
                                                        <span lang="EN-GB" style="font-size:10.0pt">One-sided 97.5% repeated CI   (lower limit)</span>
                                                    </p>
                                                </td>
                                                <td colspan="5" style="width:219.7pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="293">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">-11.6
                                                            <sup>b</sup>
                                                        </span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="2" style="width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="319">
                                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                                        <b>
                                                            <span lang="EN-GB" style="font-size:10.0pt">PGA score clear or almost clear,</span>
                                                        </b>
                                                        <span lang="EN-GB" style="font-size:10.0pt">n (%)</span>
                                                    </p>
                                                </td>
                                                <td colspan="3" style="width:106.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="142">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">88 (33.0)</span>
                                                    </p>
                                                </td>
                                                <td colspan="2" style="width:113.4pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="151">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">102 (37.4)</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="2" style="width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="319">
                                                    <p class="MsoNormal" style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">p-value</span>
                                                    </p>
                                                </td>
                                                <td colspan="5" style="width:219.7pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="293">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">0.0007
                                                            <sup>b</sup>
                                                        </span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="2" style="width:239.3pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="319">
                                                    <p class="MsoNormal" style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid">
                                                        <span lang="EN-GB" style="font-size:10.0pt">One-sided 97.5% repeated CI   (lower limit)</span>
                                                    </p>
                                                </td>
                                                <td colspan="5" style="width:219.7pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="293">
                                                    <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;    page-break-after:avoid">
                                                        <span lang="NL-BE" style="font-size:10.0pt">-13.0
                                                            <sup>b</sup>
                                                        </span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="7" style="width:459.0pt;border:none;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top" width="612">
                                                    <p class="MsoNormal" style="line-height:normal">
                                                        <span lang="EN-GB" style="font-size:9.0pt">Fumaderm = Active comparator, a combination product
with the same content of dimethyl fumarate plus 3 monoethyl hydrogen fumarate
salts; n=number of patients with available data; N=number of patients in population;
PASI=Psoriasis Area Severity Index; PGA=Physician’s Global Assessment; 
                                                            <sup>a</sup>
Superiority of Acme Product vs. Placebo with a difference of 22.2% for PASI 75
and 20.0% for PGA score clear or almost clear, superiority of Fumaderm vs
Placebo with a difference of 25.0% for PASI 75 and 24.4% for PGA score clear
or almost clear;
                                                            <sup>b</sup>Non-inferiority of Acme Product vs. Fumaderm with
a difference of -2.8% for PASI 75 and -4.4% for PGA score clear or almost
clear.
                                                        </span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr height="0">
                                                <td style="border:none" width="272"></td>
                                                <td style="border:none" width="47"></td>
                                                <td style="border:none" width="76"></td>
                                                <td style="border:none" width="47"></td>
                                                <td style="border:none" width="19"></td>
                                                <td style="border:none" width="28"></td>
                                                <td style="border:none" width="123"></td>
                                            </tr>
                                        </table>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                        <p class="MsoNormal" style="line-height:normal">
                                            <span lang="EN-GB">There was a trend in the efficacy endpoint PASI score mean % change from baseline, indicating the onset of a clinical response to Acme Product as early as week 3 (‑11.8%) which became statistically significant compared to placebo by week 8 (‑30.9%). Further improvement was seen by week 16 (‑50.8%).</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                        <p class="MsoNormal" style="line-height:normal">
                                            <span lang="EN-GB">The benefits of treatment with Acme Product were also supported by patient self-perceived improvements in their quality of life. At week 16, patients treated with Acme Product had a lower mean </span>
                                            <span lang="EN-GB">DLQI </span>
                                            <span lang="EN-GB">compared to placebo (5.4 vs 8.8). </span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                        <p class="MsoNormal" style="line-height:normal">
                                            <span lang="EN-GB">Rebound (defined as worsening of ≥125% of baseline PASI value) was assessed after 2 months off treatment and was shown not to be a clinical concern with fumaric acid esters, as it was documented in very few patients (Acme Product 1.1% and active comparator 2.2%, compared to 9.3% in the placebo group). </span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                        <p class="MsoNormal" style="line-height:normal">
                                            <span lang="EN-GB">Long-term efficacy data are currently not available for Acme Product, however, in the pharmacokinetic and clinical studies the systemic exposure, efficacy and safety of Acme Product were shown to be comparable to the active comparator containing dimethyl fumarate. Hence it is reasonable to expect the long-term efficacy of Acme Product to also be comparable to dimethyl fumarate-containing products. Maintenance of long term efficacy has been well described for other dimethyl fumarate-containing products, and therefore</span>
                                            <span lang="EN-GB">the treatment benefits seen with Acme Product at 16 weeks can be expected to be maintained in patients treated over the long term for at least 24 months.</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                    </div>
                                </text>
                            </section>
                            <section id="5ab2635e-33fb-43f8-a230-331d9af876af">
                                <title value="Paediatric population" />
                                <code>
                                    <coding>
                                        <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                        <code value="37" />
                                        <display value="Paediatric population" />
                                    </coding>
                                </code>
                                <text>
                                    <status value="additional" />
                                    <div xmlns="http://www.w3.org/1999/xhtml">
                                        <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                            <span lang="EN-GB">The European Medicines Agency has waived the obligation to submit the results of studies with Acme Product in all subsets of the paediatric population in this indication (see section 4.2 for information on paediatric use).</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                    </div>
                                </text>
                            </section>
                        </section>
                        <section id="720b477a-8a7b-40aa-af90-a3f7e50d859b">
                            <title value="5.2     Pharmacokinetic properties" />
                            <code>
                                <coding>
                                    <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                    <code value="38" />
                                    <display value="5.2 Pharmacokinetic properties" />
                                </coding>
                            </code>
                            <text>
                                <status value="additional" />
                                <div xmlns="http://www.w3.org/1999/xhtml">
                                    <p class="MsoNormal" style="margin-right:-.1pt;line-height:normal;page-break-after:  avoid">
                                        <u>
                                            <span lang="EN-GB"></span>
                                        </u>
                                    </p>
                                </div>
                            </text>
                            <section id="da20d2ae-98f5-496e-94bc-1802b8385182">
                                <title value="Absorption" />
                                <code>
                                    <coding>
                                        <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                        <code value="39" />
                                        <display value="Absorption" />
                                    </coding>
                                </code>
                                <text>
                                    <status value="additional" />
                                    <div xmlns="http://www.w3.org/1999/xhtml">
                                        <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                            <span lang="EN-GB">After oral administration, dimethyl fumarate is not detected in plasma because it is rapidly hydrolysed by esterases to its active metabolite monomethyl fumarate. After oral administration of a single Acme Product 120 mg tablet in healthy subjects, </span>
                                            <span lang="EN-GB">monomethyl fumarate</span>
                                            <span lang="EN-GB">reached plasma peak concentrations of around 1325 ng/mL and 1311 ng/mL
under fasted or fed conditions, respectively. Taking Acme Product with food delayed
the t
                                                <sub>max</sub>of
                                            </span>
                                            <span lang="EN-GB">monomethyl fumarate</span>
                                            <span lang="EN-GB">from 3.5 to 9.0 hours.</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                    </div>
                                </text>
                            </section>
                            <section id="e8921b14-906e-43ac-9b4a-9dc29bc75193">
                                <title value="Distribution" />
                                <code>
                                    <coding>
                                        <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                        <code value="40" />
                                        <display value="Distribution" />
                                    </coding>
                                </code>
                                <text>
                                    <status value="additional" />
                                    <div xmlns="http://www.w3.org/1999/xhtml">
                                        <p class="MsoNormal" style="margin-right:-.1pt;line-height:normal;page-break-after:  avoid">
                                            <span lang="EN-GB">The plasma protein binding of </span>
                                            <span lang="EN-GB">monomethyl fumarate</span>
                                            <span lang="EN-GB">is around 50%. Dimethyl fumarate does not show any binding affinity to serum proteins which may further contribute to its rapid elimination from the circulation.</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                    </div>
                                </text>
                            </section>
                            <section id="9023e2fa-7fef-4797-a49d-cbe33662b539">
                                <title value="Biotransformation" />
                                <code>
                                    <coding>
                                        <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                        <code value="41" />
                                        <display value="Biotransformation" />
                                    </coding>
                                </code>
                                <text>
                                    <status value="additional" />
                                    <div xmlns="http://www.w3.org/1999/xhtml">
                                        <p class="MsoNormal" style="margin-right:-.1pt;line-height:normal;page-break-after:  avoid">
                                            <span lang="EN-GB">The biotransformation of dimethyl fumarate does not involve cytochrome P450 isoenzymes.</span>
                                            <i>In vitro </i>studies have shown that monomethyl fumarate at the therapeutic dose
does not inhibit or induce any of the cytochrome P450 enzymes, it is not a
substrate or inhibitor of P‑glycoprotein and is not an inhibitor of the
most common efflux and uptake transporters
                                            <span style="color:#4BA524;  background:white">. </span>
                                            <span style="color:black;background:white">In vitro studies have shown that dimethyl fumarate at a therapeutic dose does not inhibit CYP3A4/5 and BCRP and is a weak P-glycoprotein inhibitor.</span>
                                        </p>
                                        <p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"></p>
                                        <p class="MsoNormal" id="8a56455c-0939-4203-b538-47f084199bc9" style="margin-right:-.1pt;line-height:normal"></p>
                                        <i>
                                            <span lang="EN-GB">In vitro</span>
                                        </i>
                                        <none></none>
                                        <p class="MsoNormal" id="8a56455c-0939-4203-b538-47f084199bc9" style="margin-right:-.1pt;line-height:normal">
                                            <span lang="EN-GB">studies have shown that hydrolysis of dimethyl fumarate to </span>
                                            <span lang="EN-GB">monomethyl fumarate</span>
                                            <span lang="EN-GB">occurs rapidly at pH 8 (pH in the small intestine), but not at pH 1 (pH in the stomach). A part of the total dimethyl fumarate is hydrolysed by esterases and the alkaline milieu of the small intestine, while the remainder enters the portal vein blood. Further studies have shown that dimethyl fumarate (and to a lesser extent monomethyl fumarate) reacts partially with reduced glutathione forming a glutathione-adduct. These adducts were detected in animal studies in the intestinal mucosa of rats and to a smaller extent in portal vein blood. Unconjugated dimethyl fumarate, however, cannot be detected in the plasma of animals or psoriatic patients following oral administration. By contrast, unconjugated monomethyl fumarate is detectable in plasma. Further metabolism occurs through oxidation via the tricarboxylic acid cycle forming carbon dioxide and water.</span>
                                        </p>
                                        <p class="MsoNormal" style="margin-right:-.1pt;line-height:normal">
                                            <u>
                                                <span lang="EN-GB"></span>
                                            </u>
                                        </p>
                                    </div>
                                </text>
                            </section>
                            <section id="eb9c8a8f-0479-46a7-a0bd-ef051ba2f140">
                                <title value="Elimination" />
                                <code>
                                    <coding>
                                        <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                        <code value="42" />
                                        <display value="Elimination" />
                                    </coding>
                                </code>
                                <text>
                                    <status value="additional" />
                                    <div xmlns="http://www.w3.org/1999/xhtml">
                                        <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                            <span lang="EN-GB">Exhalation of CO
                                                <sub>2</sub>resulting from the metabolism of monomethyl
fumarate is the primary route of elimination; only small amounts of intact monomethyl
fumarate are excreted through urine or faeces. The portion of dimethyl fumarate
that reacts with glutathione, forming a glutathione-adduct, is metabolised further
to its mercapturic acid, which is excreted in the urine.
                                            </span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                        <p class="MsoNormal" style="line-height:normal">
                                            <span lang="EN-GB">The apparent terminal elimination half-life of monomethyl fumarate is about 2 hours.</span>
                                        </p>
                                        <p class="MsoNormal" style="margin-right:-.1pt;line-height:normal">
                                            <u>
                                                <span lang="EN-GB"></span>
                                            </u>
                                        </p>
                                    </div>
                                </text>
                            </section>
                            <section id="8d925827-abee-49bc-a037-513c0e9fe36d">
                                <title value="Linearity/non-linearity" />
                                <code>
                                    <coding>
                                        <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                        <code value="43" />
                                        <display value="Linearity/non-linearity" />
                                    </coding>
                                </code>
                                <text>
                                    <status value="additional" />
                                    <div xmlns="http://www.w3.org/1999/xhtml">
                                        <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                            <span lang="EN-GB">Despite the high inter‑subject variability, the exposure
measured as AUC and C
                                                <sub>max</sub>was generally dose‑proportional after
single dose administration of 4 x 30 mg dimethyl fumarate
tablets (total dose of 120 mg) and 2 x 120 mg dimethyl
fumarate tablets (total dose of 240 mg).
                                            </span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal">
                                            <u>
                                                <span lang="EN-GB"></span>
                                            </u>
                                        </p>
                                        <p class="MsoNormal" style="margin-right:-.1pt;line-height:normal;page-break-after:  avoid">
                                            <u>
                                                <span lang="EN-GB">Renal impairment</span>
                                            </u>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                            <span lang="EN-GB">No specific studies have been performed in patients with renal impairment. However, because renal elimination plays a minor role in the total clearance from plasma, it is unlikely that renal impairment may affect the pharmacokinetic characteristics of Acme Product (see section 4.2).</span>
                                        </p>
                                        <p class="MsoNormal" style="line-height:normal"></p>
                                        <p class="MsoNormal" style="margin-right:-.1pt;line-height:normal;page-break-after:  avoid">
                                            <u>
                                                <span lang="EN-GB">Hepatic impairment</span>
                                            </u>
                                        </p>
                                        <p class="MsoNormal" style="margin-right:-.1pt;line-height:normal;page-break-after:  avoid">
                                            <span lang="EN-GB">No specific studies have been performed in patients with hepatic impairment. However, as dimethyl fumarate is metabolised by esterases and the alkaline milieu of the small intestine without the involvement of cytochrome P450, hepatic impairment is not expected to influence exposure (see section 4.2).</span>
                                        </p>
                                        <p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"></p>
                                    </div>
                                </text>
                            </section>
                        </section>
                        <section id="1f440f74-bf3d-4bb2-8c68-71ab0ef0f1b1">
                            <title value="5.3     Preclinical safety data" />
                            <code>
                                <coding>
                                    <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                    <code value="45" />
                                    <display value="5.3 Preclinical safety data" />
                                </coding>
                            </code>
                            <text>
                                <status value="additional" />
                                <div xmlns="http://www.w3.org/1999/xhtml">
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                    <p class="MsoNormal" style="margin-right:-.1pt;line-height:normal;page-break-after:  avoid">
                                        <span lang="EN-GB">Non-clinical safety pharmacology and genotoxicity data reveal no special hazard for humans.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="margin-right:-.1pt;line-height:normal;page-break-after:  avoid">
                                        <u>
                                            <span lang="EN-GB">Toxicology</span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">The kidney was identified as a major target organ of toxicity in
non-clinical studies. Renal findings in dogs included minimal to moderate
tubular hypertrophy, increased incidence and severity of tubular vacuolation
and minimal to slight tubular degeneration, which were considered
toxicologically relevant. The no‑observed adverse-effect-level (NOAEL) after
3 months of treatment was 30 mg/kg/day, which corresponds to 2.9‑fold
and 9.5‑fold the human systemic exposure at the highest recommended dose
(720 mg/day), as AUC and C
                                            <sub>max</sub>values, respectively.
                                        </span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="margin-right:-.1pt;line-height:normal;page-break-after:  avoid">
                                        <u>
                                            <span lang="EN-GB">Reproduction toxicity</span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">No fertility or pre- and post-natal development studies have been conducted with Acme Product.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">There were no effects on foetal body weights or malformations attributed to maternal administration of dimethyl fumarate</span>
                                        <span lang="EN-GB">during the embryo‑foetal development study in rats. However, there
was an increased number of foetuses with the variations “supernumerary liver
lobe” and “abnormal iliac alignment” at maternally toxic doses. The NOAEL for
maternal and embryo‑foetal toxicity was 40 mg/kg/day, corresponding
to 0.2‑fold and 2.0‑fold the human systemic exposure at the highest
recommended dose (720 mg/day), as AUC and C
                                            <sub>max</sub>values, respectively.
                                        </span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">Dimethyl fumarate has been shown to cross the placental membrane into foetal blood in rats.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="margin-right:-.1pt;line-height:normal;page-break-after:  avoid">
                                        <u>
                                            <span lang="EN-GB">Carcinogenicity</span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">No carcinogenicity studies have been performed for </span>
                                        <span lang="EN-GB">Acme Product. Based on available data suggesting that fumaric acid esters may activate cellular pathways related to the development of renal tumours, a potential tumorigenic activity of exogenously administered dimethyl fumarate on the kidneys cannot be excluded. </span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                </div>
                            </text>
                        </section>
                    </section>
                    <section id="19c20d39-2aec-47da-bd18-652906b34674">
                        <title value="6.       PHARMACEUTICAL PARTICULARS" />
                        <code>
                            <coding>
                                <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                <code value="47" />
                                <display value="6. PHARMACEUTICAL PARTICULARS" />
                            </coding>
                        </code>
                        <text>
                            <status value="additional" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                            </div>
                        </text>
                        <section id="e42a068f-0638-4e16-8922-63a0f7f57950">
                            <title value="6.1     List of excipients" />
                            <code>
                                <coding>
                                    <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                    <code value="48" />
                                    <display value="6.1 List of excipients" />
                                </coding>
                            </code>
                            <text>
                                <status value="additional" />
                                <div xmlns="http://www.w3.org/1999/xhtml">
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="EN-GB">Acme Product 30 mg</span>
                                        </u>
                                        <u>
                                            <span lang="EN-GB">and Acme Product 120 mg</span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <i>
                                            <span lang="EN-GB">Core:</span>
                                        </i>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Lactose monohydrate</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">Cellulose microcrystalline</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">Croscarmellose sodium</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">Colloidal anhydrous silica</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">Magnesium stearate</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="EN-GB">Acme Product 30 mg</span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <i>
                                            <span lang="EN-GB">Coating:</span>
                                        </i>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Methacrylic acid-ethyl acrylate copolymer (1:1)</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="IT">Talc</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="IT">Triethyl citrate</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="IT">Titanium dioxide (E171)</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="IT">Simethicone</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="IT">Acme Product 120 mg</span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <i>
                                            <span lang="IT">Coating:</span>
                                        </i>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="IT">Methacrylic acid‑ethyl acrylate copolymer (1:1)</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="IT">Talc</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="IT">Triethyl citrate</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="IT">Titanium dioxide (E171)</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="IT">Simethicone</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="IT">Indigo carmine (E132)</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="IT">Sodium hydroxide</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                </div>
                            </text>
                        </section>
                        <section id="dee6ec5e-c60c-4d3d-9102-028d52f66401">
                            <title value="6.2     Incompatibilities" />
                            <code>
                                <coding>
                                    <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                    <code value="49" />
                                    <display value="6.2 Incompatibilities" />
                                </coding>
                            </code>
                            <text>
                                <status value="additional" />
                                <div xmlns="http://www.w3.org/1999/xhtml">
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">Not applicable.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                </div>
                            </text>
                        </section>
                        <section id="ed475b82-681f-451a-975d-f5dff771bb6e">
                            <title value="6.3     Shelf life" />
                            <code>
                                <coding>
                                    <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                    <code value="50" />
                                    <display value="6.3 Shelf life" />
                                </coding>
                            </code>
                            <text>
                                <status value="additional" />
                                <div xmlns="http://www.w3.org/1999/xhtml">
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">3 years.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                </div>
                            </text>
                        </section>
                        <section id="6f70519b-7d31-4a8b-a8c0-b0cac0305010">
                            <title value="6.4     Special precautions for storage" />
                            <code>
                                <coding>
                                    <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                    <code value="51" />
                                    <display value="6.4 Special precautions for storage" />
                                </coding>
                            </code>
                            <text>
                                <status value="additional" />
                                <div xmlns="http://www.w3.org/1999/xhtml">
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">This medicinal product does not require any special storage conditions.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                </div>
                            </text>
                        </section>
                        <section id="2ef2c4b5-814c-4b7a-9caa-f3e162cc3721">
                            <title value="6.5     Nature and contents of container" />
                            <code>
                                <coding>
                                    <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                    <code value="52" />
                                    <display value="6.5 Nature and contents of container &lt;and special equipment for use administration or implantation&gt;" />
                                </coding>
                            </code>
                            <text>
                                <status value="additional" />
                                <div xmlns="http://www.w3.org/1999/xhtml">
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="EN-GB">Acme Product 30 mg</span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">42, 70 and 210 gastro‑resistant tablets in PVC/PVDC‑aluminium blister packs.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <u>
                                            <span lang="EN-GB">Acme Product 120 mg</span>
                                        </u>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">40, 70, 90, 100, 120, 180, 200, 240, 300, 360 and 400 gastro‑resistant tablets in PVC/PVDC‑aluminium blister packs.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal">
                                        <span lang="EN-GB">Not all pack sizes may be marketed.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                </div>
                            </text>
                        </section>
                        <section id="21dbeb54-74c6-459c-b1c2-45de7b3f7fc5">
                            <title value="6.6     Special precautions for disposal" />
                            <code>
                                <coding>
                                    <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                    <code value="53" />
                                    <display value="6.6 Special precautions for disposal &lt;and other handling&gt;" />
                                </coding>
                            </code>
                            <text>
                                <status value="additional" />
                                <div xmlns="http://www.w3.org/1999/xhtml">
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                        <span lang="EN-GB">No special requirements for disposal.</span>
                                    </p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                    <p class="MsoNormal" style="line-height:normal"></p>
                                </div>
                            </text>
                        </section>
                    </section>
                    <section id="d5d42c5e-8403-4a80-a88b-80cecd512160">
                        <title value="7.       MARKETING AUTHORISATION HOLDER" />
                        <code>
                            <coding>
                                <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                <code value="55" />
                                <display value="7. MARKETING AUTHORISATION HOLDER" />
                            </coding>
                        </code>
                        <text>
                            <status value="additional" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                    <span lang="EN-GB">Almirall, S.A.</span>
                                </p>
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                    <span lang="EN-GB">Ronda General Mitre, 151</span>
                                </p>
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                    <span lang="EN-GB">08022 Barcelona</span>
                                </p>
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                    <span lang="EN-GB">Spain</span>
                                </p>
                                <p class="MsoNormal" style="line-height:normal"></p>
                                <p class="MsoNormal" style="line-height:normal"></p>
                            </div>
                        </text>
                    </section>
                    <section id="d6ced554-6fec-456f-9486-3f9734a0cfb0">
                        <title value="8.       MARKETING AUTHORISATION NUMBERS" />
                        <code>
                            <coding>
                                <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                <code value="56" />
                                <display value="8. MARKETING AUTHORISATION NUMBER(S)" />
                            </coding>
                        </code>
                        <text>
                            <status value="additional" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                    <span lang="PT">EU/1/17/1201/001
                                        <br />
EU/1/17/1201/002
                                        <br />
EU/1/17/1201/003
                                        <br />
EU/1/17/1201/004
                                        <br />
EU/1/17/1201/005
                                        <br />
EU/1/17/1201/006
                                        <br />
                                    </span>
                                    <span lang="PT">EU/1/17/1201/007
                                        <br />
                                    </span>
                                    <span lang="PT">EU/1/17/1201/008
                                        <br />
EU/1/17/1201/009
                                        <br />
                                    </span>
                                    <span lang="PT">EU/1/17/1201/010
                                        <br />
EU/1/17/1201/011
                                    </span>
                                </p>
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                    <span lang="EN-GB">EU/1/17/1201/012</span>
                                </p>
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                    <span lang="EN-GB">EU/1/17/1201/013</span>
                                </p>
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                    <span lang="EN-GB">EU/1/17/1201/014</span>
                                </p>
                                <p class="MsoNormal" style="line-height:normal"></p>
                                <p class="MsoNormal" style="line-height:normal"></p>
                            </div>
                        </text>
                    </section>
                    <section id="911c0af5-bcba-4be7-824f-98340e25012d">
                        <title value="9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION" />
                        <code>
                            <coding>
                                <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                <code value="57" />
                                <display value="9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION" />
                            </coding>
                        </code>
                        <text>
                            <status value="additional" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p>
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                    <span lang="EN-GB">Date of first authorisation: 23 june 2017</span>
                                </p>
                                <p class="MsoNormal" style="line-height:normal"></p>
                                <p class="MsoNormal" style="line-height:normal"></p>
                            </div>
                        </text>
                    </section>
                    <section id="cfe505d7-6992-4128-a84d-606d2a8f0680">
                        <title value="10.     DATE OF REVISION OF THE TEXT" />
                        <code>
                            <coding>
                                <system value="http://spor.ema.europa.eu/v1/example-sections" />
                                <code value="58" />
                                <display value="10. DATE OF REVISION OF THE TEXT" />
                            </coding>
                        </code>
                        <text>
                            <status value="additional" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p class="MsoNormal" style="margin-right:-.1pt;line-height:normal;page-break-after:  avoid"></p>
                                <p class="MsoNormal" style="line-height:normal;page-break-after:avoid">
                                    <span lang="EN-GB">Detailed information on this medicinal product is available on the website of the European </span>
                                    <span lang="EN-GB">Medicines</span>
                                    <span lang="EN-GB">Agency </span>
                                    <span lang="EN-GB">
                                        <a href="http://www.ema.europa.eu">
                                            <span class="Hipervnculo">http://www.ema.europa.eu</span>
                                        </a>
                                    </span>
                                    <span lang="EN-GB" style="color:blue">.</span>
                                </p>
                                <p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"></p>
                                <span lang="EN-GB" style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;,serif">
                                    <br clear="all" style="page-break-before:always" />
                                </span>
                            </div>
                        </text>
                    </section>
                </section>
            </Composition>
        </resource>
    </entry>
</Bundle>